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ABSTRACT 
Medication nonadherence is a well-recognised problem in chronic diseases with a 
global prevalence rate estimated to be 50%. Determinants of nonadherence are 
multifactorial, although increasing complexity of disease and medication regimen 
contribute to nonadherence. End-stage kidney disease (ESKD) patients undergoing 
haemodialysis are prescribed complex regimens and are at high risk of medication 
nonadherence. Current clinical practice places significant emphasis on selecting 
medications that have been shown to improve patient outcomes, however little 
attention is paid to measuring and ensuring patient adherence to their prescribed 
treatments. Our understanding of factors contributing to medication nonadherence in 
patients undergoing haemodialysis is limited. This research sought to determine 
potential predictors of medication nonadherence, explore current practices and 
barriers to assessing adherence, and identify strategies to improve adherence 
assessment practices in clinical settings. The specific research objectives were to: 
• summarise existing literature on medication nonadherence and identify factors
associated with medication nonadherence in patients undergoing
haemodialysis;
• investigate the prevalence pattern, and socio-demographic, clinical and
psychosocial factors contributing to medication nonadherence in Australian
haemodialysis patients, and
• identify current practices of assessing medication adherence in renal patients
by  health professionals, barriers to assessment, and strategies to improve
adherence assessment practices in Australian dialysis centres.
xv 
These research aims were investigated in four distinct studies. The first study 
summarised the existing literature on medication nonadherence using a systematic 
review. From the 44 relevant publications identified through the systematic review, the 
prevalence of medication nonadherence in patients undergoing haemodialysis varied 
between 12.5% and 98.6%. This wide variation occurred due to the heterogeneity in 
measures and definitions employed by the included studies. This inconsistency in the 
reporting of results did not allow us to conduct a more effective synthesis of results, 
such as meta-analysis, as part of the systematic review. However, through a narrative 
synthesis approach we identified a number of patient-, disease-, and medication-
related factors contributing to nonadherence in patients undergoing haemodialysis.   
The second study was a prospective study of 53 adult (≥ 18 years) patients 
undergoing haemodialysis, recruited from an outpatient dialysis centre in Hobart, 
Australia. More than half (56.6%, n = 30) of these patients were found to be 
nonadherent based on self-reports. Comparatively, nonadherence was much higher 
among the subset of patients (n = 33) analysed using pre-dialysis serum phosphate 
levels, as an objective measure (72.7%, n = 24). Increasing age was the only 
significant predictor of self-reported adherence (odds ratio (OR) 1.05; 95% CI 1.00–
1.11), whereas older age (OR 1.10; 95% CI 1.00–1.21), higher level of comorbidity 
(OR 1.58; 95% CI 1.03–2.42), and higher medication regimen complexity index (OR 
1.14; 95% CI 1.02–1.27) were independent predictors of objective adherence.  
The third study was a qualitative study aimed at exploring haemodialysis patients’ 
perspectives on their medication-taking behaviour. Thirty patients undergoing 
haemodialysis from the aforementioned prospective study, completed one-on-one 
semi-structured interviews. The qualitative themes identified were mapped against 
WHO (World Health Organisation) determinants of adherence and comprised of 
xvi 
patient-related (knowledge, awareness, attitude, self-efficacy, action control, and 
facilitation); health system/healthcare team-related (quality of interaction, and mistrust 
and collateral arrangements); therapy-related (physical characteristics of medicines, 
packaging, and side effects); condition-related (symptom severity); and 
social/economic factors (access to medicines, and relative affordability).  
Findings from the second and third study, led to the inception of the fourth study 
on healthcare professionals’ perspectives on the issue of medication nonadherence in 
patients undergoing haemodialysis. As such, the fourth study consisted of cross-
sectional surveys and follow-up interviews with renal healthcare professionals, aimed 
at measuring their perceptions and practices of assessing adherence in clinical 
practice. A total of 113 renal nurses and 41 specialist renal pharmacists participated 
in this study. Attempts to engage renal doctors were unsuccessful despite trying 
various recruitment strategies. Renal nurses (83.2%, n = 89), relied heavily upon 
objective blood results to determine adherence, compared to pharmacists (57.1%, n 
= 16). Patient engagement via self-reported measures were rarely used by the 
pharmacists (27.6%, n = 8) compared to the nurses (55.1%, n = 59); this was mainly 
due to absence of a dedicated pharmacist to conduct such activities. Perceived 
barriers to assessing adherence by the renal professionals included: lack of time, 
administrative support, and patients’ disinterest in discussing medication related 
issues.  
Survey participants were followed-up for a qualitative interview to expand on the 
survey findings and identify strategies to improve adherence assessment practices. 
Eighteen participants, comprising 12 nurses and six pharmacists, were interviewed. 
Three categories of barriers with seven underlying themes were identified: 
organisation-level (prioritisation of resources), professional-level (interplay between 
xvii 
 
workload and available time, awareness and training deficits, and concerns around 
practicality/suitability of adherence tools), and patient-level (communication and 
assessment services, patient participation, and trust). Similarly, strategies that were 
identified to improve adherence assessment practices, included: formalisation of 
assessment process, integration of assessment process and tools into routine, and 
using multidisciplinary support.  
Despite the widespread prevalence of medication nonadherence among Australian 
haemodialysis patients, little attention has been given to ensuring patients adhere to 
their prescribed medicines. Communication and dialogue between patients and 
healthcare providers concerning medication-related issues are lacking within the 
dialysis settings. In order to improve this status quo, measuring nonadherence is vital. 
However, renal professionals placed too much emphasis on objective measures while 
assessing adherence; using such measures is subject to overlooking actual 
understanding of patient’s medication-taking behaviour. As patient self-reported 
measures are important tools to supplement the objective measures, they should be 
promoted to healthcare providers so an open dialogue on medication nonadherence 
can be initiated. This may be a first step in a right direction in improving medication 
adherence in patients undergoing dialysis. In addition, current adherence assessment 
practices could be improved by formalising and integrating these practices into 
hospital policies and procedures. For example, by integrating adherence checklists 
into treatment sheets for routine assessments. Although easier said than done, having 
a dedicated and trained healthcare professional to measure adherence, is another key 
initiative that may improve medication adherence among dialysis patients. Finally, the 
importance of frequent discussion with patients to identify concerns they may have 
related to their medications cannot be overestimated.  
xviii 
TABLE OF CONTENTS 
DECLARATION OF ORIGINALITY .............................................................................................................. ii 
STATEMENT OF AUTHORITY OF ACCESS ................................................................................................ iii 
STATEMENT OF ETHICAL CONDUCT....................................................................................................... iv 
STATEMENT OF CO-AUTHORSHIP ........................................................................................................... v 
PUBLICATIONS ........................................................................................................................................ vi 
ACKNOWLEDGEMENTS ........................................................................................................................... x 
ABBREVIATIONS .................................................................................................................................... xii 
ABSTRACT ..............................................................................................................................................xiv 
LIST OF TABLES ..................................................................................................................................... xxii 
LIST OF FIGURES .................................................................................................................................. xxiii 
LIST OF APPENDICES ........................................................................................................................... xxiv 
STRUCTURE OF THE THESIS .................................................................................................................. xxv 
CHAPTER ONE ......................................................................................................................................... 1 
1. INTRODUCTION ................................................................................................................................... 1 
1.1. Background .................................................................................................................................. 1 
1.2. Aims and Objectives ..................................................................................................................... 4 
1.3. Methodology ................................................................................................................................ 5 
1.4. Literature Review ......................................................................................................................... 7 
1.4.1. Terminologies Used to Define Adherence ............................................................................ 7 
1.4.2. Methods of Measuring Adherence ....................................................................................... 9 
1.4.3. Magnitude of the Problem of Medication Nonadherence ................................................. 12 
1.4.4. Consequences of Medication Nonadherence ..................................................................... 14 
1.4.5. Economic Implications of Nonadherence ........................................................................... 17 
1.4.6. Determinants of Poor Medication Adherence .................................................................... 20 
1.4.8. Medication Nonadherence in Chronic Kidney Disease ....................................................... 26 
CHAPTER TWO ...................................................................................................................................... 27 
2. NONADHERENCE TO MEDICATION THERAPY IN HAEMODIALYSIS PATIENTS: A SYSTEMATIC REVIEW
 .............................................................................................................................................................. 27 
2.1. Abstract ...................................................................................................................................... 27 
2.2 Introduction ................................................................................................................................ 29 
2.3. Methods ..................................................................................................................................... 31 
2.3.1. Data Source and Search Strategy ........................................................................................ 31 
2.3.2. Study Selection .................................................................................................................... 31 
2.3.3. Data Extraction and Analysis ............................................................................................... 34 
xix 
 
2.3.4. Quality Assessment ............................................................................................................. 35 
2.4. Results ........................................................................................................................................ 35 
2.4.1. Description of Included Studies .......................................................................................... 35 
2.4.2. Assessment of Nonadherence ............................................................................................ 46 
2.4.3. Definitions of Nonadherence .............................................................................................. 47 
2.4.4. Prevalence of Nonadherence to Medication ...................................................................... 48 
2.4.5. Factors Associated with Nonadherence ............................................................................. 51 
2.4.6. Perceived Barriers of Adherence to Medication ................................................................. 55 
2.4.7. Study Quality ....................................................................................................................... 56 
2.5. Discussion ................................................................................................................................... 56 
2.6. Conclusion .................................................................................................................................. 60 
CHAPTER THREE .................................................................................................................................... 62 
3. MEDICATION REGIMEN COMPLEXITY AND ADHERENCE IN HAEMODIALYSIS PATIENTS: AN 
EXPLORATORY STUDY ........................................................................................................................... 62 
3.1. Abstract ...................................................................................................................................... 62 
3.2. Introduction ............................................................................................................................... 64 
3.3. Methods ..................................................................................................................................... 65 
3.3.1. Data Collection .................................................................................................................... 65 
3.3.2. Statistical Analysis ............................................................................................................... 67 
3.4. Results ........................................................................................................................................ 68 
3.5. Discussion ................................................................................................................................... 74 
4. MEDICATION ADHERENCE PERSPECTIVES IN HAEMODIALYSIS PATIENTS: A QUALITATIVE STUDY . 78 
4.1. Abstract ...................................................................................................................................... 78 
4.2. Introduction ............................................................................................................................... 80 
4.3. Methods ..................................................................................................................................... 81 
4.3.1. Study Design ........................................................................................................................ 81 
4.3.2. Research Team and Reflexivity ........................................................................................... 81 
4.3.3. Participants ......................................................................................................................... 81 
4.3.4. Data Collection and Analysis ............................................................................................... 82 
4.4. Results ........................................................................................................................................ 83 
4.4.2. Theme 2: Health System/Healthcare Team-related Factors .............................................. 93 
4.4.3. Theme 3: Therapy-related Factors ...................................................................................... 94 
4.4.4. Theme 4: Social/Economic Factors ..................................................................................... 95 
4.4.5. Theme 5: Condition-related Factors ................................................................................... 96 
4.5. Discussion ................................................................................................................................... 97 
4.6. Conclusions .............................................................................................................................. 100 
xx 
CHAPTER FIVE ..................................................................................................................................... 102 
5. RENAL PHARMACISTS’ PERCEPTIONS AND CURRENT PRACTICES OF ASSESSING MEDICATION
ADHERENCE IN DIALYSIS PATIENTS: DEVELOPMENT AND PILOTING OF A SURVEY TOOL ................. 102 
5.1. Abstract .................................................................................................................................... 102 
5.2. Impact of Findings on Practice ................................................................................................. 104 
5.3. Introduction ............................................................................................................................. 104 
5.4. Aim of the Study ...................................................................................................................... 106 
5.5. Ethics Approval ........................................................................................................................ 107 
5.6. Method .................................................................................................................................... 107 
5.6.1. Study Design ...................................................................................................................... 107 
5.6.2. Setting and Recruitment of Participants ........................................................................... 107 
5.6.3. Data Collection .................................................................................................................. 107 
5.6.4. Survey Development ......................................................................................................... 108 
5.6.5. Statistical Analysis ............................................................................................................. 109 
5.7. Results ...................................................................................................................................... 110 
5.7.1. Reliability of Scales ............................................................................................................ 110 
5.7.2. Perceived Prevalence and Contributors of Nonadherence .............................................. 112 
5.7.3. Perceived Effectiveness and Barriers to Assessing Adherence ......................................... 114 
5.7.4. Participants’ Confidence in Assessing Adherence ............................................................ 114 
5.7.5. Differences in Perceptions based on Study Demographics .............................................. 116 
5.7.6. Current Adherence Assessment Practices ........................................................................ 118 
5.7.7. Qualitative Comments ...................................................................................................... 119 
5.8. Discussion ................................................................................................................................. 119 
5.8.1. Study Limitations............................................................................................................... 123 
5.9. Conclusion ................................................................................................................................ 123 
CHAPTER SIX ........................................................................................................................................ 125 
6. RENAL NURSES’ PERCEPTIONS AND CURRENT PRACTICES OF ASSESSING MEDICATION ADHERENCE
IN DIALYSIS PATIENTS: A CROSS-SECTIONAL SURVEY ......................................................................... 125 
6.1. Abstract .................................................................................................................................... 125 
6.2. Contribution of the Paper ........................................................................................................ 127 
6.3. Introduction ............................................................................................................................. 128 
6.4. Methods ................................................................................................................................... 129 
6.4.1. Study Design ...................................................................................................................... 129 
6.4.2. Setting and Recruitment of Participants ........................................................................... 130 
6.4.3. Data Collection .................................................................................................................. 130 
6.4.4. Development of Survey Instrument .................................................................................. 130 
xxi 
6.4.5. Statistical Analysis ............................................................................................................. 131 
6.4.6. Ethical Considerations ....................................................................................................... 131 
6.5. Results ...................................................................................................................................... 132 
6.5.1. Internal Consistency Reliability of Scales .......................................................................... 133 
6.5.2. Perceived Prevalence and Contributors of Nonadherence .............................................. 134 
6.5.3. Perceived Effectiveness and Barriers to Assessing Adherence ......................................... 136 
6.5.4. Participants’ Confidence in Assessing Adherence ............................................................ 136 
6.5.5. Differences in Perceptions Based on Study Demographics .............................................. 138 
6.5.6. Current Practices of Assessing Adherence ........................................................................ 140 
6.5.7. Qualitative Comments ...................................................................................................... 141 
6.6. Discussion ................................................................................................................................. 142 
6.6.1. Study Limitations............................................................................................................... 146 
6.7. Conclusion ................................................................................................................................ 146 
CHAPTER SEVEN .................................................................................................................................. 148 
7. BARRIERS TO ASSESSING ADHERENCE AND CONSIDERATIONS TO IMPROVE ADHERENCE
ASSESSMENT PRACTICES IN DIALYSIS SETTINGS: A QUALITATIVE STUDY .......................................... 148 
7.1. Abstract .................................................................................................................................... 148 
7.2. Introduction ............................................................................................................................. 150 
7.3. Methods ................................................................................................................................... 151 
7.3.1. Participants ....................................................................................................................... 152 
7.3.2. Data Collection and Analysis ............................................................................................. 152 
7.4. Results ...................................................................................................................................... 153 
7.4.1. Barriers to Assessing Medication Adherence ................................................................... 155 
7.4.2. Considerations for Improving Adherence Assessment Practices ..................................... 162 
7.5. Discussion ................................................................................................................................. 165 
CHAPTER EIGHT ................................................................................................................................... 171 
8. CONCLUSION AND FUTURE DIRECTION .......................................................................................... 171 
8.1. Practice Implications ................................................................................................................ 177 
8.2. Limitations of the research ...................................................................................................... 178 
8.3. Future direction ....................................................................................................................... 179 
8.4. Conclusion ................................................................................................................................ 180 
REFERENCES ........................................................................................................................................ 181 
xxii 
 
LIST OF TABLES 
Table 1. Methods of measuring medication adherence ....................................................................... 11 
Table 2. Prevalence rates of medication nonadherence in chronic diseases ....................................... 14 
Table 3. Complications resulting from medication nonadherence ...................................................... 16 
Table 4. Intervention used to improve medication adherence in chronic diseases ............................. 24 
Table 5. Characteristics of studies included in systematic review ........................................................ 37 
Table 6. Factors associated with nonadherence (n = 38) ..................................................................... 52 
Table 7. Study Characteristics based on Patient Self-reported Adherence .......................................... 69 
Table 8. Predictors of Adherence using Logistic Regression Analysis ................................................... 73 
Table 9. Characteristics of Study Participants (n = 30) ......................................................................... 84 
Table 10. Determinants of medication adherence in patients undergoing haemodialysis .................. 86 
Table 11. Demographics of survey respondents (n = 41) ................................................................... 111 
Table 12. Perceived prevalence and contributors of nonadherence in patients undergoing dialysis 113 
Table 13. Perceived effectiveness, barriers and confidence to assessing adherence in patients 
undergoing dialysis ............................................................................................................................. 115 
Table 14. Differences in perceptions based on study demographics across all scales ....................... 117 
Table 15. Demographics of survey respondents (n = 113) ................................................................. 132 
Table 16. Perceived prevalence and contributors of nonadherence in patients undergoing dialysis 135 
Table 17. Perceived effectiveness, barriers and confidence to assess adherence in patients 
undergoing dialysis ............................................................................................................................. 137 
Table 18. Differences in perceptions based on study demographics across all scales ....................... 139 
Table 19. Demographics of participants (n = 18) ................................................................................ 154 
Table 20. Considerations for improving adherence assessment practices ........................................ 162 
  
xxiii 
LIST OF FIGURES 
Figure 1. Structure of the thesis ....................................................................................................... xxviii 
Figure 2. Research methodology ............................................................................................................ 6 
Figure 3. Illustration of the process of adherence to medications ......................................................... 9 
Figure 4. Persistence with secondary prevention medication over 24 months after ischemic stroke 13 
Figure 5. Relationship between nonadherence and associated healthcare costs................................ 17 
Figure 6. Avoidable cost of nonadherence to medication .................................................................... 18 
Figure 7. Selected determinants of medication adherence ................................................................. 21 
Figure 8. Five interacting dimensions affecting medication adherence ............................................... 22 
Figure 9. Flowchart of study selection for systematic review .............................................................. 33 
Figure 10: Prevalence rates of medication nonadherence in HD patients ........................................... 49 
Figure 11. Characteristics of Patient Prescribed with Phosphate Binders (n = 33). ............................. 71 
Figure 12. Pharmacists’ reports on current practices of assessing medication adherence in patients 
undergoing dialysis in Australia .......................................................................................................... 118 
Figure 13. Nurses’ reports on current practices of assessing medication adherence in patients 
undergoing dialysis in Australia .......................................................................................................... 141 
Figure 14. Barriers to assessing medication adherence in patients undergoing dialysis ................... 156 
xxiv 
 
LIST OF APPENDICES 
Appendix 1. PRISMA Checklist ............................................................................................................ 199 
Appendix 2. Electronic search strategy, Systematic Review ............................................................... 201 
Appendix 3. Patient Medication History Interview Questions ........................................................... 203 
Appendix 4. Patient Self-reported Questionnaires ............................................................................. 204 
Appendix 5. Data collection form ....................................................................................................... 208 
Appendix 6. Medication Regimen Complexity Index, MRCI ............................................................... 209 
Appendix 7. COREQ Checklist: Patient Interview ................................................................................ 211 
Appendix 8. Interview guide: Patient Interview ................................................................................. 213 
Appendix 9. Summary of interpretation of themes with exemplar quotes: Patient Interview .......... 215 
Appendix 10. STROBE Checklist: Pharmacist Survey .......................................................................... 222 
Appendix 11. Survey Questionnaire: Renal Professionals .................................................................. 225 
Appendix 12. Inter-item correlation matrix and Cronbach’s alpha coefficients for psychometric 
scales: Pharmacist Survey ................................................................................................................... 233 
Appendix 13. Comments on perceptions and current practices: Pharmacist Survey ........................ 235 
Appendix 14. STROBE Checklist: Nurses Survey ................................................................................. 237 
Appendix 15. Inter-item correlation matrix and Cronbach’s alpha coefficients for psychometric 
scales: Nurses Survey .......................................................................................................................... 240 
Appendix 16. Comments on perceptions and current practices: Nurses Survey ............................... 242 
Appendix 17. COREQ Checklist: Renal Professionals Interview .......................................................... 246 
Appendix 18. Interview Guide: Renal Professionals ........................................................................... 248 
Appendix 19. Barriers to assessing medication adherence: Exemplar quotes Renal Professionals ... 251 
Appendix 20. Considerations to improve adherence assessment practices: Exemplar quotes Renal 
Professionals ....................................................................................................................................... 256 
Appendix 21. Tasmanian Health and Medical HREC Approval ........................................................... 260 
Appendix 22. Tasmanian Social Sciences HREC Approval ................................................................... 262 
Appendix 23. Invitation Letter for Nurses Survey ............................................................................... 264 
Appendix 24. Participant Information Sheet for Survey Participants ................................................. 265 
Appendix 25. Participant Information Sheet: Renal Dialysis Patients ................................................ 267 
Appendix 26. Consent Form: Renal dialysis Patients .......................................................................... 270 
Appendix 27. Participant Information Sheet: Renal Professionals Interview ..................................... 272 
Appendix 28. Consent Form: Renal Professionals .............................................................................. 274 
Appendix 29. Recruitment advertisement: Renal dialysis patients .................................................... 276 
Appendix 30. Recruitment advertisement: Renal Professionals ........................................................ 277 
xxv 
 
STRUCTURE OF THE THESIS  
This thesis initially describes the existing literature on medication adherence and 
gradually progresses towards study findings that investigate determinants of 
medication adherence, current practices and impediments to assessing adherence. 
Furthermore it considers, strategies to improve adherence assessment practices in 
routine dialysis care. The thesis concludes with a general discussion on issues 
surrounding assessment of medication adherence in patients undergoing dialysis, and 
recommending strategies on how to address and overcome these issues in future.  
 Chapter 1 provides a brief synopsis on medication adherence, primarily dealing 
with the general attributes of adherence in relation to chronic diseases such as: 
definition and terminology used; measurement methods; the magnitude of the problem; 
consequences and economic implications of nonadherence; determinants of 
adherence; and strategies used to improve poor adherence in patients with chronic 
diseases.  
Chapter 2, is a systematic review summarising the existing literature on 
nonadherence and identifying factors associated with medication nonadherence in 
chronic kidney failure patients undergoing haemodialysis treatment. This chapter 
highlights the nonadherence prevalence pattern and a number of patient-related, 
disease-related, and medication-related factors contributing to medication 
nonadherence in patients undergoing haemodialysis. 
 Chapter 3, describes the findings of an exploratory study that investigated 
medication regimen complexity, perceived burden of medicines, and health-related 
quality of life, as potential predictors of adherence. Fifty-three adult (≥ 18 years) 
patients undergoing haemodialysis from the outpatient haemodialysis centre at the 
Royal Hobart Hospital (RHH), Hobart, Australia, participated in this study. The findings 
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of this exploratory study suggest that older patients with higher levels of comorbidities 
and highly complex regimen are more likely to be adherent based on an objective 
measure of assessment. This study emphasised that dialysis care professionals 
should be more vigilant towards supporting younger patients during their early 
adjustment to haemodialysis treatment. 
 Chapter 4, reports on findings from the qualitative study that explored 
determinants of medication adherence and examined the differential perspectives on 
medication-taking behaviour shown by adherent and nonadherent patients undergoing 
haemodialysis. Thirty patients, who had earlier participated in an exploratory study 
described in Chapter 3, completed this qualitative study. The qualitative themes 
generated comprised of patient-related (knowledge, awareness, attitude, self-efficacy, 
action control, and facilitation); health system/healthcare team-related (quality of 
interaction, and mistrust and collateral arrangements); therapy-related (physical 
characteristics of medicines, packaging, and side effects); condition-related (symptom 
severity); and social/economic factors (access to medicines, and relative affordability).  
 Chapters 5 and 6 describe the findings from a cross-sectional survey of renal 
healthcare professionals regarding their perceptions, current practices, and barriers to 
assessing medication adherence in patients undergoing dialysis. Chapter 5 
particularly focuses on renal pharmacists’ perceptions, whereas chapter 6 deals with 
the renal nurses’ perceptions. A total of 113 renal nurses and 41 specialist renal 
pharmacists across Australia, participated in this study. The survey findings 
highlighted the fact that dialysis centres routinely rely on objective measure of 
adherence assessment, such as blood results, to detect nonadherence issues with 
little to no attention being paid to patient engagement via self-reported measures. Also, 
owing to the lack of dedicated healthcare professionals, the survey participants 
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emphasised on the importance of having a dedicated renal pharmacist in dialysis 
centres to facilitate assessment and promotion of medication adherence in patients 
undergoing dialysis treatment. 
Chapter 7, describes the outcomes of the qualitative study conducted in renal 
healthcare professionals that identified perceived barriers to assessing adherence and 
strategies to improve adherence assessment practices in dialysis settings. Eighteen 
renal professionals, including 6 renal pharmacists and 12 renal nurses, who had earlier 
participated in the cross-sectional survey, described in Chapters 5 and 6, completed 
this qualitative study. A number of organisational-related, professional-related, and 
patient-related barriers to assessing adherence were identified. Similarly, participants 
proposed a variety of ways by which adherence assessment practices could be 
improved. These included: formalisation of assessment process; integration of 
assessment process and tools into routine; and using multidisciplinary support.  
Chapter 8, discusses the findings from all the quantitative and qualitative 
studies reported in earlier chapters. It provides recommendations and future research 
directions related to adherence assessment practices designed to improve medication 
adherence in patients undergoing dialysis therapy. Figure 1 illustrates the overall 
structure of this thesis.  
 
 
 
 
 
 
 
Figure 1. Structure of the thesis 
 
 
CHAPTER ONE 
 
1. INTRODUCTION 
 
1.1. Background  
“Keep a watch…on the faults of the patients, which often make them lie about the taking of 
things prescribed. For through not taking disagreeable drinks, purgative or other, they 
sometimes die.” 
- Hippocrates of Kos, Decorum 
(460-370 BC) 
After more than 2,000 years, the above admonitions from the “father of medicine” are 
still relevant. Over half the time patients with chronic conditions do not take their 
medicines as prescribed [1], and an estimated 125,000 Americans die each year due 
to nonadherence [2]. Due to increasingly complicated medication regimens for patients 
with chronic illness, the situation is likely to worsen, unless healthcare professionals 
strive to promote adherence with their patients [1].  
  Developing a new efficacious medication requires significant time, money and 
resources. An estimated $2.6 billion is spent on developing a new drug molecule for 
therapeutic use [2], whereas the avoidable annual opportunity cost lost due to 
adherence failure is around $105 billion [3]. Despite an increasingly echoed slogan of 
patient first, the practice of medicine is mainly focused on selecting the best treatment 
for their patients while placing a much lesser emphasis on engaging them to achieve 
optimum adherence to the selected regimen. It seems like the current clinical practices 
have become oblivious to the fine thread called “adherence” that lies between the 
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“treatment” and the “outcomes” [1]. Despite the fact that various direct and indirect 
methods have been routinely used to assess patient adherence, such as monitoring 
symptoms and clinical response of therapy, measuring biological markers, and, drug 
and metabolite levels in the blood [2], information generated from such assessments 
often ends up as ‘another observation’ in patients’ medical records. A standardised 
adherence assessment protocol that actually aims at recognising the medication-
taking behaviour in patients with long-term therapy during their treatment process has 
been a missed opportunity in routine clinical settings. Effective regimens may be 
arbitrated as ineffective, dosage may be dangerously intensified, unnecessary 
diagnostic procedures may be ordered, and burden of healthcare cost may rise simply 
because of not recognising adherence as an issue during treatment process [4].  
The former US surgeon general, Dr Charles E. Koop has plainly said, “drugs 
don’t work in patients who don’t take them” [2]. The profundity of this statement is a 
gentle reminder to the medical community that unless we monitor this fine thread of 
adherence as part of the treatment process, desirable outcomes may not always be 
achieved. Medication nonadherence in patients can lead to treatment failure, 
unnecessary additional treatments, exacerbation of disease, frequent hospitalisations, 
increased resource utilisation, patient frustration, increased morbidity, and, in rare 
cases, even death [1, 2, 5, 6]. Thus, medication adherence must receive greater 
attention in clinical practice, and should be considered a subject of exploratory and 
translational studies in order to mitigate or eliminate a major obstacle such as 
nonadherence to achieve better health outcomes.  
Medication adherence becomes a challenging endeavour particularly in 
patients undergoing life-long therapies such as organ transplants, co-existing multiple 
comorbidities like diabetes and cardiovascular disorders, and end-stage kidney 
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disease (ESKD) patients undergoing dialysis [7]. In addition to their primary treatment 
regimen of dialysis, the ESKD patients often have multiple comorbidities such as 
diabetes, hypertension, anaemia, mineral and bone disorders, hyperlipidemia, and 
cardiovascular diseases [8]. Together with such comorbidities and complications 
associated with dialysis, ESKD patients require an average of 10-12 medications daily. 
Past findings suggests an overwhelmingly high median pill burden of 19 per day, with 
one quarter of dialysis patients exceeding 25 pills per day [9]. Increased pill burden is 
significantly associated with medication nonadherence in dialysis patients [9]. 
Compared to other chronic conditions like cardiovascular disease or HIV, 
nonadherence is highly prevalent in ESKD patients undergoing dialysis therapy [10], 
with nonadherence to phosphate binding medications alone ranging between 22.0% 
and 74.0% [11]. Suboptimal adherence in dialysis patients has led to increased 
morbidity and mortality, higher medication use, and repeat admissions leading to 
unwanted treatments, and higher cost burden [10]. Patients’ medication-taking 
behaviour can be highly complex and individualistic in nature, and nonadherence as 
such might only be the tip of the iceberg with underlying multifaceted motives hidden 
behind. There is a gap in our understanding as to what factors contribute to medication 
nonadherence in ESKD patients undergoing dialysis and how adherence is measured 
during routine dialysis care. Understanding determinants of adherence in patients 
undergoing dialysis and the current practices of measuring adherence in dialysis 
settings may help in designing tailored interventions to resolve this significant issue.  
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1.2. Aims and Objectives  
 
Aims 
The overall aims of this research were to determine potential predictors of medication 
nonadherence in patients undergoing haemodialysis, explore current practices and 
barriers to assessing adherence, and identify strategies to improve adherence 
assessment practices in routine dialysis care.  
 
Objectives 
The specific research objectives were to: 
• summarise existing literature on medication nonadherence and identify factors 
associated with medication nonadherence in patients undergoing 
haemodialysis;  
• investigate prevalence patterns, socio-demographic, clinical and psychosocial 
factors contributing to medication nonadherence in Australian haemodialysis 
patients, and  
• identify current practices of assessing medication adherence by the renal 
healthcare professionals, barriers to assessment, and strategies to improve 
adherence assessment practices in Australian dialysis centres.    
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1.3. Methodology 
To achieve the research aims a number of related studies were conducted applying 
various study designs. For summarising the existing literature on medication 
nonadherence in patients undergoing haemodialysis, a systematic review approach 
was used. The conduct and reporting of this systematic review followed the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline [12].  
Following this, a mixed-method explanatory sequential design study [13] was 
used for achieving other specific research objectives. In explanatory sequential design, 
the quantitative data are collected first, which is then followed by the generation of 
qualitative data to help explain or elaborate on the findings from quantitative results. 
The rationale behind this approach is that the quantitative analysis offers a general 
understanding of the research problem, whereas the qualitative data enriches the 
research findings by exploring participants’ perspectives in an in-depth manner [13]. 
Besides systematic review, this research was operationalised in two phases 
whereby in first phase a quantitative study of patients undergoing dialysis was 
conducted to determine predictors of adherence followed by the qualitative exploration 
of patients that identified socio-demographic, clinical and psychosocial factors 
associated with medication nonadherence. In the second phase of the research, renal 
healthcare professionals including renal nurses and pharmacists were surveyed to 
understand current practices of assessing medication adherence in patients 
undergoing dialysis. This was followed by qualitative investigation to identify barriers 
of measuring adherence and finding ways by which adherence measurement 
practices could be improve in dialysis settings (Figure 2).  
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Figure 2. Research methodology 
 
The conduct and reporting of quantitative survey followed the STROBE 
(Strengthening the Reporting of Observational Studies in Epidemiology) guideline [14], 
whereas the COREQ (Consolidated Criteria for Reporting Qualitative Research) 
guideline was utilised during the conduct of qualitative research [15].  
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1.4. Literature Review 
1.4.1. Terminologies Used to Define Adherence  
Adherence to medication therapy, in general, is defined as the extent to which patients 
take their medications as prescribed by their healthcare providers [2]. The World 
Health Organisation (WHO) defines adherence to long-term therapy as “the extent to 
which a person’s behaviour taking medication, following a diet, and or executing 
lifestyle changes, corresponds with the agreed recommendations of a healthcare 
provider” [16, 17]. The terms “adherence”, “compliance”, and “concordance” are often 
used interchangeably. These enact different interpretations with respect to the 
healthcare provider-patient relationship, however.  
The term “compliance” implies that a patient is passively following the 
prescriber’s instructions, and reflects a paternalistic attitude [1, 2, 6]. This has led to 
the term being criticised for its negative connotations of the patient-provider 
relationship. On the other hand, the term “concordance”, coined by the Royal 
Pharmaceutical Society of Great Britain in 1997 [18], intends to eliminate the 
implications of patient obedience by reaching a therapeutic alliance between a patient 
and a healthcare professional [19]. As healthcare services have adopted a more 
patient-focused approach to treatment, the term “adherence” is preferred by many 
healthcare professionals because it signifies that the treatment is based on a 
therapeutic alliance or an agreement established between patients and providers 
where the patient is playing an active role [2]. 
 Medication adherence and nonadherence have been conceptualised in terms 
of either primary or secondary (non) adherence [20], or in terms of intentional and 
unintentional (non) adherence [17, 20, 21]. Primary nonadherence to medication refers 
to the act of never filling a prescription, whereas secondary nonadherence refers to 
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filling a prescription, but not taking the medication as prescribed [22]. The vast majority 
of the adherence research has focused on understanding secondary nonadherence 
behaviour in patients.  In contrast, intentional nonadherence occurs when patients 
choose to ignore treatment recommendations by delaying, altering, or missing the 
dosage of their prescribed medicines [17, 23, 24]. Unintentional nonadherence, 
however, occurs due to a patient’s lack of understanding, forgetfulness, or 
miscommunication with healthcare providers [17, 23, 25].  
 Vrijens et al. defined a new taxonomy of adherence by considering the process 
of medication-taking behaviour in patients [26]. The medication adherence process 
constitutes four different components: initiation, implementation, discontinuation, and 
persistence (Figure 3). Initiation is the start of the process, where patients take their 
first dose of the prescribed regimen. This is followed by implementation, which is the 
extent to which a patient’s actual dosing corresponds to the prescribed dosing regimen 
from initiation until the last dose taken by the patient. Discontinuation refers to the end 
of therapy, and is when the next dose to be taken is omitted or no more doses are 
taken afterwards. Persistence is the window between initiation and the last dose taken, 
and occurs immediately before discontinuation.  
Based on this taxonomy, nonadherence can occur in different situations, such 
as late or non-initiation of the prescribed treatment, suboptimal implementation of the 
medication regimen, or early discontinuation of the treatment [26].   
 
9 
 
 
Figure 3. Illustration of the process of adherence to medications   
(Source: Vrijens et al. Br J Clin Pharmacol. 2012; 73(5): 691-705. Reproduced with permission from 
John Wiley and Sons, Inc.) 
 
1.4.2. Methods of Measuring Adherence  
Measuring medication adherence is a challenging endeavour. Adherence outcomes 
may vary depending upon the methods used to assess adherence [11]. Although there 
is no “gold standard” method available for assessing adherence in clinical settings [2], 
a variety of approaches have been used that can be broadly classified into two types: 
objective and subjective measures [1, 23].  
Objective measures can be either direct or indirect, as classified by Osterberg 
et al [2]. Direct methods comprise directly observed therapy, and the monitoring of 
blood levels for medicines, metabolites, or biological markers (Table 1). It should be 
noted, however, that variations in drug absorption and metabolism, a patient’s 
tendency to hide drugs in their mouths and discard them, and the practicality of use in 
routine measurement, may limit the suitability of direct methods for assessing 
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adherence [27]. Nevertheless, use of direct methods is common in research related to 
high-risk medications, or when finances, invasiveness, and resource utilisation 
outweigh the public health demands to address global healthcare crises, such as 
tuberculosis treatment with DOTS (directly observed treatment, short-course) [28, 29]. 
Indirect objective methods comprise counting pills, measuring prescription refill rates, 
electronic monitoring, observing patients’ clinical responses, and physical 
assessments [2]. Each of these methods have their own strengths and limitations 
regarding the measuring of medication adherence, as shown in Table 1, and their 
utilisation may depend upon data availability and the clinical setting involved. 
 Subjective measures of assessing adherence mainly involve asking patients, 
their families or caregivers, and health professionals about medication [1]. Subjective 
assessment can be performed either through patient interviews, or by using validated 
questionnaires [30]. In clinical settings, subjective measures are more popular among 
healthcare professionals as they provide real-time feedback, and are simple and 
economical to use [31]. Also, due to their practicality and flexibility, subjective 
measures are capable of identifying patient concerns related to their medication-taking 
behaviour, and can facilitate tailored interventions to resolve adherence issues [30].  
Nevertheless, subjective adherence assessment is also prone to recall bias and 
social desirability responses, which involves reporting overly optimistic estimations of 
medication-taking behaviour by the patients to their healthcare professionals [27, 32]. 
As adherence measures differ in their definitions and assessment methods, using a 
combination of subjective and objective methods can be effective in detecting actual 
nonadherence behaviour in patients [33]. A summary of the methods of measuring 
medication adherence is depicted in Table 1.  
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Table 1. Methods of measuring medication adherence 
Method Advantages Disadvantages 
Objective measures   
Direct methods 
 
  
Direct observation of 
medication therapy 
 
Most accurate Routine use can be impractical 
 
Measuring blood levels for 
medicine or metabolite 
Objective Expensive, may give false impression 
due to variations in metabolism and 
influenced by “white coat adherence” 
 
Tracing biological marker in 
blood 
Objective; placebos can be 
measured in clinical trials 
Biological assays can be expensive 
and requires collection of bodily fluids 
 
Indirect methods 
 
  
Pill counts Objective, easy to 
implement and, quantifiable 
Data alteration due to pill dumping, 
time consuming 
 
Prescription refill Objective and easy to 
obtain data 
Ingestion of medicine cannot be 
guaranteed and requires closed 
pharmacy system for assessment 
 
Electronic monitoring Patterns of medication-
taking behaviour can be 
easily tracked 
Expensive and requires return visits 
for downloading medication vials data 
Physical assessment (e.g., 
blood pressure, heart rate) 
Easy to perform Altered response due to poor 
absorption of drugs, increased 
metabolism, or lack of response 
 
Clinical response of patient Easy to perform Clinical responses may be altered by 
other factors besides medicine 
 
Subjective measures 
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Method Advantages Disadvantages 
Asking patients, family, 
caregiver, or professionals; 
use of validated 
questionnaires (e.g., 
MGLT-4, MMAS-8), and 
self-reports 
Simple, inexpensive, and 
widely used in routine 
clinical practices 
Susceptible for social desirability 
response and recall error due to time 
lag between clinic appointments 
Patient diaries Poor recall can be avoided Patient can easily manipulate 
 
Source: Osterberg and Blaschke. N Engl J Med 2005; 353:487-497. Abbreviations: MGLT, Morisky 
Green Levine Test; MMAS, Morisky Medication Adherence Scale 
 
1.4.3. Magnitude of the Problem of Medication Nonadherence 
According to the WHO, the incidence of medication adherence in chronic diseases in 
developed nations is estimated at only 50% [16]. The magnitude and consequence of 
suboptimal adherence in developing nations is projected to be much higher due to the 
limitation of health resources, and disparity in access to healthcare services [16]. 
Compared to acute illness, medication nonadherence rates in chronic conditions is 
remarkably higher [2], and persistence with long-term medications rapidly declines 
after the first few months of medication therapy [2, 34, 35], even if the patient has 
experienced a major cardiovascular event, such as a stroke (Figure 4). 
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Figure 4. Persistence with secondary prevention medication over 24 months after 
ischemic stroke  
(Source: Glader et al. Stroke. 2010;41(2):397-401. Reproduced with permission from Wolters Kluwer 
Health, Inc.)  
 
The rate of medication nonadherence varies across populations, disease 
conditions, and the types of medications being assessed [27, 36]. The summary of 
nonadherence rates for different chronic conditions is illustrated in Table 2.  
  
14 
 
Table 2. Prevalence rates of medication nonadherence in chronic diseases 
Conditions Prevalence rates 
(%) 
References 
Respiratory   
Asthma 30.0 – 70.0%  [37, 38] 
Chronic obstructive pulmonary disease 
(COPD) 
60.0 – 90.0%  [39] 
Musculoskeletal   
Osteoarthritis 33.0 – 44.0%  [40, 41] 
Osteoporosis 30.0 – 60.0%  [42, 43] 
Rheumatoid arthritis 20.0 – 70.0% [44] 
Mental disorders   
Schizophrenia 5.0 – 52.8%  [45] 
Depression 13.0 – 55.7% [46] 
Gastrointestinal and metabolic disorders   
Diabetes Mellitus  6.9 – 61.5%  [47] 
Inflammatory bowel disease (IBD) 43.0 – 72.0% [48, 49] 
Cardiovascular   
Heart failure 2.0 – 90.0% [50] 
Hypertension 43.0 – 65.5% [51] 
High cholesterol 8.0 – 82.0% [52] 
Infectious disease   
Tuberculosis 20.0 – 50.0% [53, 54] 
HIV/AIDS 55.0 – 77.0% [55, 56] 
Skin disease   
Psoriasis 33.4 – 78.4%  [57] 
Genitourinary   
Chronic kidney disease (CKD) 22.0 – 74.0% [11] 
Patients on Haemodialysis  12.5 – 98.6%  [23] 
Patients on Peritoneal dialysis  3.9 – 43.0%  [25] 
Cancer   
Adults on oral antineoplastic agents 0.0 – 84.0% [58, 59] 
 
 
1.4.4. Consequences of Medication Nonadherence 
Medication nonadherence can adversely affect the health outcomes of patients, 
leading to an increase in healthcare costs due to higher utilisation of medical resources, 
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unanticipated additional treatments, frequent hospitalisation, and emergency 
department visits. Nonadherence may also result in treatment failure, and ultimately 
the death of the patient. More than 10% of hospital admissions [60], and over 20% of 
preventable adverse drug events in elderly outpatients have been attributed to 
medication nonadherence [61]. Between 33% and 69% of all medication-related 
hospitalisation in the United States is linked with suboptimal adherence [2], incurring 
an annual healthcare expenditure of around $100 billion [2, 60]. 
 Adherence failure has been associated with mortality in paediatric patients with 
asthma, with death rates up to five times higher in African-American children 
compared to their Caucasian counterparts [62, 63]. It may also result in drug 
resistance and re-emergence of highly contagious infections, such as tuberculosis, 
and cause serious threats to public health [64]. Similarly, nonadherence to 
antiretroviral therapy has been associated with increased viral load in patients with 
HIV/AIDS [65].  
Another important aspect of nonadherence is the under-recognition of this issue, 
which can negatively influence medical decisions. For example, clinicians may 
attribute poor glycaemic control following nonadherence to therapeutic ineffectiveness, 
and increase the dosages of current medications or add new medications to the 
regimen. This may result in potentially adverse consequences, such as hypoglycaemia 
[66]. The consequences of medication nonadherence in chronic illnesses is 
summarised in Table 3.   
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Table 3. Complications resulting from medication nonadherence 
Conditions Consequences of nonadherence 
Respiratory  
Asthma Mortality in children [63] 
COPD  Severe exacerbations, repeat admissions and 
emergency department visits [67] 
Musculoskeletal  
Osteoporosis Bone-related fractures [68] 
Rheumatoid arthritis Increased disease activity [69] 
Mental disorders  
Schizophrenia Relapse and repeat psychiatric admission [70, 71] 
Depression Emergence of depressive symptoms and medication 
inefficacy [72] 
Gastrointestinal and metabolic 
disorders 
 
Diabetes  High blood pressure and altered lipid metabolism [73, 
74], Stroke [27] 
IBD Systemic relapse and risk of colorectal cancer [75] 
Cardiovascular  
High cholesterol  Acute myocardial infarction [76] 
Hypertension  Acute myocardial infarction [76] 
Congestive heart failure 
 
Additional inpatient, outpatient, emergency room and 
pharmacy utilisation [77] 
Infectious disease  
Tuberculosis Drug resistance and disease re-emergence [64, 78] 
HIV/AIDS Higher viral load [79, 80] 
  
Organ transplantation Transplant failure [81, 82], decreased quality of life [83] 
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1.4.5. Economic Implications of Nonadherence 
The true cost of nonadherence and its impact on health is often underestimated. The 
existing literature mainly examines the direct healthcare costs of nonadherence, which 
are often expressed as hospitalisation costs [84, 85] and hospital-related costs [86]. 
This does not consider the indirect costs of nonadherence, however, such as 
productivity and disability costs incurred by the patient and society [28]. The health-
related indirect costs are estimated to be 2.3 times higher than the direct healthcare 
costs of nonadherence [87]. The relationship between nonadherence and associated 
healthcare costs is illustrated in Figure 5. 
 
  
 
 
 
 
 
 
 
 
 
(Source: Luga and McGuire. Risk Manag Health Policy. 2014; 7: 35-44. Reproduced with permission 
from Dove Medical Press) 
Figure 5. Relationship between nonadherence and associated healthcare costs 
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Suboptimal adherence to medication therapy results in poor health outcomes 
in patients, escalating healthcare service utilisation and overall healthcare costs. 
Although this may not be true for all healthcare systems, the increased expenditure is 
passed over to the patients through higher co-payments, or through higher costs to 
employers for coverage. With the increase in patient cost sharing beyond a threshold 
impedes medication adherence (Figure 5) [28]. The avoidable direct healthcare costs 
caused by medication nonadherence in the United States is estimated at $105 billion 
a year (Figure 6) [3].  
 
 
(Source: Avoidable Costs in U.S. Healthcare: The $200 Billion Opportunity from Using Medicines More 
Responsibly. Report by the IMS Institute for Healthcare Informatics. June 2013) 
 
The economic implications of nonadherence have been investigated in relation 
to various chronic illnesses, such as cardiovascular disease [27, 76, 88-91], 
respiratory [92-96], gastrointestinal and metabolic disorders [86, 97-101], infectious 
Figure 6. Avoidable cost of nonadherence to medication 
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diseases [102-104], psychiatric illnesses [105-107], and others [2, 5, 96, 108]. In a 
study conducted with congestive heart failure patients, the total healthcare costs 
reduced by 23% annually in adherent patients compared to nonadherent ones [88]. In 
another study looking at heart failure and myocardial infarction patients, adherence 
and persistence with angiotensin receptor blockers and angiotensin converting 
enzyme inhibitors resulted in a lower risk of repeat admission, and reduced healthcare 
costs [89].  
A strong associations between healthcare costs and adherence to statin 
therapy has also been reported [90, 91]. In patients with chronic obstructive pulmonary 
disease (COPD), adherence as assessed using the proportion of days covered (PDC) 
was strongly associated with decreased emergency department visits and 
readmission, leading to a nearly 3% reduction in overall healthcare costs among the 
adherent patients [92]. Similarly, adherence to the maintenance medication therapy 
by COPD patients has been significantly associated with reduced Medicare 
expenditures, and a lower risk of repeat admissions [94].  
Unlike COPD, patients with asthma only demonstrate improved healthcare 
costs if they are in high-risk cohorts with a history of repeat admissions [95, 96]. This 
suggests that cost savings may be achieved for patients with severe illnesses through 
adherence to their prescribed regimens [28, 95, 96]. In contrast, adherence to 
antiretroviral treatment in patients with HIV/AIDS has shown mixed results, with some 
studies reporting a positive correlation between adherence and decreased healthcare 
utilisation and associated costs [102], and some reporting no significant cost variances 
[103, 104].  
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Numerous studies have also been conducted to investigate the association 
between adherence and the cost of diabetes, with the vast majority showing cost 
reduction with increased adherence to antidiabetic medications [86, 97-101]. On the 
other hand, healthcare cost research looking at other chronic illness, such as 
depression, musculoskeletal conditions, neurologic disorders, and some 
gastrointestinal and metabolic diseases, has shown variable associations with 
adherence [2, 5, 96, 105-108]. 
 
1.4.6. Determinants of Poor Medication Adherence  
Suboptimal adherence to medication therapy can severely compromise health 
outcomes in patients. Understanding the determinants of poor medication adherence 
can be helpful in designing tailored interventions to tackle nonadherence issues. An 
extensive body of literature has identified the determinants of poor adherence in 
chronic diseases, and these factors can be broadly summarised into patient-related, 
provider-related, and external factors [2, 28, 109], as shown in Figure 7. 
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Figure 7. Selected determinants of medication adherence 
(Source: Luga and McGuire. Risk Manag Health Policy. 2014; 7: 35-44. Reproduced with permission 
from Dove Medical Press) 
The WHO has classified the determinants of medication adherence into five 
broad categories: patient-, condition-, therapy-, socioeconomic-, and health system-
related factors [16, 27], as depicted in Figure 8. Medication adherence research has 
mainly focused on exploring patient-related dimensions, rather than on understanding 
other aspects of the healthcare system that may contribute to nonadherence 
behaviour in patients with chronic illnesses [110, 111]. The determinants of medication 
adherence in haemodialysis patients is discussed in detail in Chapters 3-5.  
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Figure 8. Five interacting dimensions affecting medication adherence 
(Source: Sabaté E. Adherence to long-term therapies- evidence for action. Geneva, Switzerland: World 
Health Organisation. 2003; NEJM Catalyst, catalyst.nejm.org © Massachusetts Medical Society) 
 
 
1.4.7. Strategies Used to Improve Poor Medication Adherence  
Interventions to improve medication adherence have been more successful with 
patients with acute conditions compared to patients with chronic diseases. According 
to a Cochrane review, less than 45% of the interventions reported in 70 randomised 
controlled trials were actually associated with improved adherence with long-term 
therapies, and out of that only around 30% led to improved treatment outcomes [112]. 
This shortfall is mainly attributed to the focus of the interventions being unidimensional 
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and patient-centric [16]. The success of the intervention may depend on exploring and 
identifying the issues associated with all five of the WHO dimensions [16].  
 Demonceau et al. have classified the adherence intervention components into 
eight different types [113]: (1) Treatment simplification, which involves simplifying the 
dosage schedule (e.g. qd vs bid) or changing the dosage formulations (e.g. liquid to 
tablets). (2) Cognitive–educational, which presents information individually or in a 
group setting, and delivers it verbally, in written form, and/or audio-visually. This is 
designed to educate and motivate patients to make informed decisions about their 
therapy. (3) Behavioural–counselling, which shapes or reinforces behaviour, and 
empower patients towards self-management. (4) Social–psycho-affective, which 
focuses on providing psychosocial support to facilitate behaviour change. (5) 
Electronically monitored adherence feedback, which is designed to provide feedback 
on dosing histories through electronic medication-event monitoring. (6) Technical 
reminders, such as electronic and communication devices to remind patients to take 
their medicines. (7) Technical equipment for monitoring disease management, e.g. 
blood pressure measurements. (8) Rewards such as cash reinforcements, etc. A 
summary of the interventions used to improve medication adherence in patients with 
chronic diseases is presented in Table 4. 
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 Table 4. Intervention used to improve medication adherence in chronic diseases 
Condition Intervention type Description Effect on 
clinical 
outcomes 
Hypertension Cognitive-educational In-person and telephone follow-up 
educational sessions 
 
Effective [114] 
 Treatment simplification Simplifying medication regimen, 
once daily vs twice daily 
 
Ineffective 
[115] 
 Treatment simplification, 
Cognitive-educational, 
and Use of technical 
equipment 
 
Blood pressure monitoring at home, 
education on side-effects, and 
telephone follow-up 
Effective [116] 
High cholesterol Cognitive-educational, 
Electronic monitoring-
feedback, and Use of 
technical reminders 
Providing information on disease, 
risk factors and dietary 
requirements, Electronic 
medication-event monitoring, and 
using beep-card reminder 
 
Not Available 
[117] 
Heart failure Cognitive-educational, 
and Behavioural 
counselling 
 
Providing education and written 
instructions on medication use 
Ineffective 
[118] 
 Treatment simplification  Simplifying medication regimen, 
once daily vs twice daily 
 
Ineffective 
[119] 
Diabetes Cognitive-educational, 
and Behavioural 
counselling 
 
4- weeks in-person and telephone 
follow-up educational sessions 
Effective [120] 
 Treatment simplification  Simplifying medication regimen, 
once daily vs twice daily 
 
Effective [121] 
Asthma Rewards Metered dose inhaler spacer with 
incentive toy in paediatrics 
 
Ineffective 
[122] 
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Condition Intervention type Description Effect on 
clinical 
outcomes 
 Behavioural counselling Providing written action plan for 
asthma attack and discharge 
instructions after acute-care visit 
 
Effective [123] 
HIV/AIDS Behavioural counselling, 
Social-psycho-affective 
intervention, and 
Technical reminder use 
Peer support, scheduled social 
gatherings, telephone calls to 
participants by their peers, and 
pager support 
 
Ineffective 
[124] 
 Cognitive-educational, 
Behavioural counselling, 
and Electronic 
monitoring-feedback 
Providing tailored adherence 
information, goal setting, feedback 
on adherence to estimate progress 
towards goal, self-monitoring  
 
Effective [125] 
 Treatment simplification  Simplifying medication regimen, 
once daily vs twice daily 
 
Ineffective 
[126] 
Depression Cognitive-educational, 
and Behavioural 
counselling 
 
Coaching sessions and adherence 
promotional videos 
Ineffective 
[127] 
 Behavioural counselling, 
and Electronic 
monitoring-feedback 
 
Counselling support and electronic 
monitoring-feedback 
Ineffective 
[128] 
Osteoporosis Behavioural counselling, 
and Technical 
equipment 
Interviewing, nurse monitoring, and 
monitoring biological marker and 
feedback 
 
Not Available 
[129] 
 Behavioural counselling, 
and Technical 
equipment 
Monitoring biological marker and 
feedback, and counselling on 
reminders by linking patient’s daily 
habits with taking medicines 
 
Not Available 
[130] 
Kidney 
transplantation 
Treatment simplification  Simplifying medication regimen, 
once daily vs twice daily 
Effective [131] 
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1.4.8. Medication Nonadherence in Chronic Kidney Disease  
Chronic Kidney Disease (CKD) is defined by the National Kidney Foundation (NKF) 
Kidney Disease Outcomes Quality Initiative (KDOQI) as the presence of kidney 
damage or decreased kidney function (an estimated glomerular filtration rate, eGFR, 
of <60 mL/min per 1.73 m2) for a period of three months or more [132]. Whereas end-
stage kidney disease (ESKD) is characterised by chronic kidney failure with eGFR <15 
mL/min per 1.73 m2, necessitating renal replacement therapy (RRT) in the form of 
either dialysis or transplantation. CKD often co-exists with other chronic conditions, 
such as diabetes and hypertension, and CKD patients prior to undergoing RRT have 
a daily pill burden of 6-8 medications. If the disease progresses into ESKD, however, 
the average pill burden increases to 12 medications per day [133].  
As anticipated, high pill burden imposes increased personal and financial 
burdens on patients, leading to an inevitable problem of medication nonadherence. An 
estimated 26-28% of patients with CKD who are not on dialysis are nonadherent to 
their medication therapy [134]. The rate of nonadherence is overwhelmingly high in 
ESKD patients undergoing dialysis treatment, and ranges between 22% and 74% (with 
an average of 51%) [11]. Poor medication adherence in patients with CKD has led to 
uncontrolled hypertension, disease progression into dialysis, increased medication 
use, and repeat admissions leading to unwanted treatment and increased financial 
burden [8]. The detrimental effects of medication nonadherence in CKD is of grave 
concern as it can negatively impact the quality of patients’ lives. It is imperative that 
healthcare professionals remain aware of the factors contributing to medication 
nonadherence behaviour, particularly in patients taking long-term medications, e.g. 
CKD and ESKD patients undergoing dialysis treatment. Chapter 2 discusses the issues 
surrounding medication nonadherence in patients undergoing haemodialysis in detail.  
 
 
CHAPTER TWO 
 
2. NONADHERENCE TO MEDICATION THERAPY IN HAEMODIALYSIS 
PATIENTS: A SYSTEMATIC REVIEW  
 
2.1. Abstract 
Background: Patients with end-stage kidney disease (ESKD) are often prescribed 
multiple medications. Together with a demanding weekly schedule of dialysis sessions, 
an increased number of medicines and associated regimen complexity, these patients 
are predisposed to a high risk of medication nonadherence. This review summarises 
existing literature on nonadherence and identifies factors associated with 
nonadherence to medication therapy in patients undergoing haemodialysis. 
Methods: A comprehensive search of PubMed, Embase, CINAHL, PsycInfo, and the 
Cochrane Database of Systematic Reviews covering the period from 1970 through to 
November 2014 was performed, following pre-defined inclusion and exclusion criteria. 
Reference lists from relevant materials were reviewed. Data on study characteristics, 
measures of nonadherence, prevalence rates and factors associated with 
nonadherence were collected. The Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) guidelines was followed in conducting this systematic 
review.  
Results: Of 920 relevant publications, 44 were included. The prevalence of 
medication nonadherence varied from 12.5% to 98.6%, with widespread heterogeneity 
in measures and definitions employed. Most common patient-related factors 
significantly associated with nonadherence were a younger age, non-Caucasian 
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ethnicity, illness interfering with family life, being a smoker, and being single, divorced 
or widowed. Similarly, disease-related factors include longevity of haemodialysis, 
recurrent hospitalisation, depressive symptoms and having concomitant illness like 
diabetes and hypertension. Medication-related factors such as the daily tablet count, 
the total pill burden, the number of phosphate binders prescribed and the complexity 
of the medication regimen were also associated with poor adherence. 
Conclusions: A number of patient-, disease-, and medication-related factors are 
associated with medication nonadherence in patients undergoing haemodialysis. 
Clinicians should be aware of such factors so that adherence to medications can be 
optimised in patients undergoing haemodialysis. Future research should be directed 
towards well-designed prospective longitudinal studies developing standard 
definitions and validating available measurement tools, while focusing on the role of 
additional factors, such as psychosocial and behavioural factors, in predicting 
nonadherence to medications. 
 
Keywords: Adherence; end-stage kidney disease; haemodialysis; medication 
regimen complexity 
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2.2 Introduction 
End-stage kidney disease (ESKD) is one of the leading causes of mortality with over 
one million people dying worldwide every year [135]. The incidence of ESKD is 
increasing globally, at an estimated annual rate of 7% [136]. Despite recent advances 
in the management of ESKD, the cardiovascular and non-cardiovascular mortality risk 
in patients undergoing haemodialysis is eight times greater than for people in the 
general population [137, 138]. 
The progression of chronic kidney disease to ESKD is often associated with 
additional comorbidities such as diabetes and cardiovascular diseases [8]. Patients 
with ESKD are at high risk of developing imbalances in calcium and phosphate 
haemostasis, anaemia, hyperlipidaemia, and secondary hyperparathyroidism [139]. 
Consequently, patients on haemodialysis often require an average of 10-12 regular 
medications including, but not limited to, phosphate binders, vitamin D preparations, 
calcimimetics, antihypertensives, antidiabetics, erythropoiesis-stimulating agents and 
iron supplements [140, 141]. The resultant complexity of the medication regimen in 
patients with ESKD predisposes them to a high risk of adverse drug events and 
subsequent nonadherence [140].  
Medication nonadherence can be intentional or unintentional. Intentional 
nonadherence may occur when patients choose to ignore treatment recommendations 
by delaying, altering or missing the dosage of prescribed medicines [24]. Unintentional 
nonadherence, on the other hand, is due to a patient’s lack of understanding, 
forgetfulness or miscommunication with healthcare providers [25]. Regardless of 
being intentional or unintentional, medication nonadherence prevents patients from 
gaining the full benefit of the prescribed medications. Furthermore, medication 
nonadherence in patients with ESKD has been associated with increased mortality 
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and hospitalisations [142, 143]. Thus, adherence to medication therapy is a key 
component of the effective management of patients with ESKD [142-145].  
To date, there are few review articles addressing specific issues on identifying 
predictors and determinants of nonadherence to medication therapy in patients 
undergoing haemodialysis [6, 10, 11, 146, 147]. Existing literature is limited to non-
systematic reviews examining nonadherence to dialysis treatment as a whole by 
including medication, dialysis attendance, and diet and fluid restrictions [17, 143, 148, 
149]. It has been observed that about 50% of patients with chronic conditions are 
nonadherent to medication therapy [150], and the estimates of nonadherence to oral 
medications in patients undergoing haemodialysis ranged from 3 to 80% [147]. A 
review that specifically focussed on phosphate binder medication in patients 
undergoing haemodialysis reported rates of nonadherence ranging between 22 and 
74% [11]. This wide variation in the reported rates of nonadherence was attributed 
partly due to the heterogeneity of definition and the methodology of assessing 
nonadherence in the studies.  
 
The aims of this systematic review were: 
1. to identify various methods used to assess nonadherence in patients 
undergoing haemodialysis;  
2. to summarise current literature on nonadherence and estimate the prevalence 
of medication nonadherence in patients undergoing haemodialysis, and  
3. to describe patient-, disease-, and medication-related factors associated with 
nonadherence in patients undergoing haemodialysis.  
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2.3. Methods 
 
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
guidelines were followed in conducting this systematic review [12]. The PRISMA 
checklist is supplied as Appendix 1. 
 
2.3.1. Data Source and Search Strategy  
 
We searched PubMed, Embase, CINAHL, PsycInfo, and Cochrane databases 
covering the period from 1970 through to November 2014. Search terms included 
combinations of Medical Subject Heading (MeSH) terms and keywords like 
“dialysis/haemodialysis”, “renal replacement therapy”, “end-stage renal disease”, 
“chronic renal failure”, “adherence/nonadherence”, “compliance/non-compliance”, 
“drug/medication”, and “regimen/schedule.” Details of the initial search strategy are 
provided in Appendix 2. A manual search of the references cited in each publication 
identified from the database search was conducted to identify additional relevant 
articles. 
 
2.3.2. Study Selection 
 
Titles and abstracts of the articles were screened to include relevant studies. In cases 
of insufficient information being ascertained from the title or abstract of a paper, a full 
copy of the article was obtained and screened to determine eligibility. Each article was 
evaluated for inclusion by two reviewers (SG and RLC) and disagreements between 
the reviewers were resolved by discussion with the third reviewer (STRZ).  
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Studies were included in this review if they fulfilled all of the following criteria: 
articles published in peer-reviewed journals, studies conducted in patient ≥ 18 years, 
undergoing haemodialysis treatment that included measure(s) of adherence or 
nonadherence related to medication therapy, and provided numeric results on rates of 
adherence or nonadherence. All adherence measures such as self-reporting, 
physician/nurse estimations, pill counts, prescription refills, and electronic monitoring 
were considered if a definition of nonadherence were provided, and nonadherence 
rates were reported. Studies with a longitudinal or cross-sectional design were 
included for review. Interventional studies were considered if baseline rates were 
provided. The publication language was not restricted to English only. Studies were 
excluded if they reported only adherence outcomes to non-medication interventions 
such as dialysis exchanges, diet or fluid restrictions, and exercise, if they did not clearly 
define or report rates of nonadherence, or if they were reviews, protocols, editorials, 
letters or dissertations (Figure 9).   
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Figure 9. Flowchart of study selection for systematic review 
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2.3.3. Data Extraction and Analysis 
 
Data from the included studies were extracted by one reviewer (SG) followed by 
verification of all data against the original studies by the second reviewer (RLC). 
Information extracted included: author, year of publication, country of origin, study 
design (prospective, retrospective, cross-sectional, and so on), participant 
characteristics, number of patients, age, gender, types of medications, adherence 
assessment method, definition of nonadherence, rates of nonadherence, and factors 
reported as being associated with nonadherence.  
Data analysis involved a descriptive summary of included studies. More 
effective synthesis of results such as meta-analysis was not considered due to 
inconsistent reporting of results and variation in the type of statistical analyses 
performed. Several methods of assessing nonadherence were utilised. We grouped 
these methods into three broad categories: (1) objective/ direct measures, such as pill 
count, prescription refill or using medication event monitoring devices; (2) subjective/ 
indirect measures that are based on patients’ self-reports or assessment by healthcare 
professionals and (3) biochemical measures that included measuring of pre-dialysis 
serum phosphate levels (SPL). To achieve our first objective, we performed frequency 
counts of each of the methods used to assess nonadherence. To attain the second 
objective, we grouped reported prevalence of medication nonadherence according to 
the three overarching subgroup measures and findings were collated using a summary 
bar chart. Our third objective was satisfied by extracting factors associated with 
nonadherence and presenting them in a tabular format, according to statistically 
significant and non-significant findings across studies per explanatory variables. This 
method was employed due to inconsistent reporting and unpredictable heterogeneity 
of the statistical analysis performed in the primary studies.  
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2.3.4. Quality Assessment 
 
Quality assessment of included studies was independently carried out by two 
reviewers (SG and RLC) using the Effective Public Health Practice Project (EPHPP) 
Quality Assessment Tool for Quantitative Studies [151]. This tool addresses six quality 
components: selection bias, study design, confounders, blinding, data collection 
methods, and withdrawals and dropouts. Sections on confounders and blinding were 
deleted in our adapted version as they were considered irrelevant to this review [25]. 
The components are rated as strong, moderate or weak according to a standardised 
guide and dictionary set for the instrument. Any discrepancies were resolved by 
discussion with the third reviewer (STRZ).   
 
2.4. Results 
 
2.4.1. Description of Included Studies 
 
A flow diagram of the literature search and identification of relevant articles for review 
is depicted in Figure 9. Overall, 920 potentially relevant articles were identified. In 
total, 44 articles are summarised and evaluated in this systematic review. Table 5 
shows the characteristics of included studies.  
Half (n = 22) of the studies [9, 145, 152-171] were conducted in North America, 
15 were carried out in Europe [33, 150, 172-184], four were conducted in Asia [185-
188], and two studies were performed in South America [189, 190]. One included study 
had a multi-centre site and was conducted in ten different countries [191].  
Most of the included studies (n = 32) were cross-sectional in design [9, 33, 158-
161, 163-166, 168-175, 177, 178, 180-191], with another seven having a prospective 
36 
 
nature [150, 154, 157, 162, 167, 176, 179], and five having a retrospective study 
design [145, 152, 153, 155, 156].  
The sample size varied greatly from a minimum of 19 participants [171] to a 
maximum of  11,732 participants [152]. Overall, half (n = 22) of the included studies 
had a sample size of more than 100 participants [9, 33, 145, 150, 152, 155, 160, 162, 
163, 166, 170, 172-174, 176, 178, 181, 182, 185, 187, 190, 191]. Moreover, five 
studies had more than 1000 participants each [145, 152, 155, 166, 191]. All included 
studies were comprised of patients with ESKD, receiving treatment at hospital-based 
outpatient haemodialysis centres.  
 
 
  
 
 
Table 5. Characteristics of studies included in systematic review  
Author, Year  Country Patients 
(% 
Male) 
Age 
(Years), 
Mean ± 
SD or 
Range 
Medication Assessment 
Method 
Nonadherence (NAD) to Medication Design 
(Study 
qualitya) 
Definition Rates, n (%) 
Nonadherence based on patient self-reports 
Alkatheri et al., 
2014 
Saudi 
Arabia 
89 (52.8) 15.0 – 
65.0 
PB Self-report 
(MMAS-8) 
Score < 7 classified as NAD 64 (71.9) CS (M) 
Ossareh et al., 
2014 
Iran 150 
(47.3) 
46.5 ± 
16.4 
PB [CaCO3 (n = 
136), Al(OH)3 (n = 
29), SA (n = 26)] 
Self-report 
(SMAQ) 
Responding to any of the 
question with a NAD answer  
37 (24.7) CS (M) 
Self-report 
(DIPQ) 
Taking < 66% of prescribed 
medication 
CaCO3, 66 (48.5) 
Al(OH)3,26 (89.7) 
SA, 11 (42.3) 
Chater et al., 
2014 
UK 221 
(52.0) 
58.1 ± 
14.2 
PB [CaCO3, Al(OH)3, 
SA, Ca(C2H3O2)2] 
Self-report 
(7-item 
MARS) 
Score ≤ 28 classified as low 
adherers 
68 (30.8) CS (M) 
Arenas et al., 
2013 
Spain 181 
(56.9) 
59.9 
(21-86) 
PB [CaCO3, Al(OH)3, 
Ca(C2H3O2)2 SA, 
LC], CM, Vitamin D 
Self-report 
(SMAQ) 
Responding to any of the 
question with a NAD answer 
110 (60.8)  
(at baseline visit) 
79 (71.8) 
(at 6 month) 
P (M) 
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Author, Year  Country Patients 
(% 
Male) 
Age 
(Years), 
Mean ± 
SD or 
Range 
Medication Assessment 
Method 
Nonadherence (NAD) to Medication Design 
(Study 
qualitya) 
Definition Rates, n (%) 
Santana & Diaz, 
2013 
Spain 106 
(71.0) 
61.0 ± 
13.0 
PB [CaCO3, Al(OH)3, 
SA, Ca(C2H3O2)2], 
CM (Cinacalcet) 
Self-report 
(SMAQ) 
Responding to any of the 
question with a NAD answer 
40 (37.7) CS (M) 
Theofilou, 2013 Greece 168 
(62.5) 
62.0 NA Self-report 
(5-item 
MARS) 
Score < 20 classified as low 
adherers 
42 (25.0) CS (M) 
Martins et al., 
2013 
Brazil 502 
(66.3) 
47.0 ± 
13.3 
PB Interview  Reporting missed dose 330 (65.7) CS (M) 
Garcia-Llana et 
al., 2013 
Spain 30 
(60.0)b 
60.6 ± 
16.7 
AHT (n = 17)  Self-report 
(MGLT-4) 
Responding to any of the 
question with a NAD answer 
AHT, 15 (90.9)  CS (M) 
PB (n = 25) PB, 17 (68.4) 
Rosenthal Asher 
et al., 2012 
USA 85 
(40.0)b 
55.9 ± 
13.2 
NA Self-report 
(ITAS-M) 
 
Score ≤ 9 classified as low 
adherers 
11 (13.0) P (M) 
Wileman et al., 
2011 
UK 76 (60.5) 63.1 ± 
15.4 
PB Self-report 
(MAQ) 
Responding to any of the 
question with a NAD answer 
11 (14.5) 
 
CS (M) 
Neri et al., 2011 Italy 1,238 (-) 61.7 ± 
14.5 
NA Self-report 
(MGLT-4) 
Responding to any of the 
question with a NAD answer 
644 (52.0) P (M) 
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Author, Year  Country Patients 
(% 
Male) 
Age 
(Years), 
Mean ± 
SD or 
Range 
Medication Assessment 
Method 
Nonadherence (NAD) to Medication Design 
(Study 
qualitya) 
Definition Rates, n (%) 
Cukor et al., 
2009 
USA 65 
(46.0)b 
51.1 ± 
13.0 
NA Self-report 
(ITAS-M) 
Score ≤ 9 classified as low 
adherers 
24 (37.0) P (M) 
Garcia et al., 
2008 
Spain 47 
(63.0)b 
70.0 ± 
14.5 
PB Self-report 
(MGLT-4) 
Responding to any of the 
question with a NAD answer 
24 (52.3) CS (M) 
Hirth et al., 
2008 
Multinati
onalc 
7,852 (-) 62.4 ± 
14.6 
AHT, PB, CM Self-report Reporting cost related 
medication non-purchase 
1052 (13.4) CS (M) 
Lindberg et al., 
2007 
Sweden 150 
(60.0)b 
63.6 ± 
14.3 
AHT, PB, CM, HDS Self-report Differences in the self-
reported drug and 
prescription record 
120 (80.4) CS (W) 
Holley & 
DeVore, 2006 
USA 39 
(44.0)b 
67% 
over 50 
NA Self-report Missing prescription filling,  
Reporting missed dose 
11 (22.0) 
21 (39.0) 
CS (W) 
Rahman & 
Griffin, 2004 
USA 270 
(53.0) 
60.4 ± 
16.0 
AHT (n = 205) Self-report Reporting missed dose 47 (23.0) CS (M) 
Horne et al., 
2001 
UK 47 (48.9) 49.0 ± 
17.3 
NA Self-report 
(BMQ) 
Responding to any of the 
question with a NAD answer 
27 (57.4) CS (M) 
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Author, Year  Country Patients 
(% 
Male) 
Age 
(Years), 
Mean ± 
SD or 
Range 
Medication Assessment 
Method 
Nonadherence (NAD) to Medication Design 
(Study 
qualitya) 
Definition Rates, n (%) 
Caraballo 
Nazario et al., 
2001 
USA 53 (41.7) 51.5 ± 
14.3 
AHT, PB Structured 
Interview 
Reporting missed dose 39 (75.0) CS (M) 
Gago et al., 
2000 
Spain 121 
(56.2) 
62.8 ± 
12.6 
AHT (n = 49)  Self-report Differences in the self-
reported drug and 
prescription record 
AHT, 6 (12.5)  CS (W) 
PB [CaCO3 (n = 
104)   
CaCO3, 14 (14.0) 
Al(OH)3 (n = 39)] Al(OH)3, 4 (12.5) 
Kaplan et al., 
1994 
USA 30 (40.0) 40.5 (14 
– 69) 
AHT, PB Self-report Reporting missed dose 20 (66.7) CS (M) 
Blanchard et al., 
1990 
USA 40 (50.0) 50.4 ± 
16.4 
Ca Supplements, 
PB, Vitamins 
Self-report Reporting missed dose 11 (27.5) P (M) 
 
Nonadherence based on objective measures 
Park et al., 2014 USA 11,732 
(56.2) 
69.4 ± 
12.7 
AHG (n = 3,819)  MPR MPR < 80%  
(Poor adherence) 
AHG: 2,338 
(61.2) 
R (M) 
AHT (n = 9,863)  AHT: 4,098 (41.5) 
AL (n = 4,607)  AL: 2,118 (46.0)  
CM (n= 2,436)  CM: 1,587 (65.1) 
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Author, Year  Country Patients 
(% 
Male) 
Age 
(Years), 
Mean ± 
SD or 
Range 
Medication Assessment 
Method 
Nonadherence (NAD) to Medication Design 
(Study 
qualitya) 
Definition Rates, n (%) 
PB (n = 7,753) PB: 6,068 (78.3) 
Porter 2013 USA 96 (53.1) 52.5 ± 
14.6 
PB (SA), CM, 
Vitamin D 
Refill per 
EMR 
Medication course either 
not started or partially 
completed 
35 (36.5) R (M) 
Lee at al., 2011 USA 4,923 
(53.3) 
61.8 ± 
13.8 
CM (Cinacalcet) MPR ≥ 180 days refill gap,  
MPR < 80% (Poor 
adherence) 
2,247 (45.6) 
1,304 (26.5) 
R (M) 
Gincherman et 
al., 2010 
USA 79 (43.0) 51.0 ± 
13.0 
CM (Cinacalcet) MPR MPR < 80% (Poor 
adherence) 
56 (70.9) R (M) 
Chiu et al., 2009 USA 233 
(58.0) 
52.9 ± 
14.7 
PB [CaCO3, Al(OH)3, 
Ca(C2H3O2)2, SA, 
LC] 
Pill count Taking < 80% of prescribed 
pills 
144 (62.0) CS (M) 
Curtin et al., 
1997 
USA 135 
(47.0) 
63.2 ± 
13.8 
AHT (n = 83)  
PB (n = 98) 
MEMS Instance of bottle opening AHT, 77 (92.8) 
PB, 96 (97.9) 
P (M) 
Nonadherence based on biochemical measures 
Wileman et al., 
2015 
UK 112 
(61.6) 
60.5 ± 
16.9 
PB SPL SPL > 5.0 mg/dL 79 (70.5) CS (M) 
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Author, Year  Country Patients 
(% 
Male) 
Age 
(Years), 
Mean ± 
SD or 
Range 
Medication Assessment 
Method 
Nonadherence (NAD) to Medication Design 
(Study 
qualitya) 
Definition Rates, n (%) 
O’Connor et al., 
2008 
UK 73 (60.3) 51.9 ± 
14.7 
PB SPL SPL ≥ 5.5 mg/dL 40 (55.0) P (M) 
Tijerina, 2006 USA 26 (0.0) 30 – 56 PB SPL SPL > 6.0 mg/dL 16 (61.5) CS (M) 
Saounatsou, 
1999 
Greece 60 (53.3) 49.4 PB SPL SPL > 5.0 mg/dL 17 (28.3) CS (M) 
Leggat et al., 
1998 
USA 6,251 
(49.7) 
57.8 ± 
15.5 
PB SPL SPL > 7.5 mg/dL 1,383 (22.1) R (M) 
Bame et al., 
1993 
USA 1229 
(47.1) 
56.7 (18 
– 90) 
PB SPL SPL > 6.0 mg/dL 612 (49.8) CS (M) 
Weed-Collins & 
Hogan, 1989 
USA 30 (43.0) 25 – 80 PB SPL SPL > 5.5 mg/dL 
 
19 (64.0) 
 
CS (M) 
Betts & Crotty, 
1988 
USA 46 (33.0) 41 - 60 PB SPL SPL > 5.0 mg/dL 
 
35 (76.1) 
 
CS (M) 
Cummings et 
al., 1982 
USA 116 
(54.0) 
54.8 (21 
– 76) 
PB SPL SPL > 5.5 mg/dL 81 (70.0) CS (M) 
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Author, Year  Country Patients 
(% 
Male) 
Age 
(Years), 
Mean ± 
SD or 
Range 
Medication Assessment 
Method 
Nonadherence (NAD) to Medication Design 
(Study 
qualitya) 
Definition Rates, n (%) 
Wenerowicz et 
al., 1978 
USA 19 (68.4) 36.0 (19 
– 70) 
PB SPL 
 
SPL > 4.5 mg/dL 
 
13 (68.4) 
 
CS (M) 
Nonadherence based on multiple measures 
Sgnaolin et al., 
2012 
Brazil 65 (49.2) 59.1 ± 
14.7 
AHT, PB SPL 
 
SPL > 5.5 mg/dL  
 
25 (38.5) 
 
CS (M) 
Self-report 
(MGLT-4) 
Responding to any of the 
question with a NAD answer 
36 (55.4) 
Chan et al., 
2012 
Malaysia 188 
(48.9) 
58.2 ± 
10.5 
PB SPL  
 
SPL > 5.0 mg/dL 
 
63 (33.5) 
 
CS (M) 
Self-report 
(DDFQ) 
Score ≤ 3 classified as low 
adherers 
93 (49.5) 
Arenas et al., 
2010 
Spain 165 
(63.0) 
65.2 ± 
14.7 
PB [ Al(OH)3, 
Ca(C2H3O2)2, SA] 
SPL  SPL > 5.5 mg/dL 
 
23 (13.9) 
 
CS (M) 
Self-report 
(SMAQ) 
Responding to any of the 
question with a NAD answer 
66 (40.0) 
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Author, Year  Country Patients 
(% 
Male) 
Age 
(Years), 
Mean ± 
SD or 
Range 
Medication Assessment 
Method 
Nonadherence (NAD) to Medication Design 
(Study 
qualitya) 
Definition Rates, n (%) 
Lin & Liang, 
1997 
China 86 (-) 55.0 
(45.0) 
PB MCA SPL > 5.0 mg/dL 
 
52 (61.0) 
 
CS (M) 
Nurse assessment 26 (30.8) 
Self-report 20 (23.6) 
Cleary et al., 
1995 
USA 51 
(45.1)b 
51.0 ± 
17.0 
AHT, PB, Vitamin D SPL  SPL > 4.5 mg/dL 23 (45.1) CS (M) 
Structured 
Interview 
Reporting missed dose 30 (60.0) 
Curtin et al., 
1999 
USA 135 
(46.7) 
63.2 ± 
13.8 
AHT (n = 69), PB 
(74) 
Self-report 
(BMQ)  
 
Overdosing, under dosing, or 
missing an entire day’s dose 
AHT, 14 (20.3);  
PB, 34 (45.9) 
 
CS (M) 
Pill count Number of pills added at 
each refill 
 
AHT, 63 (91.3);  
PB, 73 (98.6) 
 
MEMS Instance of bottle opening AHT, 66 (95.7);  
PB, 72 (97.3) 
Note: Where studies has reported adherence rate for each medication or for more than one assessment method, these are reported in a separate row and 
are not addable. Therefore, the overall adherence rate does not account to more than 100%. Conversion factor for unit: SPL in mg/dL to mmol/L, x0.3229. 
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Abbreviations: AHG, antihyperglycemics; AHT, antihypertensives; AL, antilipidemics; BMQ, brief medication questionnaire; CM, calcimimetics; DDFQ, dialysis 
diet and fluid nonadherence questionnaire; DIPQ, drug intake percentage questionnaire; EMR, electronic medical record; HDS, herbal and dietary supplement; 
ISAI, Iowa self-assessment inventory;  ITAS-M, modified immunosuppressive therapy adherence scale; LC, lanthanum carbonate; MAQ, medication adherence 
questionnaire; MARS, medication adherence report scale; MCA, multi-method compliance assessment (including: laboratory assessment, nurse assessment, 
and patient self-report); MEMS, medication event monitoring system; MGLT-4, Morisky 4-item Green Levine test; MMAS-8, Morisky 8-item medication 
adherence scale; MPR, medication possession ratio; PB, phosphate binder; SA, sevelamer hydrochloride; SMAQ, simplified medication adherence 
questionnaire; SPL, pre-dialysis serum phosphate level; Study design (CS, cross-sectional; P, prospective; R, retrospective); NA, not available. 
aEffective public health practice project (EPHPP) quality assessment tool for quantitative studies. Study quality (S, strong; M, moderate; W, weak). 
bSubsample of patients undergoing haemodialysis. 
cTwelve industrialised countries (Australia/ New Zealand, Belgium, Canada, France, Germany, Italy, Spain, Sweden, and UK, twenty facilities each; Japan, sixty 
facilities; and USA, eighty facilities).  
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2.4.2. Assessment of Nonadherence  
 
Half of the studies (n = 22) applied subjective measures exclusively, based on patients’ 
self-reporting in order to assess nonadherence. However, the specific method of 
subjective assessment differed across studies. Thirteen studies used self-reporting 
measures with a validated questionnaire (Brief Medication Questionnaire (BMQ) [184], 
Drug Intake Percentage Questionnaire (DIPQ) [185], Modified Immunosuppressive 
Therapy Adherence Scale (ITAS-M) [154, 157], Medication Adherence Report Scale 
(MARS) [172, 174], Morisky 4-item Green Levine Test (MGLT-4) [150, 175, 180], 
Morisky 8-item Medication Adherence Scale (MMAS-8) [186],  Medication Adherence 
Questionnaire (MAQ) [177], and Simplified Medication Adherence Questionnaire 
(SMAQ)) [173, 176, 185], whereas 9 studies utilised self-reporting via patient 
interviews or non-validated questionnaires [159-161, 165, 167, 181, 182, 190, 191]. 
Studies solely utilising biochemical measures of assessing nonadherence, 
based on pre-dialysis SPL, accounted for less than 25.0% (n = 10) of our included 
sample [33, 145, 158, 166, 168-171, 179, 183]. Furthermore, the least utilised method 
of assessing nonadherence to medication in patients undergoing haemodialysis was 
directly (13.6%, n = 6), that included either pill count or using electronic monitoring 
devices [9, 152, 153, 155, 156, 162].  
Five out of the six studies that used two or more instruments to measure 
nonadherence employed subjective (patient self-reporting) and biochemical measures 
(pre-dialysis SPL) [164, 178, 187-189]. The one remaining study [163] integrated 
subjective with objective measures such as pill count and electronic monitoring 
system, respectively.  
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2.4.3. Definitions of Nonadherence 
 
Studies reported wide variation in the definitions for each (subjective, objective, and 
biochemical) measure of nonadherence.  
Subjective measures that used validated questionnaires defined nonadherence 
based on adherence rating scales [33, 154, 157, 170, 172, 174, 186, 187]. On the 
contrary, studies relying on non-validated questionnaires or interviews defined 
nonadherence via self-reported missed doses [159-161, 164, 165, 167, 190], cost-
related medication non-purchase [191] or discrepancies in the self-reported 
adherence and prescription records [181, 182].  
For objective measures, the nonadherence definition was based on pill count 
(taking less than 80% [9] of the prescribed medication), prescription refill frequency 
[153], instances of bottle opening as detected by using medication event monitoring 
devices [162, 163], and the medication possession ratio (MPR), defined as the number 
of doses dispensed in relation to the dispensing period with a cut-off value of 80% 
[152, 155, 156]. 
Studies considering biochemical measures for estimating nonadherence 
showed variation in their definitions. The upper limit of the acceptable range for pre-
dialysis SPL was reported as being from 4.5 mg/dL [164, 171] to 7.5 mg/dL [145]. 
However, most of the studies (66.7%, n= 10) considered pre-dialysis SPL acceptable 
at the upper limit of 5 mg/dL [33, 169, 176, 183, 187, 188] to 5.5 mg/dL [168, 170, 177-
179, 189]. A clinical proxy measure, such as SPL, is often influenced by clinical 
variables and dietary intake and, therefore, could confound an exploration of the 
relationship between serum phosphate and adherence outcomes [33]. During our 
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analysis we found five studies that employed both pre-dialysis SPL and patient self-
reporting measures to assess adherence outcomes [164, 178, 187-189] (Table 5). 
 
2.4.4. Prevalence of Nonadherence to Medication 
 
In general, rates of nonadherence to medication in patients undergoing haemodialysis 
ranged from 12.5% to 98.6%. This variation was primarily observed due to different 
measures and definitions employed in estimating nonadherence rates. Figure 10 
shows the prevalence rates of medication nonadherence in patients undergoing 
haemodialysis according to the three subgroup measures of adherence (subjective, 
objective and biochemical), and also consolidates prevalence rates for similar 
measures within the three overarching subgroups.  
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Figure 10: Prevalence rates of medication nonadherence in HD patients  
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Abbreviations: AHG, antihyperglycemics; AHT, antihypertensives; AL, antilipidemics; BMQ, brief 
medication questionnaire; CM, calcimimetics; DDFQ, dialysis diet and fluid nonadherence 
questionnaire; DIPQ, drug intake percentage questionnaire; EMR, electronic medical record; HD, 
haemodialysis; HDS, herbal and dietary supplements;  ITAS-M, modified immunosuppressive therapy 
adherence scale; MARS, medication adherence report scale; MGLT-4, Morisky 4-item Green Levine 
test; MMAS-8, Morisky 8-item medication adherence scale; MPR, medication possession ratio; MAQ, 
medication adherence questionnaire; MEMS, medication event monitoring system; OBJ, objective 
measure of adherence; PB, phosphate binders; PSR, patient self-reported adherence; SA, sevelamer 
hydrochloride; SMAQ, simplified medication adherence questionnaire; SPL, pre-dialysis serum 
phosphate levels.  
 
The most frequently studied renal-specific medications were phosphate binders 
(76.1%, n = 35), with eight studies [9, 153, 172, 173, 176, 178, 182, 185] specifically 
mentioning the types of phosphate binders prescribed (aluminium hydroxide, calcium 
acetate, calcium carbonate, lanthanum carbonate, and sevelamer hydrochloride). 
Other medications studied included, antihypertensives (27.3%, n = 12) and, 
calcimimetics (17.4%, n = 8). Fewer studies (9.1%, n = 4) estimated nonadherence to 
antidiabetic agents, antidyslipidaemic drugs, and calcium and vitamin D supplement 
products.  Six studies did not specifically mention the types of medications studied 
[150, 154, 157, 159, 174, 184].  
Nonadherence to phosphate binders ranged from 13.9 – 98.6%, with an 
average of 52.5%. The mean percentage of patients classified as non-adherent 
assessed by pre-dialysis SPL, subjective measures and objective measures, was 
28.6%, 47.9% and 78.4%, respectively.    
The estimates of nonadherence to antihypertensive medication in patients 
undergoing haemodialysis ranged between 12.5% and 95.7% (mean 38.2%). When 
assessed using different measures of nonadherence, such as patient self-reporting 
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and objective measures, the mean prevalence rates were 24.3% and 38.5%, 
respectively. The rate of nonadherence to other medications, such as antidiabetics 
and antidyslipidaemics, was 61.2% and 46.0%, respectively.   
Among five studies [164, 178, 187-189] that used composite methods for 
measuring adherence, the rates of nonadherence varied greatly depending on the 
types of adherence measures used. The rates of nonadherence were lower when 
assessed using pre-dialysis SPL (ranged from 13.9% to 45.1%), whereas the same 
studies reported higher rates of nonadherence when using patient self-reporting 
measures (ranging from 40.0% to 60.0%) [164, 178, 187, 189]. The opposite was true 
in one study which  showed that the rate of nonadherence was higher with pre-dialysis 
SPL (61.0%) and lower with patient self-reporting measures (23.6%) [188] (Table 5).  
 
2.4.5. Factors Associated with Nonadherence 
 
A total of 38 studies reported factors associated with nonadherence in patients 
undergoing haemodialysis. Data synthesis on the factors associated with 
nonadherence was based on the statistical significance and direction (positive or 
negative) of the association. The majority of studies relied on a univariate analysis to 
explore the factors associated with nonadherence, with only 15 studies using 
multivariate analyses [9, 33, 145, 150, 152, 154, 155, 157, 166, 172, 177-179, 185, 
187]. A quantitative summary of statistically significant factors and their logical 
categorisation is presented as Table 6.   
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Table 6. Factors associated with nonadherence (n = 38) 
Factors No of 
studies 
Significant association 
with measures of 
nonadherencea 
References 
SPL PSR PC/ MEMS 
Socio-demographic variables      
Age  27     
   Younger  8 8  [33, 150, 
153, 166, 
169, 170, 
172, 177, 
178, 181, 
185-187, 
189] 
   Older 1 2 1 [9, 145, 157, 
174] 
Gender 22     
   Male  1  [185] 
   Female  2  [150, 177] 
Low education (≤ high school) 15  1  [186] 
Ethnicity (non-Caucasian) 7 1 1 2 [145, 162, 
163, 172] 
Marital status (single, divorced or 
widowed) 
6  2  [174, 186] 
Employment status (unemployed) 6  1  [174] 
Lack of support from health care 
provider 
2  2  [150, 170] 
Family problems (illness interfering 
with family life) 
2  1  [170] 
Smoker 1 1   [145] 
Clinical variables      
Long-term on HD  16  3  [150, 174, 
187] 
Comorbidity (DM, HTN) 9 1 1  [178] 
Number of hospitalisation 2  1  [150] 
Psycho-social variables      
Depressive symptoms 6  4  [154, 157, 
174, 185] 
Belief about medicine  5     
   Concern 1 2  [172, 177, 
184] 
   Benefit 1 1  [170] 
   Necessity 1 3  [33, 172, 
177] 
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Factors No of 
studies 
Significant association 
with measures of 
nonadherencea 
References 
SPL PSR PC/ MEMS 
   Necessity-concern differential   
score 
 2  [33, 177] 
Health locus of controlb 3 2 1  [171, 188] 
   Internal  1  [174] 
   Doctors  1  [174] 
Emotional representation 1 1   [179] 
Medication related factors      
Poor knowledge about medicine 5 1 1  [170, 187] 
Number of prescribed medicines 3   1 [162] 
Daily tablet count 2 1 1  [150, 178] 
Total no of PB prescribed 2 1 1  [178] 
Total pill burden 2  1 1 [9, 150] 
Pill burden from PB  1   1 [9] 
PB equivalent dosage 1 1   [33] 
Regimen complexity (frequency 
and dosage schedule) 
1 1   [170] 
Drug coverage by insurance 1   1 [152] 
Health care cost (inpatient) 1   1 [155] 
Abbreviations: DM, diabetes mellitus; HD, haemodialysis; HTN, hypertension; MEMS, medication 
event monitoring system; PB, phosphate binders; PC, pill count; PSR, patient self-report; SPL, pre-
dialysis serum phosphate level.  
aLevel of significance (p < 0.05, p < 0.01, and p < 0.001) varies between studies. 
bDefined as having high expectation that one’s actions will have a causal relationship with the 
consequences produced. 
 
Taking into account the relative number of studies that explored variables 
associated with nonadherence and the actual studies that found a significant 
association, we have identified a number of variables that are likely to influence 
medication adherence in patients undergoing haemodialysis. A number of 
demographic factors were found to be significantly associated with nonadherence. 
Age was one of the most frequently reported variables. Although younger age was 
commonly associated with nonadherence, four studies found nonadherence prevalent 
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in the older population as well. Other factors significantly associated with measures of 
nonadherence were: non-Caucasian ethnicity, illness interfering with family life, being 
a smoker, and being single, divorced or widowed. Very few studies found female 
gender, low education, and unemployment to be significantly associated with 
nonadherence. Support from healthcare providers had a significant positive effect on 
adherence to medication therapy.  
Longevity of haemodialysis (five or more years on dialysis) was reported as the 
most common clinical factor but only three studies [150, 179, 187] found it to be 
significantly associated with nonadherence. Other clinical variables influencing 
adherence were having a concomitant illness like diabetes and hypertension, and 
recurrent hospitalisation (Table 6).  
The psycho-social variables that were identified to influence nonadherence 
included: depressive symptoms, negative belief about medicines (concern, benefit, 
necessity, and necessity-concern differential score, calculated by subtracting the 
concerns subscale scores from the necessity subscale score, where the negative 
scores indicate that patients rate their concerns about medication above their beliefs 
in the necessity of taking it) [33, 170, 172, 177, 184], health locus of control, defined 
as having a high expectation that one’s actions will have a causal relationship with the 
consequences produced [171, 174, 188], and emotional representation, that is 
emotional distress specific to the illness (Table 6).  
Overall, nine studies [9, 33, 150, 152, 155, 162, 170, 178, 187] reported 
medication-related factors that were found to be significantly associated with 
nonadherence. These included daily tablet count, knowledge of medicines, total pill 
burden, total number of phosphate binders prescribed, phosphate binder equivalent 
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dosage (the relative phosphate binding coefficient based on the weight of each binder 
that can be estimated relative to calcium carbonate), pill burden from phosphate 
binder, medication regimen complexity (frequency and dosage schedule), drug 
coverage by insurance, and health care cost as inpatients (Table 6).  
Fewer studies [33, 170, 178] evaluated factors associated with nonadherence 
using more than one measure of nonadherence (pre-dialysis SPL and patient self-
reporting). The factors that showed significant correlation with both patient self-
reported adherence and pre-dialysis SPL were: age [33, 178], comorbidity [178], total 
number of phosphate binders prescribed [178], belief about phosphate binder 
medicine (necessity) [33], and beliefs about medicine (benefits) [170]. However, 
beliefs about phosphate binder medicine (concern) were not significantly associated 
with both measures of adherence [33]. The study suggested that although patients 
had some concerns about their phosphate binder medicines, this did not appear to 
consistently influence their medication-taking behaviour.  
 
2.4.6. Perceived Barriers of Adherence to Medication 
 
Eight studies reported patients’ perceived barriers to adherence to medication therapy. 
The most common reasons given by the patients to explain nonadherence were 
forgetfulness (n = 6 studies), poor tolerance of side effects (n = 4 studies), pill burden 
(n = 3 studies), and large tablet size (n = 2 studies). Other reasons included 
unpalatable taste, medication regimen complexity (frequency and dosage schedule), 
difficulty opening the medication container, prescription refilling, medication cost, 
transportation, knowledge of phosphate binder medicines, diet and fluid restrictions, 
knowledge of the importance of taking medicines, lack of interest, monotony, being 
away from home, and social discomfort [159, 160, 164, 165, 168, 173, 176, 187].  
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2.4.7. Study Quality 
 
Based on the EPHPP Quality Assessment Tool, most studies (n = 41) were rated as 
being of moderate quality (Table 5). The reasons behind this moderate rating were, 
weak study design largely based on cross-sectional data [9, 33, 158-161, 163-166, 
168-175, 177, 178, 180-191], using non-validated measures of data collection such as 
patient interviews or the lack of reliable data from the use of validated measures [153, 
154, 157, 159-161, 163-165, 167, 172-176, 180-182, 185, 186, 189-191], and failure 
to report withdrawals and dropout rates of participants completing the study [145, 150, 
152, 153, 155-159, 165, 166, 168, 170-172, 178-183, 185, 188, 191].  
 
2.5. Discussion  
 
The present systematic review summarised findings from 44 studies over a period of 
three decades to identify factors associated with nonadherence to medications in 
patients undergoing haemodialysis. Given the absence of a unified standardised 
approach to measuring nonadherence [192], the current review observed significant 
variability in the methodological quality of included studies.  
A number of methods of assessing nonadherence to medication were observed 
in this review, such as objective measures of pill count, subjective measures of patient 
self-reporting and biochemical methods of measuring pre-dialysis SPL. Half of the 
studies exclusively applied subjective measures based on patients’ self-reporting to 
assess nonadherence, compared with the two previous reviews [11, 147] that reported 
measurement of SPL as the most frequent method. These changes may be due to the 
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availability of validated medication adherence scales to measure nonadherence in 
clinical practice [193]. Additionally, limitations of SPL are increasingly being 
recognised as it can be influenced by non-medication related factors, such as 
adherence to dietary restrictions, dialysis attendance, residual renal function, 
hormonal and acid-base balance, and the type and intensity of dialysis treatment [11, 
194].   
Discrepancies in defining nonadherence were observed among studies that 
used subjective measures with non-validated questionnaires [159-161, 164, 165, 167, 
190], and biochemical measures like pre-dialysis SPL [145, 164, 171]. Owing to these 
inconsistent definitions, a wide variation in the reported rates of nonadherence was 
observed. A study defining the acceptable range of pre-dialysis SPL at a higher cut-
off value of 7.5 mg/dL reported the lowest rates of nonadherence (22.1%) [145], 
whereas the study adopting a lower cut-off value of 4.5 mg/dL reported one of the 
highest rates of nonadherence (68.4%) [171]. Combining information across studies 
becomes problematic when a patient defined as adherent, based on certain criteria in 
one study, would be defined as non-adherent, based on different criteria in another 
study [195]. Hence, there is a need for a consensus on defining or assessing 
medication adherence to study the problem effectively, to understand the underlying 
factors, and to develop and test interventions to improve adherence. 
Overall, the prevalence rates of nonadherence to medication ranged between 
12.5% and 98.6%, which is comparatively higher than with other chronic conditions 
such as diabetes (prevalence rates ranged from 6.9% to 61.5%) [47], schizophrenia-
spectrum disorders (5.0% to 52.8%) [45], and chronic skin conditions such as psoriasis 
(33.4% and 78.4%) [57]. Nonadherence rates in patients undergoing haemodialysis 
are higher in comparison with other dialysis modalities such as peritoneal dialysis (PD) 
58 
 
that ranged from 3.9% to 43.0% [25]. These divergent findings between two modalities 
of dialysis treatment might have been influenced by the intermittent nature of 
maintenance haemodialysis sessions that require more stringent dietary and 
medication requirements as compared with PD. Other factors include that PD is often 
a starter therapy, and patients may not have been sick for as long as those on 
haemodialysis [196]. Also some PD patients receive kidney transplant or eventually 
switch to haemodialysis. This often selects out a younger population who may have a 
lesser dialysis vintage, as well as a disparity in health literacy and dialysis knowledge 
[137].  
A number of demographic and clinical factors were found to be significantly 
associated with nonadherence. Not surprisingly, the findings correspond with the 
results of a systematic review of determinants of patient adherence conducted by 
Kardas et al [197]. Besides that, different aspects of beliefs about medicines were 
found to be possible barriers for adherence; this includes necessity, concerns, and 
benefits from the medication therapy. Patients who expressed lower necessity beliefs 
and greater concerns about potential adverse effects of medications were more likely 
to be nonadherent [33, 170, 172, 177, 184]. A significant majority of patients 
undergoing haemodialysis is prescribed with phosphate binders and antihypertensive 
medications; these account for high pill burden [9], are associated with adverse 
effects, and result in nonadherence [9]. Phosphate binders often cause constipation 
and gastrointestinal discomfort to the patients [198]. Similarly, antihypertensive 
medicines potentially add to hypotension post-dialysis treatment [199], and patients 
can cease these medications due to the haemodynamic effects they experience. 
Therefore, taking account of patients’ beliefs about necessity and concerns about 
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medicines is essential to support informed choice and optimal adherence to prescribed 
treatment [200].  
The need for lifelong and complex medication regimens can contribute to 
nonadherence [139]. Surprisingly, among the nine studies that assessed medication-
related factors, only one study identified that medication regimen complexity 
(frequency and dosage schedule) was significantly associated with nonadherence 
[170]. Medication regimen complexity can be measured with the Medication Regimen 
Complexity Index (MRCI), a validated instrument developed by George et al [201]. 
Unfortunately, in most chronic illness, including ESKD, researchers have not 
measured regimen complexity until recently [202]. Change in MRCI scores following 
an intervention has been studied in diabetic, elderly and home haemodialysis patients 
[203-205]. Initiatives aiming to improve medication adherence should consider the 
above-mentioned determinants to ensure that patients are actively involved in 
designing medication regimens considering the relative contribution of each medicine 
to the regimen complexity.  
This study has some limitations. They are mostly related to the original studies 
included in this review. The majority of the reviewed studies were cross-sectional in 
design and, considered to be of limited suitability for assessing adherence behaviour 
[45]. Furthermore, the reverse causation bias (which suggests that the direction of 
cause and effect may be difficult to assess: Did the “outcome” affect the measured 
exposure level or did the exposure affect the outcome?) [206] cannot be ruled out in 
cross-sectional studies. Therefore, readers are encouraged to exercise caution in the 
interpretation of the findings from this review. An examination of clinical outcomes and 
consequences of nonadherence to medication therapy was beyond the scope of this 
review. Due to time and resource limitations, we predominantly relied on the full-text 
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articles published in peer-reviewed journals and did not search conference 
proceedings for relevant abstracts. Nevertheless, the studies included in this review 
represent a diverse community of patients from wide geographic locations. 
Furthermore, more than half of the included studies had large sample sizes of over 
100 participants.  
 
2.6. Conclusion 
 
Nonadherence to medication therapy is a significant issue in patients undergoing 
haemodialysis. Differences in definitions and tools to measure nonadherence are 
widespread in the current literature. This necessitates a consensus on defining or 
assessing medication nonadherence in order to study underlying issues effectively, to 
understand barriers to adherence properly, and to develop and test intervention 
measures in order to improve adherence in patients undergoing haemodialysis. 
Abiding by the definition of clinical targets for biochemical measures, such as pre-
dialysis SPL, as recommended by international clinical practice guidelines (for 
example, Kidney Disease Improving Global Outcomes (KDIGO), National Kidney 
Foundation- Kidney Disease Outcomes Quality Initiative (NKF- KDOQI) or Kidney 
Health Australia- Caring for Australasians with Renal Impairment (KHA- CARI)) and 
adapting a consistently measured method to assess medication nonadherence can be 
promising steps. Also, triangulation can be tried when objective data are available for 
assessment. Clinicians should be aware of different strategies to promote adherence 
in this unique patient group, including reducing the pill burden, being aware of potential 
adverse effects of medications which promote nonadherence, and other strategies 
such as using combination products. It is also imperative to improve education 
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regarding the patient’s medication regimens, and to provide concise instructions to 
prevent confusion. Future research should be directed towards more rigorous 
approaches, such as a prospective longitudinal study design, and should aim towards 
developing standard definitions and validating available measurement tools, while 
focusing on the role of additional factors such as psychosocial and behavioural factors 
in predicting nonadherence to medications. 
 
 
Supporting Information 
 
Appendix 1. PRISMA Checklist.  
Appendix 2. Electronic search strategy.  
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CHAPTER THREE 
 
3. MEDICATION REGIMEN COMPLEXITY AND ADHERENCE IN 
HAEMODIALYSIS PATIENTS: AN EXPLORATORY STUDY 
 
3.1. Abstract 
Background. The impact of medication regimen complexity on adherence in patients 
undergoing haemodialysis is unknown. We investigated regimen complexity, 
perceived burden of medicines (PBM), and health-related quality of life (HR-QoL) as 
potential predictors of adherence. 
Methods. Adult (≥ 18 years) patients undergoing haemodialysis were recruited from 
outpatient dialysis centre, Hobart, Australia. Data on medication regimen complexity 
index (MRCI), self-reported and objective adherence, comorbidity index, PBM, and 
HR-QoL were obtained using established measures. Socio-demographic and clinical 
characteristics were collected during interviews and by reviewing medical records. 
Predictors of adherence were determined using logistic regression.  
Results. Fifty-three out of 70 patients undergoing haemodialysis participated 
(response rate, 75%; male, 58.5%; age, 67.9±11.5 years). The mean MRCI, HR-QoL, 
and PBM scores were 27.0±10.9, 0.70±0.13 and 1.7±0.6, respectively. Based on self-
reports, 43.4% (n = 23) were adherent, whereas for subset of patients analysed using 
objective measure (n = 33), much lower adherence rate was observed (27.3%, n = 9). 
The self-reported and objective measure were significantly correlated (r = 0.43, p = 
0.01). Older age was the only significant predictor of self-reported adherence (odds 
ratio [OR], 1.05; 95% CI, 1.00–1.11) whereas, older age (OR, 1.10; 95% CI, 1.00–
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1.21), higher comorbidity (OR, 1.58; 95% CI, 1.03–2.42) and MRCI (OR, 1.14; 95% 
CI, 1.02–1.27) were independent predictors of objective adherence.  
Conclusions. The findings of this exploratory study suggest that older patients with 
high comorbidities and highly complex regimen are more likely to be adherent based 
on an objective measure. Future research is needed using objective measures of 
adherence suitable for all patients and reflecting all medications.   
 
Keywords: Adherence; chronic kidney failure; haemodialysis; health-related quality 
of life; medication regimen complexity; perceived burden of medicines 
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3.2. Introduction 
Medication nonadherence is associated with poor patient outcomes and costs 
approximately US $100 billion a year [2]. The estimated prevalence of medication 
nonadherence in patients undergoing dialysis ranges between 12.5% and 98.6% [23]. 
A recent Australian study on research priorities in chronic kidney disease (CKD) 
identified simplifying medication regimens as one of the topmost priorities in patients 
undergoing haemodialysis, to facilitate adherence [207]. A number of comorbidities 
often co-exist with end stage kidney disease (ESKD), with diabetes and cardiovascular 
disease being the most common [8]. Additionally, complications more frequently noted 
in patients undergoing dialysis are imbalances in calcium and phosphate haemostasis, 
anaemia, hyperlipidaemia, and secondary hyperparathyroidism [23, 139]. Owing to 
these comorbid conditions and dialysis-related complications, patients undergoing 
dialysis often have a high pill burden, with a median number of prescribed medications 
ranging between 12 and 19 per day [9]. The additional complexity of medication 
regimens, such as variation in the dosing frequency, differences in the prescribed 
dosage forms and administration instructions, further add to the regimen complexity 
and predispose these patients to a high risk of medication nonadherence [140, 201, 
202, 204, 208]. 
Medication regimen complexity and perceived burden of medicines (PBM) have 
been noted as potential contributors to medication nonadherence in chronic diseases 
[150, 202].  An Italian study conducted in patients undergoing haemodialysis found an 
inverse relationship between regimen complexity (as defined by the number of 
medicines prescribed), patients’ PBM and self-reported adherence [150]. In another 
instance, high pill burden posed by phosphate binders significantly lowered medication 
adherence and affected health-related quality of life (HR-QoL) in patients undergoing 
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haemodialysis [9]. Medication regimen complexity index (MRCI) is one of the most 
frequently used instruments that provides an objective assessment of a regimen 
complexity in a given patient [201]. However, only a small number of studies have 
assessed regimen complexity using the MRCI tool in chronic illnesses, including ESKD 
[202]. A significant increase in MRCI scores was observed over time when patients 
were switched from hospital-based to home-based haemodialysis modality [203]. To 
the best of our knowledge, studies exploring regimen complexity as a likely 
determinant of medication adherence in patients undergoing haemodialysis are 
lacking. The primary aim of this research was to determine the association between 
the medication regimen complexity and medication adherence in patients undergoing 
haemodialysis. A secondary aim was to examine the association between regimen 
complexity and patients’ PBM and HR-QoL.    
 
3.3. Methods 
This was a cross-sectional study of patients undergoing haemodialysis at the 
outpatient dialysis unit, Hobart, Tasmania, Australia.  The unit comprises 20 dialysis 
chairs and operates daily with two in-centre daytime haemodialysis sessions. Patients 
undergo three dialysis sessions of up to 5 hours each, per week. Seventy patients with 
ESKD were receiving haemodialysis during the study period between February and 
June 2015.  
 
3.3.1. Data Collection 
All 70 adult (≥ 18 years) English speaking patients receiving haemodialysis were 
invited to participate in the study. Consented patients were interviewed by a 
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pharmacist researcher to obtain a comprehensive medication history, as per the 
guidelines of the Australian Commission on Safety and Quality in Health Care on 
medication history taking [209]. The accuracy of the medication history was verified by 
reviewing patients’ medical records.  
Regimen complexity was assessed using the validated 65-item medication 
regimen complexity index (MRCI) tool [201]. The MRCI is divided into three sections 
covering pharmaceutical dosage forms, dosing frequency, and additional instructions. 
The minimum MRCI score for someone on medication is 1.5, which represents a single 
tablet or capsule taken once a day when needed while there is no established 
maximum as the score increases in line with the increase in regimen complexity. Daily 
pill burden (or number of pills taken daily) was calculated based on total number of 
pills (including tablets, capsules, injections, inhalations, etc.) prescribed for patients to 
be taken on a daily basis, but excluding medications that contained instructions like 
‘as directed’ or ‘on prn basis’.   
Data on self-reported medication adherence was obtained using the 4-item 
Morisky scale [20, 150]. Patients having a Morisky score of zero were defined as 
adherent in this study, similar to other studies assessing self-reported adherence [150]. 
Objective adherence was measured using the mid-week, pre-dialysis serum 
phosphate levels (SPL) in the sub-group of patients who were prescribed phosphate 
binders, in line with adherence studies conducted in patients undergoing 
haemodialysis [33]. Patients were considered to be nonadherent when the average of 
the monthly pre-dialysis SPL (past 3 months from data collection) exceeded 1.6 
mmol/L, based on the recommendations from Kidney Health Australia – Caring for 
Australasians with Renal Impairment (KHA-CARI) guidelines [210].  
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PBM and HR-QoL were measured using a validated 6-item Burden of Oral 
Therapy (BOT) scale [150] and EQ-5D-5L, a standardised instrument developed by 
the EuroQoL group [211], respectively. The BOT items were rated on a 5-point Likert 
scale, with 1 considered not at all bothered and 5 considered extremely bothered. The 
EuroQoL-5D descriptive system is composed of 5 dimensions: mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels 
ranging from 1-5, where 1 means no problem and 5 means an extreme problem with 
a particular dimension. The digits for 5 dimensions can be combined in a 5-digit 
number describing the respondent’s health state. EQ-5D-5L index value sets for the 
Australian population are not available, and the United Kingdom value sets were used 
as per the recommended practice in measuring the quality of life [212, 213].  
Data on Charlson’s comorbidity index [214], years on dialysis, the number of 
hospitalisations, and dialysis sessions missed in the preceding 12 months were 
collected from patients’ medical records. Data on socio-demographic variables, such 
as age, gender, highest education, employment status, marital status and smoking 
history, were obtained through interview and confirmed, where possible, from the 
medical records. The study was approved by the Tasmanian Health and Medical 
Human Research Ethics Committee (HREC approval number H0014506) and the 
work was performed in accordance with the Declaration of Helsinki. 
 
3.3.2. Statistical Analysis 
Statistical analysis was performed using SPSS Version 21.0 (IBM Corp., Armonk, NY, 
USA).  Mean with standard deviation was used to summarise continuous variables 
and independent samples t-tests were used for inferential analyses, whereas 
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frequencies and percentages were calculated for binomial data and Chi-squared tests 
were used for inferential analyses. Correlations between the study variables were 
tested using Pearson’s correlation coefficient. Study variables with probability (p) 
values ≤ 0.10 in the univariate analysis were entered into the multivariate logistic 
regression model to identify predictors of self-reported and objective adherence. A p-
value of < 0.05 was considered statistically significant.   
 
3.4. Results 
Fifty-three out of 70 patients undergoing haemodialysis provided consent to participate 
(response rate, 75%). Socio-demographic and clinical characteristics of non-
participants were not available due to ethical considerations however the reason for 
nonparticipation was mainly due to disinterest, inconvenience or tiredness. More than 
half of the patients were male (58.5%, n = 31) and the mean age was 67.9±11.5 years.  
Patients, on average, were prescribed 11.1 ± 4.2 medications, with a daily pill 
burden of 16.3 ± 6.9 pills. More than half (58.5%, n = 31) of the patients were taking, 
at least, one antihypertensive medication, followed by medications for anaemia (50.6%, 
n = 27) and ischaemic heart disease (47.2%, n = 25). The most common medicines 
prescribed were aspirin (56.6%, n = 30), sevelamer hydrochloride (49.1%, n = 26), 
paracetamol (37.7%, n = 20), esomeprazole and allopurinol (each 30.2%, n = 16), and 
furosemide (28.3%, n = 15). Among the patients prescribed phosphate binders, more 
than two-thirds were taking sevelamer hydrochloride, with an average dosage of 3200 
mg/day (78.8%, n = 26), followed by aluminium hydroxide (15.2%, n = 5; average 
dosage 1920 mg/day) and lanthanum carbonate (6.1%, n = 2; average dosage 3000 
mg/day). Few patients (11.3%, n = 6) had missed at least one dialysis session in the 
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preceding 12 months while most patients (64.2%, n = 34) had had at least one 
unplanned hospital admission during the same period (Table 7).  
 
Table 7. Study Characteristics based on Patient Self-reported Adherence 
Variables Total cohort 
(n = 53) 
Adherent 
(n = 23) 
Nonadherent 
(n = 30) 
P  
Age (years) 67.9±11.5 71.7±11.1 64.9±11.1 0.03 
Gender (male) 31 (58.5) 15 (65.2) 16 (53.3) 0.3 
Education (≥ high school) 40 (75.5) 15 (65.2) 25 (83.3) 0.1 
Employment (unemployed) 47 (88.7) 22 (95.7) 25 (83.3) 0.1 
Marital status (married) 37 (69.8) 19 (82.6) 18 (60.0) 0.1 
Living with family 39 (73.6) 18 (78.3) 21 (70.0) 0.4 
Smoking history (non-smoker)  44 (83.0) 20 (87.0) 24 (80.0) 0.5 
Years on dialysis 3.7±3.4 3.7±4.0 3.7±2.9 0.9 
Charlson’s comorbidity index 6.3±2.1 6.8±1.9 5.9±2.2 0.1 
Pre-dialysis SPL (mmol/L) 1.7±0.5 1.5±0.4 1.9±0.5 0.01 
Dialysis session missed+  6 (11.3) 2 (8.7) 4 (13.3) 0.5 
Hospitalisation (past one year)µ 34 (64.2) 14 (60.9) 20 (66.7) 0.6 
Patients prescribed with PB  33 (62.3) 11 (47.8) 22 (73.3) 0.05 
Number of medicines prescribed 11.1±4.2 11.3±4.1 10.9±4.4 0.7 
Daily pill burdenβ 16.3±6.9 16.2±6.4 16.3±7.4 0.9 
MRCI (total score)  27.0±10.9 27.9±12.2 26.3±10.1 0.6 
EQ-5D-5L index  0.70±0.13 0.71±0.14 0.69±0.12 0.6 
Perceived burden of medicines 1.7±0.6 1.6±0.6 1.8±0.6 0.1 
Note: For continuous variables, mean±SD and p-value indicated from t-test; for categorical variables, 
frequency (numbers with percentages in parentheses) and p-value indicated from Chi-squared test; 
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EQ-5D-5L, developed by EuroQol group for the measurement of health-related quality of life. The 
index value sets lies between 0 and 1, where one represents best possible health and zero is equivalent 
to death. A negative valuation can be given for certain health states regarded as being worse than 
death. Abbreviations: MRCI, medication regimen complexity index; PB, phosphate binders; SPL, pre-
dialysis serum phosphate level (averaged over 3 months prior to the month of data collection). 
+ At least one dialysis session missed, past one year prior to the month of data collection. Study cohort 
missing ≥ 2 sessions past one year were less than 5% (n = 2). 
µ At least one event of hospitalisation, past one year prior to the month of data collection. Study cohort 
having ≥ 2 events of hospitalisation past one year were 41.5% (n = 22).  
β The number of tablets, capsules, or other dosage forms that a person takes on a regular basis. 
 
 
Less than half of the patients were adherent to prescribed medications (43.4%, 
n = 23) as assessed by self-reported measure. The mean age of adherent patients 
was significantly higher than the nonadherent ones (Table 7). The MRCI value in the 
studied population showed a mean score of 27.0±10.9 (range, 9.5–55.0).  The most 
relevant factors contributing to the final score of regimen complexity were dosing 
frequency (r = 0.93, p < 0.001) and additional instructions given for taking medications 
(r = 0.84, p < 0.001), followed by pharmaceutical dosage forms (r = 0.74, p < 0.001). 
The number of medicines prescribed, daily pill burden and MRCI scores did not differ 
between adherent and nonadherent patients while a significant number of patients 
prescribed with phosphate binders (73.3%, n = 22) were found to be nonadherent on 
self-reports (Table 7).  
Among the patients prescribed phosphate binders, adherence was determined 
using pre-dialysis SPL as an objective measure (n = 33). Only one-fourth of the 
patients (27.3%, n = 9) were considered adherent. The adherent patients had a 
significantly higher age, higher comorbidity index, daily pill burden and regimen 
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complexity scores (Figure 11). The self-reported and objective measure of adherence 
were significantly correlated in those taking phosphate binders (r = 0.43, p = 0.01).   
 
 
 
 
Figure 11. Characteristics of Patient Prescribed with Phosphate Binders (n = 33).  
Adherence was determined using pre-dialysis serum phosphate levels (SPL) as a clinical proxy measure 
of adherence. Patients were considered to be nonadherent when the average of the monthly pre-
dialysis SPL (past 3 months from data collection) exceeded 1.6 mmol/L, based on recommendations 
from Kidney Health Australia – Caring for Australasians with Renal Impairment (KHA-CARI) guidelines. 
For continuous variables, mean±SD and p-value indicated from t-test; MRCI, medication regimen 
complexity index. 
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The average PBM and HR-QoL scores were 1.7±0.6 and 0.70±0.13, 
respectively. The mean PBM scores were not different between adherent and 
nonadherent patients. Similarly, HR-QoL, as measured using EQ-5D-5L index, was 
not different between the adherent and nonadherent groups (Table 7).  
Table 8 depicts the predictors of self-reported and objective adherence, as 
determined using logistic regression. The only significant predictor of self-reported 
adherence was old age (odds ratio [OR], 1.05; 95% CI, 1.00–1.11). Being married (OR, 
3.17; 95% CI, 0.86–11.65) and prescribed with phosphate binders (OR, 0.33; 95% CI, 
0.11–1.05) had a borderline significant association. Whilst, the analysis based on the 
objective measure identified higher regimen complexity (OR, 1.14; 95% CI, 1.02–1.27), 
increasing comorbidity (OR, 1.58; 95% CI, 1.03–2.42), and increasing age (OR, 1.10; 
95% CI, 1.00–1.21) as the significant predictors of adherence. The PBM and HR-QoL 
scores were not associated with both measures of adherence. 
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Table 8. Predictors of Adherence using Logistic Regression Analysis 
Variables Adjusted OR  
(95% CI) 
P 
Predictors of self-reported adherence a   
MRCI (total score) 1.00 (0.95–1.06) 0.96 
Age (per year) 1.05 (1.00–1.11) 0.04 
Charlson’s comorbidity index 1.22 (0.92–1.60) 0.16 
Marital status (married) 3.17 (0.86–11.65) 0.08 
Phosphate binders (prescribed) 0.33 (0.11–1.05) 0.06 
Predictors of objective adherence b   
MRCI (total score) 1.14 (1.02–1.27) 0.02 
Age (per year) 1.10 (1.00–1.21) 0.04 
Charlson’s comorbidity index 1.58 (1.03–2.42) 0.03 
Note: Objective adherence was determined using pre-dialysis serum phosphate levels (SPL) as a 
clinical proxy measure of adherence (n = 33). Patients were considered to be nonadherent when the 
average of the monthly pre-dialysis SPL (past 3 months from data collection) exceeded 1.6 mmol/L, 
based on recommendations from Kidney Health Australia – Caring for Australasians with Renal 
Impairment (KHA-CARI) guidelines. Abbreviations: 95% CI, 95% confidence interval; MRCI, medication 
regimen complexity index; OR, odds ratio. 
a Adjusted for age, Charlson’s comorbidity index, marital status, and phosphate binders prescribed  
b Adjusted for age and Charlson’s comorbidity index 
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3.5. Discussion 
We reported the role of medication regimen complexity on medication adherence in 
patients undergoing haemodialysis. A low rate of medication adherence (below 50%) 
was noted using self-reported and an objective measure of adherence. Higher regimen 
complexity, increasing comorbidity and increasing age were significant predictors of 
adherence using an objective measure, whereas only increasing age was associated 
with self-reported adherence. Being married and prescribed with phosphate binders 
depicted a borderline significant association.  Interestingly, PBM and HR-QoL scores 
did not differ between adherent and nonadherent patients, using both the self-reported 
and an objective measure of adherence.  
 The mean MRCI score in this study was comparable to that reported in home 
haemodialysis patients [203], though expectedly much higher than the previous 
studies in non-ESKD (mean MRCI, 15.5) [215] and institutionalised elderly people 
(mean MRCI, 18.2) [216]. Our results of low rates of medication adherence among 
patients undergoing haemodialysis corroborated earlier findings [9, 11, 150]. We did 
not find any association between regimen complexity and self-reported adherence. 
This is in contrast to the only other study in patients undergoing dialysis that found an 
inverse association between regimen complexity and patient self-reported adherence. 
Notably, the study by Neri et al. [150] defined regimen complexity based on the number 
of pills prescribed daily and did not consider dosage forms, frequency of dosing and 
additional usage instructions; all of these factors are important contributors to a 
regimen complexity [201]. Although daily pill burden poses a threat to optimal 
adherence in patients undergoing haemodialysis [9], there is an equal possibility that 
having a few or many pills daily may result into equally high regimen complexity scores 
when all the dosage characteristics are considered. Moreover, we also found a strong 
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correlation between daily pill burden and MRCI scores (r = 0.88, p < 0.001). As such, 
we investigated the relationship between regimen complexity and adherence using the 
MRCI scores.  
Lower rates of adherence to phosphate binders have been linked with the type 
of binders prescribed [217]. More than two-thirds of the patients prescribed with 
phosphate binders were taking sevelamer hydrochloride (SH) in our sample. SH has 
a large tablet size, is non-chewable, needs frequent dosing and poses a higher pill 
burden in patients as compared to lanthanum carbonate (LC) [218]. Optimising 
regimen with alternative phosphate binders has been found effective in previous 
studies. The daily pill burden from phosphate binders was reduced to half after 
changing from SH to LC, and the adherence rate increased from 46.9% at baseline to 
72.5% at 12 months, with a significant decrease in the treatment cost incurred from 
phosphate binders [217].  
We found younger patients more likely to be nonadherent as compared to their 
older counterparts, and this finding is in agreement with previous studies in dialysis 
patients [11, 23, 150]. This can be partly explained by the fact that older patients with 
multiple comorbidities may be more concerned about mortality and prefer structured 
lives and adhere to medication therapy [11], despite increasing polypharmacy and 
associated regimen complexity. On the other hand, younger patients often report 
treatment-related issues for having difficulty in coming to terms with chronic illness [11, 
150] and might be at increased risk of nonadherence. On the contrary, increasing age, 
higher comorbidities and polypharmacy with complex regimen has been associated 
with poor medication adherence in other chronic diseases [44, 219]. Therefore, 
intervention programs targeting medication nonadherence often focus on older 
patients with multiple comorbid conditions [220]. It is extremely important that 
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intervention programs aimed at improving adherence in patients undergoing dialysis 
are mindful of the differences between other chronic conditions and ESKD, and should 
be more vigilant towards supporting younger patients undergoing dialysis.   
Our study has some limitations. The eminent one being the single-centred study 
with small sample size and subset nature of the objective measure of adherence. 
Though we had a small number of patients prescribed with phosphate binders, a 
significant negative correlation (r = – 0.26, p = 0.05) between prescribing phosphate 
binders and patient self-reported adherence was observed. The objective measure of 
pre-dialysis SPL only considers phosphate binders whereas the MRCI incorporates all 
medications. Furthermore, the reliability of measuring pre-dialysis SPL can be 
questioned as it is subjected to dietary and clinical factors. Moreover, the value may 
also be influenced by the ‘white-coat adherence’ phenomenon [2]. To overcome this 
issue, we collected preceding 3 months routinely measured pre-dialysis SPL of 
patients from medical records to estimate objective adherence to phosphate binders. 
On the other hand, self-reported Morisky questionnaire can be susceptible to recall 
bias and also evoke a social desirability response in the patients, which may result in 
an overestimation of the actual adherence behaviour [32]. Nevertheless, in lack of a 
gold-standard tool for measuring adherence in clinical practice [208], we considered 
using both measures and found a relatively strong association between them, further 
assuring that our assessment of adherence was reliable [33, 221]. The cross-sectional 
nature of this study can limit the suitability of measuring adherence behaviour due to 
reverse causation bias [206]. However, an investigation of patients’ preceding 12 
months medical history revealed few patients having missed dialysis sessions while 
most patients had been hospitalised at least once for non-elective reasons, indicating 
that patients’ non-responsiveness to therapy may be due to poor adherence and the 
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observed high nonadherence rates were not due to chance. Considering the 
exploratory nature of this study conducted in a small sample of patients undergoing 
haemodialysis, generalisability of the findings can be compromised. Therefore, we 
encourage readers for a cautious interpretation of our findings. Nonetheless, the 
regimen complexity scores, medication burden scores, demographic profiles and 
comorbidity scores identified in this study were similar to previous findings [9, 150, 
203].  
In conclusion, medication regimen complexity was not associated with patient 
self-reported adherence. Small subset of patients analysed using objective adherence 
measure found older patients having high comorbidity and highly complex medication 
regimens more likely to be adherent to their medications. Dialysis care professionals 
should be more vigilant towards supporting younger patients during their early 
adjustment to haemodialysis prescription. Future research should consider recruiting 
large sample of patients undergoing haemodialysis and using objective measures of 
adherence suitable for all patients and reflecting all medications (for e.g. medication 
possession ratio) to help confirm or not the exploratory findings of this study. 
Furthermore, future studies should explore the potential use of triangulation method 
whereby subjective and objective adherence assessment measures can supplement 
each other in determining the actual patient adherence to medication.    
 
Supporting Information 
Appendix 3. Patient Medication History Interview Questions 
Appendix 4. Patient Self-reported Questionnaires 
Appendix 5. Data collection form 
Appendix 6. Medication Regimen Complexity Index, MRCI 
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CHAPTER FOUR 
 
4. MEDICATION ADHERENCE PERSPECTIVES IN HAEMODIALYSIS PATIENTS: 
A QUALITATIVE STUDY 
 
4.1. Abstract 
Background: Medication nonadherence is highly prevalent among end-stage kidney 
disease patients undergoing haemodialysis. The aims of this study were to explore 
factors associated with medication adherence, and, to examine the differential 
perspectives on medication-taking behaviour shown by adherent and nonadherent 
patients undergoing haemodialysis, based on self-reported measures of adherence.   
Methods: A qualitative exploratory design was used. One-on-one semi-structured 
interviews were conducted with 30 patients undergoing haemodialysis at the 
outpatient dialysis facility in Hobart, Australia. Patient self-reported adherence was 
measured using the 4-item Morisky Green Levine scale. Interview transcripts were 
analysed using a template analysis method and mapped against the World Health 
Organisation (WHO) determinants of medication adherence.  
Results: Participants were 44-84 years old and were prescribed with 4-19 medications 
daily. More than half of the participants were nonadherent to their medications, based 
on self-reporting measure (56.7%, n = 17). Themes mapped against the WHO 
adherence model were patient-related (knowledge, awareness, attitude, self-efficacy, 
action control and facilitation), health system/ healthcare team related (quality of 
interaction, and mistrust and collateral arrangements), therapy-related (physical 
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characteristics of medicines, packaging, and side effects), condition-related (symptom 
severity), and social/ economic factors (access to medicines and relative affordability). 
Conclusions: Patients expressed a number of concerns that led to nonadherence 
behaviour. Many of the issues identified were patient-related and potentially modifiable 
by using psycho-educational or cognitive-behavioural interventions. Healthcare 
professionals should be more vigilant towards identifying these concerns in order to 
address adherence issues. Future research should be aimed at understanding 
healthcare professionals’ perceptions and practices of assessing medication 
adherence in patients undergoing dialysis that may guide intervention, in order to 
resolve this significant issue of medication nonadherence.      
 
Keywords: End-stage kidney disease; haemodialysis; medication adherence; 
patients’ perspectives; qualitative study 
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4.2. Introduction 
An estimated 2.6 million people worldwide received dialysis treatment for end-stage 
kidney disease (ESKD) in 2010, and a two-fold increase is expected by 2030 [222]. 
Developing a new molecule into a medicine for clinical use costs about $2.6 billion 
[223], whereas the cost of treating complications from medication nonadherence 
averages about $100 billion a year [2]. Medication nonadherence is highly prevalent 
in ESKD patients undergoing haemodialysis with an average prevalence rate of 52.5% 
[23]. The consequences of medication nonadherence are detrimental and costly in 
patients undergoing haemodialysis [23, 191, 224], as these patients have an increased 
burden of co-existing illness and have been prescribed with multiple complex regimens 
[140, 202, 208, 225]. Younger age, higher comorbidities, frequent hospitalisations, 
poly-pharmacy, experience of side effects, and high pill burden have been consistently 
reported as predictors of low medication adherence in patients undergoing 
haemodialysis [8, 11, 23, 146]. These adherence predictors have been mainly 
identified through quantitative methods. However, these methods are less capable of 
exploring patients’ perspectives on medication-taking behaviour and the challenges 
they face while adhering to their prescribed regimens [226]. There is a limited number 
of studies that have examined the patients’ perspectives on renal failure, treatment 
adherence, dietary constraints, and phosphate binding medications [226-228]. To date, 
little is known about haemodialysis patients’ perceptions regarding their prescribed 
regimen and the factors influencing their medication-taking behaviour. Understanding 
patients’ perspectives can help identify potentially modifiable factors such as patients’ 
intention to adhere, beliefs about medicines, features about treatment regimens, 
experiences of side effects, and provision of support mechanisms required to facilitate 
adherence [7]. As such, we aimed to explore qualitatively factors associated with 
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medication adherence, and to examine the perspectives on medication-taking 
behaviour, as shown by adherent and nonadherent patients undergoing 
haemodialysis.  
 
4.3. Methods 
 
4.3.1. Study Design 
A qualitative exploratory design was used. The consolidated criteria for reporting 
qualitative research (COREQ) guideline [15] was followed during the conduct and 
reporting of the study (Appendix 7). Ethics approval was granted by the Tasmanian 
Health and Medical Human Research Ethics Committee (H0014506). Written informed 
consent was obtained from all the participants. 
 
4.3.2. Research Team and Reflexivity 
Interviews were conducted by a pharmacist researcher (SG). The interviewer was 
external to the study site, and both the participants and the interviewer were unknown 
to each other before the study. The study aims and professional status of the 
interviewer were discussed with the participants prior to conducting the interviews.   
 
4.3.3. Participants 
All adult (≥ 18 years), English speaking patients, undergoing haemodialysis at the 
outpatient dialysis unit in Hobart, Australia were eligible to participate. Participant 
recruitment was sought from patients who had earlier participated in a cross-sectional 
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study [229] that investigated the association between medication regimen complexity 
and medication adherence in patients undergoing haemodialysis. This study had a 
good response rate of above 75%, with 53 patients undergoing haemodialysis 
completing the study. These patients were re-invited for participation in the qualitative 
interview. Thirty patients consented and completed the qualitative interview, the non-
participation of the remaining 23 patients was mainly due to lack of interest, fatigue or 
perceived inconvenience.    
 
4.3.4. Data Collection and Analysis  
One-to-one semi-structured interviews were held during the dialysis session. All 
interviews were conducted by SG between February and June 2015, using the 
interview guide (Appendix 8), and the median interview duration was 17.5 minutes 
(range, 6-41 minutes). All interview sessions were audio-recorded and transcribed 
verbatim; patients were not remunerated for their participation. Data on socio-
demographic and clinical characteristics were obtained during interviews and by 
reviewing medical records. Adherence was determined by self-reporting using the 4-
item Morisky Green Levine scale [20]. Patients with a Morisky score of zero were 
considered adherent and those scoring 1-4 were considered nonadherent, based on 
similar studies assessing self-reported adherence in patients undergoing 
haemodialysis [150, 229].   
Interview transcripts were analysed using the template analysis method [230]. 
Transcripts were repeatedly read for familiarisation and data immersion. Two 
investigators (SG and STRZ) independently coded and reviewed the first five 
transcripts to ensure concordance was reached. Remaining transcripts were coded by 
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SG and the final themes were agreed upon by both SG and STRZ. The analysis was 
iterative during data collection and carried out following each interview. Data saturation 
was assumed after 18 interviews. However, all participants who consented for the 
study were interviewed. Themes generated were mapped against the World Health 
Organisation (WHO) determinants of medication adherence that included patient-
related-, health system/ healthcare team related-, therapy-related-, condition-related-, 
and social/ economic related factors [16]. Patient-related factors within the WHO 
model were further sub-divided into such aspects as knowledge, awareness, attitude, 
self-efficacy, action control, and facilitation, based on an adherence support taxonomy 
of behaviour change techniques [231].  
 
4.4. Results 
Table 9 shows the study characteristics of the participants. The median age was 71 
years (range: 44-87 years), and the patients were taking 4-19 medications daily. More 
than half of the participants were nonadherent to their medications, based on self-
reporting measure (56.7%, n = 17).  
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Table 9. Characteristics of Study Participants (n = 30) 
Variables Number (%) 
Age, in years 69.6±11.0  
40-59 5 (16.7) 
60-79 18 (60.0) 
≥80 7 (23.3) 
Gender, male 23 (76.7) 
Marital status, married 17 (56.7) 
Living with family 18 (60.0) 
Level of education, ≥ high school 24 (80.0) 
Smoking history, non-smoker 24 (80.0) 
Number of medicines prescribed 11.4±4.3  
1-5 4 (13.3) 
6-10 7 (23.3) 
≥11 19 (63.3) 
Daily pill burden 16.0±6.1  
1-9 4 (13.3) 
10-19 15 (50.0) 
≥20 11 (36.7) 
Years on dialysis 4.1±4.1  
<1 6 (20.0) 
1-5 17 (56.7) 
≥6 7 (23.3) 
Hospitalisation (past one year)ƚ 22 (73.3) 
Dialysis session missed ƚ 5 (16.7) 
Diabetes 7 (23.3) 
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Variables Number (%) 
Hypertension 17 (56.7) 
Cardiovascular disease 16 (53.3) 
Adherence to medication µ    
Adherent 13 (43.3) 
Nonadherent 17 (56.7) 
Note: For continuous variables, Mean±SD; for categorical variables, numbers with percentages in 
parentheses. 
µ Adherence to medication was based on self-reported measure using 4-item Morisky Green Levine 
scale. Patients scoring zero were considered adherent.  
ƚ At least one event of hospitalisation or dialysis session missed in past one year prior to the month of 
data collection. 
 
 
The exemplar quotes for each theme are provided in Table 10. A full 
compilation of quotations is supplied as Appendix 9. The major themes, classified 
according to WHO determinants of adherence, are presented below. Please note the 
following abbreviation for the section below: P = patient (with a number to indicate the 
interview sequence, for example, P5 is the fifth interviewed patient).  
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Table 10. Determinants of medication adherence in patients undergoing 
haemodialysis  
Themes based on WHO taxonomy Exemplar quotes 
Patient-relatedµ  
Knowledge and belief about 
medicines 
 
- Lack of understanding 
about medicines 
“Well, I just don’t know what some of them are for.” (P1, male, 53 years, 
PSR NAD) 
 “I don’t know what’s really important and… if you missed [medication] 
once or twice it wouldn’t matter, I’ve no idea.” (P5, female, 58 years, 
PSR NAD) 
 “As far vitamins are no much point for me because it all gets dialysed 
out of here [pointing to the dialysis machine].” (P8, male, 71 years, PSR 
NAD) 
- Lack of benefit “I don’t know if they doing any good? […] I thought well, you know, I am 
taking all this in the morning, um… are they doing any good? I don’t 
know.” (P5, female, 58 years, PSR NAD) 
- Safety concerns  “There’s one medicine that is a statin which I’m very unhappy about. It’s 
Atorvastatin. And, I’m unhappy about that… because they… they, ah, 
studies have shown that there are lots of side effects of that.” (P6, 
female, 74 years, PSR NAD) 
- Relative importance “I think blood pressure one is important. Yes, I think that is important to 
keep my blood pressure down…” (P6, female, 74 years, PSR NAD) 
- Perceived need “There’s something to do with my kidney and that. […] it’s not working 
very well. If I started not taking them, I could for been… you know in 
trouble. They all they are for a reason. Yeah.” (P15, male, 78 years, PSR 
AD) 
- Perceived effectiveness “I put myself on that [medicine] because I didn’t have any arthritis or 
anything before I started [dialysis] and all of a sudden my fingers going, 
and I put it on that now for a month and it stopped the pain…” (P12, 
female, 80 years, PSR AD) 
 
Awareness and attitude  
- Motivation to live “I don’t know how much longer I got to live. But I want to get up to 80. 
If I become 80, that will be the longest lived in all our family. And if I 
make 80…  I’m the champion.” (P15, male, 78 years, PSR AD) 
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Themes based on WHO taxonomy Exemplar quotes 
- Positive attitude “I got to take them as they keep me healthy. And I don’t have a problem 
with it.” (P21, male, 84 years, PSR AD) 
- General dislike “I don’t like the fact that I need to take them… Not happy about taking 
medications but the alternatives not good.” (P13, female, 63 years, PSR 
NAD) 
Self-efficacy  
- Disruption to daily routine  “Well it’s in the morning and night, I’m just used to doing that. It’s the 
middle one I have to take care of… I take it at night. Take two at night 
instead of three, spreading three during the day, which the doctor asked 
me to try, because it might be more effective. I haven’t yet succeeded.” 
(P8, male, 71 years, PSR NAD) 
- Inconvenience during 
travel 
“People don’t make it difficult for me, but it’s the fact that I’ve, I travel, 
I like to travel of course make it difficult, because I’ve got to take all the 
stuffs with me, organise something every day or whatever. Yes, 
traveling.” (P6, female, 74 years, PSR NAD) 
- Accustomed regimen “I got all these medications every day, morning, evening, night. So, I 
never forget it, now.” (P15, male, 78 years, PSR AD) 
 “I’ve been taking it for a long time and it’s just natural.” (P27, male, 79 
years, PSR AD) 
- Unaccustomed regimen “I’m supposed to take a medicine for my [restless leg], but I keep 
forgetting… So, um, I’ve only been told this few days ago and I haven’t 
got used to it, to taking it.” (P8, male, 71 years, PSR NAD) 
Action control  
- Forgetfulness “Well, I think that I’m much more, I don’t know, forgetful then I used to 
be, I can’t think this clearly… seems I pick but I don’t. Um. Remembering 
to take it. I think that’s the biggest thing.” (P6, female, 74 years, PSR 
NAD) 
- Stimuli or cues for action “I have a little pill boxes, it holds all morning, noon and night… I just 
take whatever is required during dinner, or at meal in the night.” (P15, 
male, 78 years, PSR AD) 
- Visual allocation of pills “I’ve got them [medicines] in the kitchen table, so I can’t forget.” (P10, 
female, 53 years, PSR AD) 
- Association with meals “If I don’t have lunch, I don’t remember my medicines, always. Lunch is 
sort of tied to the medicines. So, if I wouldn’t eat, I wouldn’t take the 
medicines so regularly, I think.” (P6, female, 74 years, PSR NAD) 
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Themes based on WHO taxonomy Exemplar quotes 
Facilitation  
- Role of support “My wife makes sure I take them... she helps. She gets all medicines 
ready, tablets ready… she does all, mostly.” (P27, male, 79 years, PSR 
AD) 
 “Some medicines make me dizzy. It is a problem. Especially when I get 
no support at home. Coz my husband, he works at night, and I got to be 
careful. Coz I got no support at home.” (P7, female, 65 years, PSR NAD) 
Health system/ HCT-related  
Quality of interaction with HCT  
- One-way communication “[Asking Dr about the need of so many medicines…] I saw doctor at the 
clinic last time and he said, “No, they are all good”. He went through 
one by one [medicines] and no, that’s good, you need that, you need 
that, so…” (P7, female, 65 years, PSR NAD) 
- Lack of engagement “[Consultations are] never very long usually, you know. Just checks the 
figures, just look at your blood figures and everything’s ok and you 
know.” (P2, male, 61 years, PSR NAD) 
- Lack of time “I really need to speak to the pharmacist. Um, but they’re very busy, but 
I will, I must speak to, I want to know what every medicines, especially 
12 medicines in the morning are for.” (P5, female, 58 years, PSR NAD) 
- Support from HCT “It’s always great with my GP. I’ve been going to him for 15 years and 
we’re quite informal and he’s very helpful and if I complained about 
what these things, he investigates them properly.” (P11, male, 84 years, 
PSR AD) 
 “You know, just, give all your tablets to the chemist and he’ll sort them 
out. Makes it so much easier. He puts them in [Webster-Pak] … for two 
weeks and you got a just twist and pop a tablets… so I don’t need to 
worry about what one of this, one of this, anymore.” (P16, male, 65 
years, PSR AD) 
Mistrust and collateral 
arrangements 
 
- Pressure to hide “I forgot to say [doctor] about it [not taking phosphate binders]. 
Because, I think what they will gonna tell me is, I have to take it. I’m 
frightened obvious the doctor’s gonna say, which they probably will, 
because it’s very important, the phosphate, I know that.” (P5, female, 
58 years, PSR NAD) 
89 
 
Themes based on WHO taxonomy Exemplar quotes 
- Being a good patient “I don’t. I don’t know I take it because I’ve been told to take it, and I do 
that. But I don’t take it very seriously. And if I miss it, I don’t get panic, 
so.” (P8, male, 71 years, PSR NAD) 
- Personal control of 
treatment 
“I discuss it with myself. Or, I go to [doctor] who gets upset because I 
decide to take more than what I’m prescribed. Like the Sifrol, it wasn’t 
holding, so I lifted the [dose] up to two. And checked it [in the internet] 
and it was okay to do that and then she [doctor] got most upset because 
she said it effects the kidney, and I said well they’re pretty shot already, 
and she said they can always get worse.” (P8, male, 71 years, PSR NAD) 
- Trust in HCT “I take my medicines. They give me the right thing, so I just take them. 
Except when I’m allergic to.”  (P10, female, 53 years, PSR AD) 
 “I keep taking them until my doctor takes me out of it. I just take the 
dose that’s on the charts I got.” (P25, male, 72 years, PSR AD) 
 
Therapy-related   
Physical characteristics of 
medicines 
 
- Pill size “I’ve got the one [medicine], got to cut it half, I’ve got a cut five or six in 
half so I’ve got half for in the morning and half at night.” (P9, female, 
63 years, PSR NAD) 
- Palatability “Some of them, as soon as you get them on the tongue…I swear it, 
dissolves straight away and it tastes disgusting! First thing in the 
morning they, oh! […] Just bitter, you know, one of them.” (P5, female, 
58 years, PSR NAD) 
Medicine packaging “One I have very hard to get it out. A little capsule, that for pain. Yeah. 
Very hard to put out. The capsules are completely crushed by the time 
it gets out of its thing! That’s the only problem.” (P11, male, 84 years, 
PSR AD) 
Side effects of medicines “Sometimes they work, sometimes really make me sick. Makes me 
dizzy. It’s a bit stronger. I don’t take them. If they are not too strong, I’ll 
take them… but if they make me dizzy, I don’t.” (P7, female, 65 years, 
PSR NAD) 
 “I don’t like taking them, the [antibiotics], they give me toilet all the 
time.” (P29, male, 65 years, PSR NAD) 
Social/ economic  
Access to medicines  
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Themes based on WHO taxonomy Exemplar quotes 
- Acquiring script “I’m taking a lot of pain tablets at the moment… I was taking patches, 
but you can’t get more than a month’s supply. So, that means going 
back on doctors, and when I get out of here [dialysis], I don’t want… to 
get to the doctors on my days off [from dialysis], so I’m just taking 
Panadol and Panadol with Codeine. But, is not really enough, to be 
honest.” (P2, male, 61 years, PSR NAD) 
- Clinic and pharmacy 
location 
“Because I live out of town… and about 40 minutes from the chemist, 
just kind of be aware how many more medicines I’ve got, it’s nothing 
worse than running out and having to drive especially for that, yeah.” 
(P3, male, 44 years, PSR NAD) 
 “Some of the scripts you can’t get from [local pharmacy]. So, I’ve had 
issues actually getting them in the past… When my doctor goes on 
holidays, I can’t acquire a script without doing it a 100 km drive. 
[Dialysis staffs] refused to help me, and the doctors refused to give 
scripts over the phone. I can’t acquire a script over the phone…” (P1, 
male, 53 years, PSR NAD) 
Relative affordability “Well, they’re quite expensive! So they do affect me, the cost. I don’t 
have a health care card. I’ve to pay the full subsidised price… I’ve retired 
and so I’m living of an allocated pension from my superannuation.” (P4, 
male, 56 years, PSR NAD) 
 “The only thing that worries me is, coz I’m in a wheel chair and I need 
to get to the hospital to get the scripts, it means for $ 30 to get in the 
taxi to go in there and pick up the script or I drive my mobility scooter 
all the way in there, which means two hours and an hour of each waiting 
to pick them up.” (P2, male, 61 years, PSR NAD) 
Condition-related   
Symptom severity “Have you seen me 12 months ago, I am on a 100 % better [condition] 
after this year but last year and a year before, no, I didn’t really think 
I’m gonna make it. Not even everybody else also gonna make it either.” 
(P12, female, 80 years, PSR AD) 
 “I don’t notice any [improvement] from my medications, whatsoever.” 
(P1, male, 53 years, PSR NAD) 
Abbreviations: AD, Adherent; NAD, nonadherent; BP, blood pressure, HCT, healthcare team; PSR, 
patient self-reports 
µ Patient-related factors further classified based on adherence support taxonomy by de Bruin et al., 
2010.  
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4.4.1. Theme 1: Patient-related Factors 
 
4.4.1.1. Knowledge and belief about medicines   
Patients assigned varied importance to their prescribed medicines and it appeared 
that the patients who were less informed of the purpose of their medicines saw little 
reason for taking them regularly (P1, P5). This lack of understanding also led to the 
misconception that some of their medicines get washed out during dialysis and would 
become ineffective (P8). Such misconceptions triggered doubts about their necessity, 
which led to prioritising medication due to perceived lack of benefit (P1, P5), and 
relative importance given to some medicines (P6), thus encouraging nonadherence 
behaviour. Furthermore, some patients acquired nonadherent behaviour as they 
expressed safety concerns about their medications (P5, P6). On the other hand, 
patients having a better understanding of their disease process had higher perceived 
need (P11, P15, P16) and developed perceived effectiveness (P12) of their medication 
therapy, and were therefore adherent.   
 
4.4.1.2. Awareness and attitude towards medicines 
Being aware of the consequences of nonadherence, such as deterioration of the 
medical condition and, in rare cases, fear of death, was found to be a motivator to be 
adherent. Motivated patients desiring to live longer (P12, P15, P20, P21, P25) and 
those expressing positive attitude towards taking medicines (P10, P11, P15, P21, P24, 
P28) were thus found to be adherent. On the contrary, a patient who was not motivated 
to overcome a general dislike of taking medicine was likely to demonstrate a 
nonadherent behaviour (P13).   
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4.4.1.3. Self-efficacy 
Patients’ ability to manage their medication in different situations also influenced their 
medication-taking behaviour. Disruption to daily routine, particularly the midday dosing 
frequency, was identified as a practical barrier to medication adherence. This was 
pertinent in patients expressing personal preferences for taking medications at their 
convenience (P8) or in those prioritising important life events of the day over taking 
medicines (P18). Also, some participants accentuated that carrying medicines and 
remembering to take them was inconvenient during their travel and outdoor activities 
(P3, P6). Patients accustomed to their regimen, after following a routine for a relatively 
longer span of time, were found to be adherent (P15, P16, P20, P21, P27, P30), 
whereas a patient who was unaccustomed to  recent changes in his medication 
regimen had a tendency to forget and was more likely to be nonadherent (P8).  
 
4.4.1.4. Action control 
Patients’ capacity to control medication intake as planned was also influencing 
medication adherence. Participants expressed forgetfulness as an excuse for not 
taking medication and gave an impression that nonadherence was unintentional (P6, 
P8, P14). Adherent patients, however, made their circumstances favourable for taking 
medicines by using stimuli such as pill boxes (P15, P18, P25) or by visibly allocating 
their pills (P10, P12). Furthermore, some patients connected their meals and 
medicines together by stating that skipping meals during the day might result in their 
not taking their medicines (P5, P6). 
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4.4.1.5. Facilitation 
Patients who were influenced and reinforced by their family members (P12, P15, P21, 
P27) were better at adhering to their medication regimen, whereas patients expressing 
lack of support from their family members (P7) or those who lived alone (P2) were 
found to be nonadherent to their medications.  
 
4.4.2. Theme 2: Health System/Healthcare Team-related Factors 
 
4.4.2.1. Quality of interaction with healthcare team 
A few patients expressed dissatisfaction with their interaction and engagement with 
the healthcare team and were likely to demonstrate nonadherent behaviour. Some of 
the issues raised by these patients include one-sided communication with their 
physician (P7), non-concordance during consultation visits (P2, P4); and a perceived 
lack of time for medication counselling (P5). Some patients avoided discussing 
adherence related issues with their doctors as they had a preconceived notion about 
what their doctors would say. This might have occurred due to previous unpleasant 
interactions with their doctors. For instance, a participant remembered an occasion 
when the doctor showed less empathy towards her unresolved symptoms, despite her 
taking medications (P5). On the other hand, patients expressing satisfaction with their 
interaction and engagement with the healthcare professionals tended to be adherent 
to their medications (P11, P16).  
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4.4.2.2. Mistrust and collateral arrangements 
A general lack of trust in the healthcare team, particularly in the medical profession 
was reported by some patients. Those who perceived that their concerns about 
medications would not be attended to by their doctors preferred either hiding their 
concerns (P5) or portraying themselves as good patients (P6, P8). Dissatisfaction and 
mistrust, as a result of unpleasant interactions with physicians, may have further 
aggravated patients into making parallel or collateral arrangements for themselves, by 
surpassing the physicians’ decisions and recommendations regarding their 
medications. In this way, patients felt that they had exerted a sense of personal control 
over their treatment (P2, P7, P8). In contrast, patients who were experiencing a 
satisfactory and trusting relationship with their doctors seemed to have followed the 
prescribed instructions in a relatively compliant fashion (P10, P11, P15, P20, P25).   
 
4.4.3. Theme 3: Therapy-related Factors 
 
4.4.3.1. Physical characteristics of medicines  
Physical characteristics of medicines were considered to hinder adherence in some 
patients. For example, pharmaceutical characteristics such as the size of pills, 
especially the larger ones (for example, phosphate binders) which were considered 
difficult to swallow (P9, P10). In addition, a few patients complained about palatability 
of medicines to be a problem when they had to be taken early in the morning (P5, P13, 
P22).  
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4.4.3.2. Side effects of medicines  
Some patients complained about side effects such as dizziness, nausea, vomiting and 
diarrhoea after taking their medicines (P5, P7, P29). They experimented on their own 
by skipping doses and observing if the symptoms persisted. When patients were 
convinced that their past experiences of untoward symptoms were the results of taking 
their medicines (P5, P7, P29), they would prefer to avoid those medicines to ensure 
that they would not suffer from similar adverse effects in the future. 
 
4.4.3.3. Packaging of medicines  
One patient considered one of his medicine packaging to be non-user-friendly (P11), 
posing it to be a practical barrier that impeded adherence. 
 
4.4.4. Theme 4: Social/Economic Factors 
 
4.4.4.1. Access to medicine 
Medicines in Australia are supplied at a subsidised cost through the Pharmaceutical 
Benefits Scheme (PBS). However, access to some specialised medicines routinely 
used in patients undergoing dialysis (such as Lanthanum, Erythropoietin, Cinacalcet 
and so on) is restricted to specialised pharmacies and hospital based clinicians. This 
becomes an issue particularly for patients who are living far away from the major town 
or cities and requiring scripts; in their local areas they are offered only limited access 
to professional medical services (P1, P3). In addition, under the PBS, patients are 
constrained to filling their prescription to no more than a month’s supply, which makes 
frequent visits to acquire scripts inconvenient for patients having dialysis fatigue and 
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chronic incapacitation (P2, P23). This results in medicine shortage and patients are 
compelled to choose readily available over-the-counter medicines that may not always 
be effective alternatives (P2). Besides acquiring scripts, the clinic and pharmacy 
locations also posed a limitation for accessing medicines for patients living in remote 
areas (P1, P3).   
 
4.4.4.2. Relative affordability 
The relative affordability of medicines due to cost or financial constraints was another 
factor that impedes access to medicines and ultimately contributed to nonadherence. 
Some of the patients undergoing haemodialysis were over the retirement age and lived 
on disability support pensions, superannuation or disability benefits (P2, P4). Although 
patients were getting medicines with a highly subsidised price through the PBS, this 
tends to cover only a partial cost of prescription medicines. However, due to the 
complexity of disease treatment and associated symptom burden, patients often 
required additional over-the-counter medicines, including multi-vitamin preparations, 
vitamin D, iron and mineral supplements, pain medicines and so on. These medicines 
are not covered by the PBS and patients needed to pay for them out-of-pocket. The 
relative affordability of these medicines, when considering the cost of acquiring scripts, 
transportation costs to visit a health service facility and medicine costs, restrained 
patients from accessing their medicines (P2, P4, P5).  
 
4.4.5. Theme 5: Condition-related Factors 
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4.4.5.1. Symptom severity 
Severity of symptoms had an influence on patients’ risk perception, importance of 
following treatment regimen and the priority they placed on medication adherence. A 
patient who observed decreased symptom severity over time was found to be 
adherent with her prescribed regimen (P12). However, another patient who did not 
see any improvement of his health condition was found to be nonadherent (P1).   
 
4.5. Discussion 
This qualitative study explored factors associated with medication adherence in 
patients undergoing haemodialysis, and examined their perceptions on medication-
taking behaviour. A dissonance of perceptions with respect to adherence behaviour 
was observed between adherent and nonadherent patients. Most factors influencing 
medication-taking behaviour were patient-related. Some of the factors identified 
corroborated with past findings such as safety concerns of medicines [225, 226, 232], 
disruption to daily routine [226], forgetfulness [225, 232], use of reminders [226, 228], 
and the role of social support [150, 228].  
 Knowledge and beliefs about medicines were essential patient-specific factors, 
potentially impeding adherence behaviour. Patients prioritised their medicines due to 
poor understanding about medicines, perceived necessity and concerns regarding 
medicines, all of which resulted in nonadherence behaviour. These findings in relation 
to patients’ beliefs regarding their medication can be further studied through various 
behavioural models of adherence (for example the Medication Adherence Model, the 
Health Belief Model, the Theory of Planned Behaviour) [233-235]. Belief components, 
such as necessity and concerns, can be specifically targeted by utilising tools such as 
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the Beliefs about Medicines Questionnaires (BMQ), particularly the Specific-Necessity 
and Specific-Concerns scale [236]. Patients’ beliefs about necessity and concerns 
related to medicine can be overcome through psycho-educational interventions [237]. 
Thus, our study re-emphasises the need for providing medication-related information 
to combat patient ignorance about medications in those undergoing haemodialysis 
[226, 238].  
 Patients reporting poor interaction with healthcare providers displayed a 
compromised adherence behaviour. In particular, patients were less satisfied with the 
consultations that lacked inquiry about their experiences of taking medicines and any 
adverse effects they might be suffering. Although patients reporting medication-related 
symptoms to their physician is less frequent, physicians do not necessarily always 
respond to them, even if they were reported [239, 240]. Suboptimal patient-physician 
interaction may lead to patients losing trust with physicians’ recommendations and 
hiding their concerns, while trying to be a good patient [225]. This may also lead to 
patients making collateral arrangements for their medications to exert a flawed sense 
of control over their treatment, resulting in nonadherence. Thus, it is extremely 
important for the healthcare professionals to routinely instigate dialogues about 
medication issues with patients and encourage them to volunteer such information if 
they were not being asked for it during consultations [239].  
Socio-economic factors, such as access to medicine and its affordability, also 
raised concerns that hindered adherence. Access to prescribed medicines and 
professional medical services gradually decline when moving away from metropolitan 
cities through to rural and remote locations [241]. Although our study site was located 
in the metropolitan city, some patients visiting the dialysis centre lived in rural areas 
and were required to travel to the city where they could access professional advice for 
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acquiring prescriptions or repeating them at the pharmacy. Though eligible patients 
benefitted from the government subsidy schemes for cost reductions in prescription 
medicines [242], the large financial burden accumulated from the number of 
prescription and non-prescription medicines, the cost of acquiring scripts, 
transportation, and out-of-pocket payments annulled the cost benefits from the subsidy 
for patients undergoing haemodialysis. Medicine affordability can be much more 
challenging for patients in developing countries where a public healthcare system does 
not guarantee subsidy of prescription medicines and patients generally do not 
subscribe to health coverage schemes [243].   
This study finding has both clinical and research implications. As dialysis 
patients, coupled with comorbid illness and dialysis-associated complications, 
continually demand a high pill burden for treatment, we tend to lose sight of how 
polypharmacy, regimen complexity and adherence issues should be addressed. As 
such, this study provides a subjective account of patients’ concerns that may lead to 
nonadherence. Healthcare professionals could routinely instigate dialogues with 
patients and encourage them to volunteer information concerning their current 
medicines, their readiness to start new therapy, any changes with dose or dosage 
requirements and any side-effects or safety concerns with which they might be dealing. 
Any transitioning of medication therapy could be facilitated by providing personalised 
education, capitalising on the need for and importance of taking medicines. Improving 
access to professional medical and pharmaceutical services, developing dialysis 
centre-based intervention programs and focussing on psycho-educational support 
could be effective. The same framework could be utilised in research settings to 
develop behavioural and educational interventions for examining patient concerns 
associated with medication adherence.     
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Study limitations require a mention. This is a single-centred study that could 
limit the generalisability of the findings. Interviews were conducted with English 
speaking patients only, thus, the findings may not be generalisable to non-English 
speaking patients. Although the participants were interviewed in an outpatient setting 
in a tertiary care metropolitan hospital, some of the patients came from rural areas, 
necessitated by access limited healthcare services and support mechanisms. Hence, 
the access barrier gained attention in our themes, which might only be true for patients 
living in rural areas [232]. As interviews were conducted during dialysis sessions, 
patients could have been hesitant in responding freely while sharing their experiences. 
Furthermore, interviews for research purposes could have facilitated a social 
desirability response [244], although it was unlikely as wide-ranging viewpoints were 
expressed. Despite limitations, we used a purposive sampling method to identify 
participants of different demographic characteristics, showing different medication-
taking behaviour that best represented the perspectives of patients regarding the 
phenomenon under study.  
 
4.6. Conclusions 
Patients undergoing haemodialysis expressed a number of concerns that led to 
nonadherence behaviour. Many of the issues identified were patient-related and 
potentially modifiable by using psycho-educational or cognitive-behavioural 
interventions. Healthcare professionals should be more vigilant towards identifying 
these concerns to address adherence issues. Future research should be aimed at 
understanding healthcare professionals’ perceptions and practices of assessing 
medication adherence in patients undergoing dialysis. This could guide intervention to 
resolve this significant issue of medication nonadherence.      
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CHAPTER FIVE 
 
5. RENAL PHARMACISTS’ PERCEPTIONS AND CURRENT PRACTICES OF 
ASSESSING MEDICATION ADHERENCE IN DIALYSIS PATIENTS: 
DEVELOPMENT AND PILOTING OF A SURVEY TOOL 
 
5.1. Abstract 
Background: Medication nonadherence is a major problem in chronic kidney failure 
patients undergoing dialysis. Pharmacists play a vital role in improving medication-
related patient outcomes, reducing drug-related problems, and improving medication 
adherence. However, little is known about the current practices of pharmacists in 
assessing adherence in patients undergoing dialysis.  
Objective: To develop and pilot a survey instrument to measure pharmacists’ 
perceptions, current practices, and barriers to assessing medication adherence in 
patients undergoing dialysis.  
Methods and materials: Specialist renal pharmacists in Australia were surveyed 
during March and May 2016. The survey included five psychometric scales measuring 
perceived prevalence and contributors of nonadherence, effectiveness of methods, 
barriers and confidence to assess adherence on a 10-point Likert scale (1 = strongly 
disagree, to 10 = strongly agree). Current adherence assessment practices were 
identified using a 4-point graded response (1 = do not practise at all, to 4 = practise 
for every patient). 
Results: The survey tool demonstrated an acceptable overall reliability with a 
Cronbach’s alpha of 0.79. A total of 41 pharmacists completed the survey (response 
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rate, 91.1%); a majority (91.9%, n = 34; median = 8.0) believed that patients were 
nonadherent to their medication. Objective blood monitoring was most frequently used 
to determine nonadherence (57.1%, n = 16); subjective patient interviews were rarely 
conducted (27.6%, n = 8). Time constraints (43.8%, n = 14) and lack of administrative 
support (31.3%, n = 10) were perceived as barriers to assessing adherence. Although 
all pharmacists (100%, n = 33) support the presence of dedicated pharmacists for 
assessing adherence, only 24.2% were actually performing this function. 
Conclusions: Pharmacists were rarely assigned to assess adherence in dialysis 
settings. Established self-reporting methods to measure adherence were under-
utilised compared with objective blood monitoring. Having renal-specialised 
pharmacists in dialysis centres might facilitate adherence promotion and early 
identification of medication-related issues in patients undergoing dialysis. 
 
Keywords: Adherence assessment practices; cross-sectional studies; dialysis; kidney 
failure, chronic; medication adherence; pharmacists 
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5.2. Impact of Findings on Practice 
 
• Medication nonadherence in chronically ill patients is a major determinant of 
poor patient outcomes. 
• Dialysis centres routinely rely on blood results to detect medication 
nonadherence, with little to no attention being paid to patient engagement via 
self-reporting measures. 
• Renal pharmacists are highly confident in their ability to identify and resolve 
medication-related issues in patients undergoing dialysis.  
• Having dedicated renal pharmacists in dialysis centres would facilitate 
assessment and promotion of medication adherence in patients undergoing 
dialysis.  
 
5.3. Introduction 
Medication nonadherence is a global problem of striking magnitude [16]. An estimated 
50% of patients with chronic diseases do not take their medicines as prescribed [16]. 
Poor patient adherence has led to increased morbidity and mortality in patients, 
incurring an annual direct expenditure of approximately $100 billion [2]. The vast 
majority of clinical research has been focussed on improving patient outcomes from 
medication therapy [1]. Yet, little emphasis is given in validating whether or not patients 
are actually adhering to their prescribed regimen. Not that adherence is not measured 
in routine settings; various objective and subjective tools have been designed to 
measures adherence [2]. However, in clinical practices, the use of proxy measures, 
such as objective blood monitoring for drugs, physical assessment and monitoring 
vitals, observing clinical responses or side effects from therapy, checking pills and so 
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on, are more common [2, 33]. Assessment from these methods could give skewed 
results as they do not tend to truly reflect on the medication-taking behaviour of the 
patients. Similarly, self-reporting methods, although prone to social desirability 
responses [229], can be effective means to get closer to the patients and better 
understand their concerns, as related to medicines. However, identifying patients’ 
medication-taking behaviour can be a challenging endeavour in routine clinical 
practice [1]. Lack of time, increased work pressure and other clinical priorities may not 
allow healthcare professionals to spend a dedicated amount of time to discuss 
medication-related problems with patients [232]. On the other hand, end-stage kidney 
disease (ESKD) patients undergoing chronic dialysis are unique patient cohorts who 
provide an opportunity to frequently interact with the healthcare professionals, usually 
three times a week for a period of three to five hours a day. Such an engagement 
provides an excellent opportunity for the renal healthcare professionals to educate and 
encourage medication adherence in patients undergoing dialysis.  
Medication nonadherence is a major problem in ESKD patients receiving 
dialysis and they have the highest daily pill burden compared with patients who have 
chronic cardiovascular diseases or HIV [10]. The median pill burden in patients 
undergoing dialysis has been reported as high as 19 pills per day, with a quarter of 
them taking more than 25 medications daily [9]. Such high pill burden may have 
resulted from the increased burden of concomitant illness and dialysis-associated 
complications, leading to an increased complexity of various treatment regimens [229]. 
Overall, half of the dialysis-treated patients are nonadherent to at least part of their 
dialysis regimen, with medication nonadherence ranging between 12.5% and 98.6% 
[23, 139]. The deterioration of the underlying disease conditions in patients undergoing 
dialysis following nonadherence has been associated with increased mortality and 
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recurrent hospitalisations, incurring a substantial economic burden on the healthcare 
system [23].  
Healthcare professionals, including pharmacists, strive for the selection of best 
possible medications for their patients. Pharmacists are well positioned to optimise 
medication therapy, identify impediments to adherence and develop methods to 
address and educate patients, as well as the allied healthcare team, on medication-
related issues [245]. Pharmacists’ involvement has significantly reduced 
hospitalisation rates and cumulative time spent in hospitals in patients undergoing 
dialysis [246], with trends towards a reduction in all-cause mortality [247]. Furthermore, 
pharmacist implemented protocols have improved the phosphate and anaemia 
management in patients undergoing dialysis [248, 249]. However, there is insufficient 
evidence as to the extent of pharmacists’ awareness of adherence assessment 
practices and of how much time is devoted to assess and promote adherence in 
dialysis settings. To implement adherence assessment practices in routine patient 
care, it is imperative to understand how pharmacists perceive the issue of 
nonadherence in patients undergoing dialysis. No prior studies have attempted to 
study current practices and barriers faced by renal pharmacists while measuring and 
promoting medication adherence in patients undergoing dialysis.  
 
5.4. Aim of the Study 
To develop a survey tool and understand renal pharmacists’ perceptions, current 
practices, and barriers to assessing medication adherence in patients undergoing 
dialysis. 
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5.5. Ethics Approval 
Approved by the Tasmanian Social Sciences Human Research Ethics Committee, 
University of Tasmania (H0015433).  
 
5.6. Method 
5.6.1. Study Design 
A cross-sectional survey design was used. We followed the STROBE (Strengthening 
the Reporting of Observational Studies in Epidemiology) guideline (Appendix 10) for 
the conduct and reporting of this study [14].   
 
5.6.2. Setting and Recruitment of Participants  
All renal-specialised pharmacists currently registered to practise in Australian dialysis 
centres were eligible to participate. Recruiting participants directly was not feasible 
due to the lack of an assured means of identifying pharmacists involved in the care of 
patients undergoing dialysis; thus we sought recruitment through a professional renal 
forum, The Australasian Renal Pharmacists (ARP), a renal-specialised pharmacists’ 
discussion forum, associated with The Society of Hospital Pharmacists of Australia 
(SHPA). The ARP consisted of 45 active members during the time of data collection.  
 
5.6.3. Data Collection 
The survey was hosted online for a period of 12 weeks between March and May 2016. 
During this period, an invitation flyer describing the study aims and a hyperlink to the 
online survey were circulated to participants on a fortnightly basis through email alerts, 
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e-newsletters, and social media posts, in cooperation with the SHPA. Survey 
completion was followed by a lucky draw to randomly select eight participants to 
receive gratitude gift vouchers worth AUD $100 each for participation.    
 
5.6.4. Survey Development  
Survey instruments that measured pharmacists’ perceptions and practices of 
assessing medication adherence in patients undergoing dialysis could not be identified. 
Hence, we designed a survey tool following an extensive literature review [23, 111, 
250-253], applying the basic principles of survey research [254, 255]. Initially, 82 
survey items were generated within the themes: perceived prevalence and 
contributors of nonadherence, barriers to measuring adherence, confidence in 
assessing adherence, and effective measures of identifying nonadherence. Following 
content review, five items were removed due to duplication and relevance. Following 
this, expert consultants (a nephrologists, two renal nurses and a pharmacist) were 
sought to review the questionnaire. Following suggestions, five more items were 
removed, limiting the questionnaire to 72 items. For the face and content validity, 
readability and comprehensiveness of the questionnaire, a convenient sample of ten 
renal healthcare professionals (five renal nurses, three renal pharmacists and 2 
nephrologists) were invited to complete the survey and feedback was requested about 
the completion time, ease of completion and clarity of the questionnaire. This step led 
to a further deletion of 15 more items from the instrument. 
The final instrument was comprised of 57 items, subdivided into seven sections. 
The first section contained 14 questions about study demographics. The following five 
sections sought to understand participants’ perceptions on the prevalence of 
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medication nonadherence (ten questions), contributors of nonadherence (ten 
questions), perceived effectiveness of methods to identify nonadherence (six 
questions), barriers to assessing adherence (six questions), and participants’ 
confidence in assessing adherence (five questions). Participants’ perceptions were 
measured on a 10-point Likert scale of agreement, where 1 = strongly disagree and 
10 = strongly agree. The final section, contained six questions that surveyed current 
practices of assessing adherence through a 4-point graded response, including 
practice for some patients (with a higher risk of adverse effects), for most patients 
(routine practice except for lower risk patients), practice for every patient, and not 
applicable (do not practice at all). The survey questionnaire was also intended for 
administration to other renal healthcare professionals besides pharmacists. Hence, 
the demographic information section of the questionnaire is also capable of capturing 
professional designation for other renal healthcare professionals, including renal 
nurses and physicians. The survey questionnaire is supplied as Appendix 11.  
 
5.6.5. Statistical Analysis 
Data were analysed using SPSS version 23.0 (IBM Corp., USA). Descriptive analysis 
was performed to describe demographic characteristics and frequency rates. 
Normality of data was tested using the Kolmogorov-Smirnov and Shapiro-Wilks tests. 
The Median with Inter Quartile Range (IQR) was used to summarise continuous 
variables. For non-normally distributed data, the Mann-Whitney or Kruskal-Wallis tests 
was performed to detect the differences in median scores. A post-hoc analysis, using 
the Dunn-Bonferroni test, was employed to identify statistically significant differences 
between intergroup variables [256]. A p value of < 0.05 was considered statistically 
significant.  
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5.7. Results 
A total of 41 renal pharmacists completed the survey, with a response rate of 91.1%. 
The majority of the participants was females (68.3%, n = 28), and aged between 31-
40 years (51.2%, n = 21). The study characteristics of respondents are presented in 
Table 11.  
 
5.7.1. Reliability of Scales 
The internal consistency and reliability of perception scales was measured using 
Cronbach’s alpha coefficient. The overall reliability, comprising all five scales, 
demonstrated an acceptable level of internal consistency, with an alpha of 0.79. The 
reliability coefficient for each scales was as follows: perceived prevalence scale (0.91), 
perceived contributors (0.74), perceived effectiveness (0.60), perceived barriers (0.50), 
and participants’ confidence (0.93). The details of the Inter-Item Correlation Matrix and 
Cronbach’s alpha coefficients for each scale are included as Appendix 12.  
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Table 11. Demographics of survey respondents (n = 41) 
Variable Category Number (%) 
Age, Years  35 (range, 25-59) 
 20-30 12 (29.3) 
 31-40 21 (51.2) 
 ≥ 41 8 (19.5) 
Gender   
 Male 13 (31.7) 
 Female 28 (68.3) 
Level of education   
 Bachelors 13 (31.7) 
 Graduate certificate 17 (41.5) 
 Masters and doctorate  11 (26.8) 
Experience in renal 
unit, Years 
 4 (range, 1-27) 
 1-5 30 (73.2) 
 ≥ 6 11 (26.8) 
Australian State/ 
territory 
  
 New South Wales  11 (26.8) 
 Queensland  11 (26.8) 
 Victoria 9 (22.0) 
 Western Australia  5 (12.2) 
 Other territory 5 (12.2) 
Organisation type   
 Public 38 (92.7) 
 Private 3 (7.3) 
Dialysis unit location   
 Metropolitan 31 (75.6) 
 Rural 10 (24.4) 
Characteristics of 
dialysis unit 
  
 Number of dialysis chairs (n = 27) 15 (range, 3-30) 
 Presence of nursing educator, Yes 32 (78.0), 1.0 FTE (range, 0.5-
1.0) 
 Presence of pharmacist, Yes 29 (70.7), 1.0 FTE (range, 0.6-
1.0) 
 In-centre haemodialysis (HD) 20 (48.8) 
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Variable Category Number (%) 
 Peritoneal dialysis service (PD) 1 (2.4) 
 All services (HD, Home HD, PD)  20 (48.8) 
 
Note: For continuous variables, Median (Range); for categorical variables, numbers with percentage 
in parentheses; Abbreviation: FTE, full-time equivalent of service 
 
5.7.2. Perceived Prevalence and Contributors of Nonadherence 
The majority of renal pharmacists believed that patients undergoing dialysis often 
forget to take their medicines (median = 8.0), changed the dosage schedule according 
to their lifestyles (median = 7.0), have limited understanding of their medicines (median 
= 7.0), were often confused and could not answer questions about their medicines 
(median = 7.0). The majority of the participants perceived that patients having limited 
understanding of their disease (median = 9.0), being prescribed with complex 
medication regimens (median = 9.0), lacking family or social support (median = 7.0), 
having a different language or cultural background (median = 8.0), and financial 
constraints (median = 8.0) contributed to medication nonadherence in patients 
undergoing dialysis (Table 12).    
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Table 12. Perceived prevalence and contributors of nonadherence in patients 
undergoing dialysis  
Statements for  Participant’s response, n (%) Median (IQR) 
Perceived prevalence Scoring ≤ 5 Scoring ≥ 6  
Have limited understanding of their medications (n = 37) 8 (21.6) 29 (78.4) 7.0 (6.0-8.0) 
Rarely ask questions about medications (n = 36) 10 (27.8) 26 (72.2) 7.0 (5.0-8.0) 
Do not take their medications as prescribed (n = 37) 12 (32.4) 25 (67.6) 7.0 (5.0-8.0) 
Stop taking some medications when feel better (n = 37) 15 (40.5) 22 (59.5) 6.0 (5.0-7.0) 
Are often confused about medicines (n = 37) 9 (24.3) 28 (75.7) 7.0 (5.5-8.0) 
Change dose/dosing interval that suits lifestyles (n = 37) 7 (18.9) 30 (81.1) 7.0 (6.0-8.0) 
Express difficulty in swallowing larger pills (n = 37) 11 (29.7) 26 (70.3) 7.0 (5.0-8.0) 
Don’t believe current medicines are helping them (n = 37) 15 (40.5) 22 (59.5) 6.0 (5.0-8.0) 
Can’t answer questions about current medications (n = 37) 9 (24.3) 28 (75.7) 7.0 (5.5-8.0) 
Forget to take medications sometimes (n = 37) 3 (8.1) 34 (91.9) 8.0 (7.0-9.0) 
Perceived contributors Scoring ≤ 5 Scoring ≥ 6  
Older patients are more nonadherent (n = 34) 27 (79.4) 7 (20.6) 3.0 (3.0-5.0) 
Male patients are more nonadherent (n = 33) 23 (69.7) 10 (30.3) 5.0 (3.0-6.0) 
Patients with multiple co-morbidities (n = 34) 6 (17.6) 28 (82.4) 6 (6.0-8.0) 
Patients lacking family/social support (n = 34) 1 (2.9) 33 (97.1) 8.0 (7.0-9.0) 
Patients having low income (n = 34) 5 (14.7) 29 (85.3) 8.0 (7.0-8.25) 
Patients having low level education background (n = 34) 8 (23.5) 26 (76.5) 7.0 (5.75-8.25) 
Having different language/cultural background (n = 33) 4 (12.1) 29 (87.9) 8 (7.0-8.5) 
Having limited understanding of disease state (n = 34) 1 (2.9) 33 (97.1) 9.0 (7.0-10.0) 
Patients not satisfied with their treatment/care (n = 34) 9 (26.5) 25 (73.5) 7.0 (5.0-9.0) 
Patients with complex medication regimens (n = 34) 2 (5.9) 32 (94.1) 9.0 (8.0-9.0) 
 
Note: Perception measured on a scale of 1-10, Where 1 = strongly disagree and 10 = strongly agree; 
Abbreviation: IQR, Inter-quartile range. 
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5.7.3. Perceived Effectiveness and Barriers to Assessing Adherence  
Participants unanimously agreed that having a pharmacist to conduct medication 
reviews and reconciliation (median = 9.0), or having a dedicated professional taking 
their medication history (median = 8.0), can be effective in assessing adherence. High 
median ratings were also observed for effectiveness of subjective methods of 
conducting medication history interviews (median = 8.0) and of objective methods to 
assess adherence through blood monitoring or physical assessment, such as blood 
pressure monitoring (median = 8.0).  
Pharmacists unanimously disagreed about lacking knowledge and skills to 
assess adherence (median = 1.0). However, nearly half of them perceived that they 
lack time to undertake adherence promoting activities (median = 5.0). Furthermore, 
over a quarter of participants reported that there is no support from administration in 
conducting adherence promoting activities (median = 5.0). Nearly all the participants 
disagreed that patients would be disinterested in discussing medication-related issues 
with the pharmacists (median = 2.0) (Table 13).  
 
5.7.4. Participants’ Confidence in Assessing Adherence 
Renal pharmacists were highly confident about their ability to conduct adherence 
assessment activities. These include the ability to conduct a medication history 
interview (median = 10.0), to provide medication counselling (median = 10.0), to clarify 
patients’ medication queries (median = 10.0), to suggest strategies to improve 
adherence (median = 10.0), and to assess patients’ knowledge and beliefs about 
medicines (median = 10.0) (Table 13).  
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Table 13. Perceived effectiveness, barriers and confidence to assessing adherence 
in patients undergoing dialysis  
Statements Participant’s response, n (%)  Median (IQR) 
Perceived effectiveness Scoring ≤ 5 Scoring ≥ 6  
Interviewing patients to obtain medication history (n = 33) 0 (0.0) 33 (100.0) 8.0 (7.0-9.0) 
Asking patient’s family/carer about medication (n = 33) 4 (12.1) 29 (87.9) 7.0 (6.5-8.0) 
Measuring objective indicators such as SPL/BP (n = 33) 3 (9.1) 30 (90.9) 8.0 (7.0-8.0) 
Asking patients to bring medications and count (n = 33) 7 (21.2) 26 (78.8) 7.0 (6.0-8.0) 
Having a dedicated professional to take medication history (n 
= 33) 
1 (3.0) 32 (97.0) 8.0 (8.0-9.0) 
Conducting medication reviews and reconciliation by 
Pharmacist (n = 33) 
0 (0.0) 33 (100.0) 9.0 (8.5-10.0) 
Perceived barriers Scoring ≤ 5 Scoring ≥ 6  
Lack of knowledge and skills to assess nonadherence (n = 32) 32 (100.0) 0 (0.0) 1.0 (1.0-2.75) 
Lack of time (n = 32) 18 (56.3) 14 (43.8) 5.0 (2.25-7.0) 
Not my role (n = 32) 32 (100.0) 0 (0.0) 1.0 (1.0-2.0) 
Patient’s disinterest on discussing medication issues (n = 32) 31 (96.9) 1 (3.1) 2.0 (1.0-3.75) 
No support from hospital administration (n = 32) 22 (68.8) 10 (31.3) 5.0 (2.25-6.0) 
Never thought about adherence before this survey (n = 32) 32 (100.0) 0 (0.0) 1.0 (1.0- 1.0) 
Participants’ confidence    
Ability to conduct a medication history interview (n = 32) 0 (0.0) 32 (100.0) 10.0 (9.0-10.0) 
Ability to provide medication counselling (n = 32) 0 (0.0) 32 (100.0) 10.0 (9.0-10.0) 
Ability to clarify patient’s medication queries (n = 32) 0 (0.0) 32 (100.0) 10.0 (9.0-10.0) 
Ability to suggest strategies to improve adherence (n = 32) 0 (0.0) 32 (100.0) 10.0 (8.0-10.0) 
Ability to assess patient’s knowledge and beliefs about 
medications (n = 32) 
0 (0.0) 32 (100.0) 10.0 (8.0-10.0) 
Note: Perception measured on a scale of 1-10, Where 1 = strongly disagree and 10 = strongly agree; 
Abbreviation: IQR, Inter quartile range; SPL, serum phosphate levels; BP, blood pressure. 
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5.7.5. Differences in Perceptions based on Study Demographics    
Male pharmacists perceived fewer barriers compared with the experience of females 
(U = 183.0, z = 2.55, p = 0.01; male = 1.0 vs female = 2.0). Similarly pharmacists’ 
experience in renal units significantly affected their median perceived effectiveness 
scores (U = 177.0, z = 2.19, p = 0.03). Compared with pharmacists working for ≥ 6 
years, pharmacists with one to five years of experience perceived that current methods 
to assess adherence were less effective (median: 7.75 vs 8.5, p < 0.05). No significant 
differences in perceptions were observed based on age or level of education (Table 
14).  
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Table 14. Differences in perceptions based on study demographics across all scales 
Variables Perceived 
prevalence  
Perceived 
contributors  
Perceived 
effectiveness  
Perceived barriers  Participants’ 
confidence  
 Median Mean 
Rank 
Median Mean 
Rank 
Median Mean 
Rank 
Median Mean 
Rank 
Median Mean 
Rank 
Age, years a           
20-30 5.5 13.4 7.0 16.9 8.0 14.5 1.5 16.0 10.0 16.6 
31-40 7.0 19.7 7.0 15.0 8.0 15.6 1.5 16.2 10.0 15.7 
≥ 41 7.0 25.0 8.0 25.1 8.5 23.2 2.0 18.2 10.0 19.1 
Gender b           
Male 7.25 11.3 7.5 16.6 8.0 18.9 1.0 11.3* 10.0 19.5 
Female 6.75 19.7 7.75 18.0 7.5 15.9 2.0 19.7 10.0 14.7 
Level of education a           
Bachelors 6.0 16.3 7.5 19.7 8.0 16.8 1.5 17.8 10.0 14.4 
Graduate certificate 7.0 23.2 8.0 20.2 8.5 20.9 1.5 16.4 10.0 17.3 
Masters and doctorate  6.75 15.3 6.75 11.6 7.0 11.7 1.5 15.5 10.0 17.4 
Experience in renal 
unit, Years b 
          
1-5 6.5 16.9 7.0 16.2 7.75 14.5* 1.25 15.4 10.0 15.7 
≥ 6 7.0 23.9 8.0 20.3 8.5 22.1 2.0 19.0 10.0 18.2 
Dialysis unit location b           
Metropolitan  7.0 19.4 7.5 16.9 8.0 18.0 1.5 16.4 10.0 16.3 
Rural 7.0 17.8 8.0 19.6 7.0 13.1 2.0 17.0 10.0 17.2 
Note: Perception measured on a scale of 1-10, where 1 = strongly disagree and 10 = strongly agree  
a Kruskal-Wallis Test. b Mann-Whitney Test. 
* P < 0.05 
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5.7.6. Current Adherence Assessment Practices 
Figure 12 illustrates current practices of assessing adherence in dialysis centres. The 
majority of the participants reported that pharmacists were asked for medication 
reviews and reconciliation only for high-risk patients (37.9 %, n = 11). Nearly half the 
time dedicated professionals were not assigned to participate in a medication history 
interview (41.4%, n = 12). As such, medication history interviews to assess adherence 
were rarely conducted for every patient (27.6%, n = 8). However, assessing adherence 
objectively through blood monitoring or physical assessment was routinely conducted 
in every patient (57.1%, n = 16). Asking a patient’s family or carer about medications 
(10.3%, n = 3) or asking patients to bring their medication and counting them was 
rarely practised (3.4%, n = 1).  
 
 
 
Figure 12. Pharmacists’ reports on current practices of assessing medication 
adherence in patients undergoing dialysis in Australia 
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5.7.7. Qualitative Comments  
Participants’ comments strengthened the survey findings about contributors to 
nonadherence. Some of the recurring themes include knowledge and understanding 
of medicines, communication barriers, forgetfulness, the role of support, and the 
relative affordability of medicines. Participants also emphasised a substantial need for 
a designated renal pharmacist in dialysis settings, in order to assess medication-
related issues in patients undergoing dialysis. Participants’ comments are provided as 
Appendix 13.  
 
5.8. Discussion 
We developed and administered a survey questionnaire to measure pharmacists’ 
perceptions and practices for assessing medication adherence in dialysis settings. The 
survey tool demonstrated an acceptable overall reliability. The study findings shows 
that current adherence measurement practices in dialysis settings were very limited 
and the established methods to screen medication nonadherence were utilised less in 
dialysis settings. Although renal pharmacists were highly confident in conducting 
adherence assessment activities, time constraints and support from administration 
presented as barriers to assessing adherence. Pharmacists firmly believed that having 
a dedicated professional or a renal-specialised pharmacist in dialysis settings would 
be effective in promoting adherence activities, as these services were mostly 
unavailable in current dialysis settings.  
As medication nonadherence is highly prevalent among patients undergoing 
dialysis [23], renal pharmacists can play a significant role in early detection of the 
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underlying medication-related issues, through activities such as medication reviews 
and medication history interviews [257]. When reasons behind nonadherence have 
been identified, pharmacists can actively support the patient to achieve better 
therapeutic outcomes through medication counselling, education and enhancing 
memory through reminder calls, texts or emails, and arranging provisions such as 
dosage administration aids [258]. Pharmacists in this survey recognised various 
factors that may impede medication-taking behaviour in patients undergoing dialysis. 
Pharmacists’ perceptions resonated well with earlier findings that patient-related 
factors such as lack of knowledge and understanding about medicines, lack of family 
or social support, forgetfulness, multiple illnesses, increased pill burden, relative 
affordability, and culture and communication barriers can influence medication-taking 
behaviour [141, 226, 228, 252]. Having a trustworthy patient-provider relationship can 
have a significant impact on a patient’s medication-taking behaviour [225]. Patients 
become candid about discussing their medications with their healthcare professionals 
only when they feel free to admit their difficulties regarding medicines, when there is 
no risk of criticism and when there is a true patient-provider partnerships or 
concordance [259]. Renal pharmacists are well positioned in their roles to routinely 
instigate discussions on medication-related issues with the patients. Pharmacists can 
actively contribute towards designing tailored interventions that can be suitably 
incorporated during dialysis sessions, such as educating patients on problem solving, 
guiding behavioural change and taking actions in response to deteriorating signs and 
symptoms; all of these activities can help facilitate medication self-management in 
patients undergoing dialysis and improve adherence [226].   
Implementing adherence assessment practices in dialysis settings may depend 
essentially on overcoming barriers identified by the pharmacists, such as time 
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constraints, support from hospital administration and, most importantly, willingness 
from both patients and health professionals to actively participate in dialogues to 
resolve medication-related issues in patients undergoing dialysis. Delivering 
adherence support activities by the pharmacists will also depend upon the knowledge 
and skills acquired through tailored education, training and routine practices [260, 261]. 
Pharmacists in this survey unanimously disagreed that they lack knowledge or skills 
for assessing and promoting adherence; instead they were highly confident about 
conducting such activities. Pharmacists possess advanced skills in clinical 
pharmacotherapy and delivering pharmaceutical care services, such as optimising 
medication regimens, assessing adherence and educating patients and allied 
healthcare teams on medication-related issues. These skills are integral to their role 
[262] and could have contributed to a higher confidence scoring.  
Not surprisingly, the majority of the pharmacists were of the opinion that 
dedicated renal pharmacists should be assigned to undertake adherence assessment 
activities in dialysis settings. This could be viewed as a biased attitude towards their 
professional role, although past reports have shown that other allied health 
professionals who worked in collaboration with the pharmacists in the past were more 
aware of the competency and contribution of pharmacists in delivering pharmaceutical 
care services and were more likely to recommend them being assigned to clinical 
wards [263-265]. Pharmacists’ intervention has contributed to reduced hospitalisation, 
improved patient satisfaction and decreased overall treatment costs in patients 
undergoing dialysis [245]. Moreover, the presence of a pharmacist in dialysis settings 
can be complementary to helping patients with their medication management, 
educating and counselling about medicines and life style changes through motivational 
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interviews, providing advice for their minor ailments and most importantly, identifying 
medication issues and promoting adherence [245].  
Current Australian outpatient dialysis settings have limited access to fully-
fledged renal pharmacy services [245]. Outpatient dialysis centres provide pharmacy 
services on an as required basis where pharmacists may be requested for medication 
reviews but only in situations when the patients’ conditions demand higher scrutiny of 
their medication regimen. Although inclusion of dedicated professionals who could 
solely focus on medication management and adherence promotion would be an ideal 
solution, it is unlikely that this provision would be incorporated into dialysis settings in 
the near future. Various factors may hinder the sustainability of such programs 
including the limitations of time and resources [111], funding and organisational 
priorities [245, 266]. Our findings hint towards the pharmacists’ longing for becoming 
active team members to provide medication management services to the patients in 
outpatient dialysis settings. Another possibility would be to empower the predominant 
nursing faculty available in the dialysis settings, as they are the professionals closely 
interacting with the patients on a daily basis and are ideally placed for delivering 
medicines, monitoring patient progress, and engaging patients in strategies to promote 
adherence [139, 267]. Nevertheless, we may need to consider carefully the existing 
workload of the renal nurses and barriers to successful incorporation of auxiliary roles, 
such as adherence assessment and promotion activities for the patients undergoing 
dialysis.  
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5.8.1. Study Limitations 
The study sample in this survey was low. However, the sample is considered 
representative as it was purposefully targeted at the members of the professional 
forum that largely constitutes specialist renal pharmacists in Australia. As individual 
practices may vary between the dialysis centres and many of the outpatient dialysis 
centres do not have pharmacist representation, the survey findings may not be 
generalisable. Furthermore, no a priori hypothesis was set during the conduct of this 
study. Items were also not generated by qualitative interviews and factor analysis, nor 
was there principal component analysis for item reduction attempted. Hence, this 
study has numerous measure variables. Nevertheless, being a first study of its kind 
and having a detailed questionnaire to measure renal pharmacists’ perceptions on the 
issue of medication nonadherence, this exploratory study may provide a baseline 
observation for informing future studies.  
 
5.9. Conclusion 
Pharmacists were rarely assigned to assessing adherence in dialysis settings. 
Established self-reporting methods to measure adherence were under-utilised, 
compared with objective blood monitoring. Pharmacists were supportive of dedicating 
more time to assess and promote adherence, although important barriers such as lack 
of both time and administrative support, were preventing the conduct of these activities. 
Having renal-specialised pharmacists in dialysis centres could facilitate adherence 
promotion and early identification of medication-related issues in patients undergoing 
dialysis. 
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Supplementary Data  
Appendix 10. The STROBE checklist 
Appendix 11. Survey Questionnaire 
Appendix 12. Inter-item correlation matrix and Cronbach’s alpha coefficients for each 
scales 
Appendix 13. Comments on perceptions and current practices  
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CHAPTER SIX 
 
6. RENAL NURSES’ PERCEPTIONS AND CURRENT PRACTICES OF 
ASSESSING MEDICATION ADHERENCE IN DIALYSIS PATIENTS: A CROSS-
SECTIONAL SURVEY 
 
 
6.1. Abstract 
Background: Renal nurses play a vital role in caring for ESKD patients undergoing 
dialysis. Despite the high prevalence of medication nonadherence in patients 
undergoing haemodialysis, little is known about renal nurses’ perceptions and the 
current practices of assessing adherence in routine patient care.  
Objectives: To develop a survey tool and measure renal nurses’ perceptions, current 
practices, and barriers to assessing medication adherence in patients undergoing 
haemodialysis.  
Design: A cross-sectional survey design. 
Settings: Australian dialysis centres.  
Participants: Study participants were renal nurses working in Australian dialysis 
centres.  
Methods: Participants completed an online survey during March, April, and May 2016. 
The survey included five psychometric scales that measured the perceived prevalence 
of and contributors to nonadherence, the effectiveness of various methods, the 
barriers to adherence, and the participants’ confidence to assess adherence using a 
10-point Likert scale (1 = strongly disagree, 10 = strongly agree). Current adherence 
126 
 
measuring practices were captured using a 4-point graded response (1 = do not 
practice at all to 4 = practice for every patient).   
Results: A total of 113 renal nurses completed the survey. The majority of nurses 
agreed that patients in their unit are not adherent to their medicines (74.5%, n = 82; 
median = 8.0). Most nurses agreed that having dedicated professionals conducting 
medication history interviews can be effective in identifying nonadherence (88.9%, n 
= 96; median = 8.0). Objective blood monitoring was the most frequently used method 
to determine nonadherence (83.2%, n = 89), with little attention being paid to patients’ 
self-reports of adherence (55.1%, n = 59). Lack of time, support from hospital 
administration, and patients’ disinterest in discussing medication-related issues with 
the nurses were perceived as barriers to assessing adherence.  
Conclusions: Established self-report methods for measuring medication 
nonadherence were under-utilised by the renal nurses, whereas objective blood 
monitoring was routinely used. Overcoming renal nurses’ work-related barriers may 
facilitate the effective monitoring and promotion of medication adherence in patients 
undergoing chronic dialysis.  
 
Keywords: Adherence assessment practices; cross-sectional survey; dialysis; Kidney 
failure, chronic; medication adherence; renal nurses  
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6.2. Contribution of the Paper 
 
What is already known about the topic? 
• Medication nonadherence in chronically ill patients is a major determinant of 
poor patient outcomes. 
• Adherence research has been primarily focused on understanding and 
changing the medication-taking behaviour of patients, with little attention being 
paid to understanding the healthcare system’s inadequacies in addressing such 
behaviour. 
• Little is known about the renal nurses’ practices of assessing medication 
adherence during the routine care of patients undergoing dialysis. 
 
What this paper adds? 
• Renal nurses rely on routine laboratory results to detect medication 
nonadherence, with little to no attention being paid to patient engagement via 
self-reported measures. 
• Lack of time, support from hospital administration, and patients’ disinterest in 
communicating medication-related issues to renal nurses were perceived as 
barriers to assessing adherence. 
• Renal nurses believed that having dedicated renal pharmacists in dialysis 
centres would facilitate assessment and the promotion of medication 
adherence in patients undergoing dialysis. 
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6.3. Introduction 
Medication nonadherence often leads to poor patient outcomes in chronic diseases 
[202]. The negative impact of nonadherence is such that alleviating it would result in 
greater public health gains than developing newer, costly therapies [202, 268]. The 
reasons for nonadherence depend on the disease and the complexity of the regimens 
prescribed [2]. CKD patients in general, and patients receiving dialysis in particular, 
are at high risk of medication nonadherence. This may be due to an increased burden 
of concomitant illness and dialysis-associated complications, leading to an increased 
complexity of various treatment regimens [229]. 
Overall, half of dialysis-treated patients are nonadherent to at least part of their 
treatment regimen, with medication nonadherence ranging between 12.5% and 98.6% 
[23, 139]. The deterioration of the underlying disease conditions in patients undergoing 
dialysis following medication nonadherence has been associated with increased 
mortality and recurrent hospitalisations, placing a substantial economic burden on the 
healthcare system [23].  
The current research on medication adherence primarily focuses on 
understanding and changing the medication-taking behaviour of patients, rather than 
on understanding and changing the healthcare system inadequacies that may affect 
adherence in patients [110, 111]. Patients who had shorter consultations with their 
doctor or a healthcare professional that lacked a discussion on medication-related 
issues were found to be nonadherent to their prescribed treatment [225, 232]. 
Engaging patients in a meaningful conversation about their medication use may not 
be a straightforward solution to this problem. Healthcare professionals have reported 
time availability and work pressures as barriers to assessing a patient’s ability to take 
medications, and to investigating any impediments to medication adherence [232].  
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Despite extensive research on the incidence, measurement, and improvement 
of medication adherence [2], little is known about the actual practices of measuring 
adherence in clinical settings. The extent to which renal nurses are aware of 
adherence measurement practices, and how much time is devoted to measuring and 
promoting adherence in patients undergoing dialysis, is unknown. Renal nurses 
working with patients get to know them well as they see them frequently, usually three 
times a week for a period of three-to-five hours a day. Such an engagement provides 
an excellent opportunity for the renal nurses to educate and encourage medication 
adherence in patients undergoing dialysis.  
Nevertheless, an understanding of renal nurses’ perceptions of medication 
nonadherence in patients undergoing dialysis, and the likely barriers to monitoring and 
improving medication adherence is essential before nurses can take part in any quality 
initiative targeting nonadherence. Therefore, we aimed to understand the renal nurses’ 
perceptions, current practices, and barriers to assessing medication adherence in 
patients undergoing dialysis.  
  
6.4. Methods 
6.4.1. Study Design 
An online cross-sectional survey method was used. We followed the STROBE 
guidelines for the design and reporting of this study [14]. The STROBE checklist is 
supplied in Appendix 14.  
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6.4.2. Setting and Recruitment of Participants  
All renal nurses currently registered to practice in Australian dialysis settings were 
eligible to participate. Recruitment was sought through the professional renal 
association, the Renal Society of Australasia (RSA). Recruiting participants directly 
was not feasible due to a lack of assured means of identifying renal nurses involved 
in the care of patients undergoing dialysis, therefore we sought participant recruitment 
through a professional organisation.  
 
6.4.3. Data Collection 
An online survey was conducted for a period of three months between March and May 
2016. We coordinated with the professional association to send an invitation flyer that 
described the study’s aims, and which gave a web address for the survey, to dialysis 
nurses through email alerts, social media posts, and e-newsletters. Reminders were 
sent on a fortnightly basis. After the survey was completed, we randomly selected 
eight participants who had opted in to win gift vouchers valued at AUD $100 for their 
contribution.    
 
6.4.4. Development of Survey Instrument 
We utilised a previously developed survey instrument (Chapter 5) that measured renal 
pharmacists’ perceptions and practices of assessing medication adherence in dialysis 
patients [269]. To briefly describe the instrument, it comprised seven sections that 
explored demographics, perceptions of the prevalence of, and contributors to 
nonadherence, the perceived effectiveness of methods used to detect nonadherence, 
barriers to adherence assessment, and participants’ confidence in assessing 
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adherence. A 10-point Likert scale of agreement was used to measure perception (1 
= strongly disagree, 10 = strongly agree). The last section comprised questions related 
to the current practices of assessing adherence in dialysis patients, and used four-
point graded response where one meant “do not practice”, and four meant “practice 
for every patient”. The survey questionnaire is supplied in Appendix 11.  
 
6.4.5. Statistical Analysis 
Data were entered and analysed in SPSS version 23.0 (IBM Corp., Armonk, 
N.Y., USA). Demographic characteristics were ascertained through descriptive 
analysis. Kolmogorov-Smirnov and Shapiro-Wilks tests were performed to assess 
normality. Continuous variables were summarised using the median and the inter 
quartile range (IQR). Mann-Whitney or Kruskal-Wallis tests was performed to detect 
the differences in median scores for non-normally distributed data. The Dunn-
Bonferroni test was used to identify statistically significant differences between 
intergroup variables, as a post-hoc analysis [256]. Cronbach’s alpha coefficient was 
used to measure the internal consistency reliability of the perception scales. A p value 
of < 0.05 was considered statistically significant. 
 
6.4.6. Ethical Considerations 
Ethics approval was granted by the Tasmanian Social Sciences Human Research 
Ethics Committee (reference number: H0015433). Completing the survey itself was 
considered implied consent to participate in this study.  
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6.5. Results 
A total of 113 renal nurses completed the survey. The majority of the participants were 
female (92.0%, n = 104), with 11-20 years of experience in renal units (47.8%, n = 54). 
As participants were recruited indirectly through the RSA, which has over 1800 
members, including nurses, technicians, social workers, dietitians, and other allied 
health professionals; we could not gauge the actual survey response rate for renal 
nurses alone. Nevertheless, this study was not aimed at generalisability, but for 
developing and piloting the survey instrument to inform larger nation-wide studies in 
dialysis settings. The characteristics of the respondents are presented in Table 15. 
 
Table 15. Demographics of survey respondents (n = 113) 
Variable Category N (%) 
Age, Years  47 (range, 25-66) 
 20-30 6 (5.3) 
 31-40 24 (21.2) 
 41-50 39 (34.5) 
 ≥ 51 44 (38.9) 
Gender   
 Male 9 (8.0) 
 Female 104 (92.0) 
Level of education   
 Diploma 11 (9.7) 
 Bachelors 48 (42.5) 
 Graduate certificate 46 (40.7) 
 Masters and doctorate  8 (7.1) 
Designation   
 Enrolled Nurse 2 (1.8) 
 Registered Nurse 76 (67.3) 
 Nurse Practitioner 7 (6.2) 
 Nurse Unit Manager 28 (24.8) 
Experience in renal unit, 
Years 
 14 (range, 1-36) 
  1-10 43 (38.1) 
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Variable Category N (%) 
  11-20 54 (47.8) 
  ≥ 21 16 (14.2) 
Australian State   
 Victoria 55 (48.7) 
 Queensland  16 (14.2) 
 Tasmania 16 (14.2) 
 New South Wales  13 (11.5) 
 Other States  13 (11.5) 
Organisation type   
 Public 99 (87.6) 
 Private 14 (12.4) 
Dialysis unit location   
 Metropolitan 52 (46.0) 
 Rural 61 (54.0) 
Characteristics of dialysis 
unit 
  
 Number of dialysis chairs (n = 111) 12 (range, 3-32) 
 Number of 1.0 FTE nurse (n = 79) 4 (range, 1-16) 
 Presence of nursing educator, Yes 49 (43.4), 0.6 FTE (range, 
0.3-1.0) 
 Presence of pharmacist, Yes 25 (22.1), 1.0 FTE (range, 
0.4-1.0) 
 In-centre haemodialysis service (HD) 83 (73.5) 
 Peritoneal dialysis service (PD) 2 (1.8) 
 Home haemodialysis (Home HD) 1 (0.9) 
 All services (HD, Home HD, PD)  27 (23.9) 
Note: For continuous variables, median (range); for categorical variables, numbers with percentage in 
parentheses; Abbreviation: FTE, full-time equivalent of service 
 
6.5.1. Internal Consistency Reliability of Scales 
The overall reliability comprising all five scales demonstrated a good level of internal 
consistency, with an alpha of 0.84. The reliability coefficients for each scale were as 
follows: perceived prevalence scale (0.85), perceived contributors (0.83), perceived 
effectiveness (0.67), perceived barriers (0.70), and participant’ confidence (0.90). 
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Appendix 15 contains the particulars of the Inter-Item Correlation Matrix, and 
Cronbach’s alpha coefficients for each scale.  
 
6.5.2. Perceived Prevalence and Contributors of Nonadherence 
The majority of renal nurses believe that patients in their unit often forget to take their 
medicines (median = 8.0), rarely ask questions about medicines (median = 7.0), are 
unable to answer medicine-related questions (median = 7.0), and are often confused 
about their medicines (median = 7.0). The majority of the nurses thought that limited 
understanding of their disease (median = 7.0), being prescribed with complex 
medication regimens (median = 7.0), lacking family or social support (median = 7.0), 
having low educational backgrounds (median = 7.0), and low income (median = 7.0) 
contributed to medication nonadherence in patients undergoing dialysis. The majority 
of the participants disagreed that being older (median = 4.0) or male (median = 5.0) 
contributed to nonadherence behavior, however (Table 16).    
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Table 16. Perceived prevalence and contributors of nonadherence in patients 
undergoing dialysis 
Statements Participant’s Response, n (%) Median (IQR) 
Perceived prevalence Scoring ≤ 5 Scoring ≥ 6  
Have limited understanding of their medications (n = 112) 48 (42.9) 64 (57.1) 6.0 (4.0-7.75) 
Rarely ask questions about medications (n = 112) 39 (34.8) 73 (65.2) 7.0 (4.0-8.0) 
Do not take their medications as prescribed (n = 112) 50 (44.6) 62 (55.4) 6.0 (4.0-7.0) 
Stop taking some medications when feel better (n = 111) 53 (47.7) 58 (52.3) 6.0 (3.0-7.0) 
Are often confused about medicines (n = 111) 42 (37.8) 69 (62.2) 7.0 (5.0-8.0) 
Change dose/dosing interval that suits lifestyles (n = 111) 54 (48.6) 57 (51.4) 6.0 (3.0-7.0) 
Express difficulty in swallowing larger pills (n = 111) 51 (45.9) 60 (54.1) 6.0 (3.0-8.0) 
Don’t believe current medicines are helping (n = 111) 74 (66.7) 37 (33.3) 4.0 (3.0-6.0) 
Can’t answer questions about medications (n = 111) 40 (36.0) 71 (64.5) 7.0 (4.0-8.0) 
Forget to take medications sometimes (n = 110) 28 (25.5) 82 (74.5) 8.0 (5.0-9.0) 
Perceived contributors    
Older patients are more nonadherent (n = 110) 91 (82.7) 19 (17.3) 4.0 (2.0-5.0) 
Male patients are more nonadherent (n = 110) 74 (67.3) 36 (32.7) 5.0 (3.0-7.0) 
Patients with multiple co-morbidities (n = 109) 47 (43.1) 62 (56.9) 6.0 (5.0-8.0) 
Patients lacking family/social support (n = 109) 31 (28.4) 78 (71.6) 7.0 (5.0-8.0) 
Patients having low income (n = 109) 39 (35.8) 70 (64.2) 7.0 (5.0-8.0) 
Patients having low level education background (n = 109) 32 (29.4) 77 (70.6) 7.0 (5.0-8.0) 
Having different language/cultural background (n = 108) 37 (34.3) 71 (65.7) 7.0 (5.0-8.0) 
Having limited understanding of disease state (n = 109) 24 (22.0) 85 (78.0) 7.0 (6.0-8.0) 
Patients not satisfied with their treatment/care (n = 109) 44 (40.4) 65 (59.6) 6.0 (4.0-8.0) 
Patients with complex medication regimens (n = 109) 31 (28.4) 78 (71.6) 7.0 (5.0-9.0) 
Note: Perception measured on a scale of 1-10, Where 1 = strongly disagree and 10 = strongly agree; 
Abbreviation: IQR, Inter-quartile range. 
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6.5.3. Perceived Effectiveness and Barriers to Assessing Adherence  
The majority of renal nurses agreed that having dedicated professionals who take 
medication histories (median = 8.0), or having pharmacists who conduct medication 
reviews and reconciliations (median = 9.0) can be effective in assessing adherence. 
High median ratings were also observed for the effectiveness of assessing adherence 
through objective methods, such as blood monitoring or physical assessment (median 
= 8.0), and through subjective methods, such as conducting medication history 
interviews (median = 8.0).  
Renal nurses disagreed that they lacked the knowledge and skills to assess 
adherence (median = 2.0), but over one-third perceived that they lacked the time 
needed to undertake adherence promoting activities (median = 4.0). Furthermore, 
over a third of the participants reported that there is no support from hospital 
administration in conducting adherence promoting activities (median = 5.0). Nearly a 
quarter of the nurses also perceived that patients are not interested in discussing 
medication-related issues with them (median = 3.0) (Table 17).  
 
6.5.4. Participants’ Confidence in Assessing Adherence 
Renal nurses’ median confidence ratings were higher in terms of ability to suggest 
strategies to improve adherence (median = 8.0), followed by ability to assess patients’ 
knowledge and beliefs about medicines (median = 8.0), conduct a medication history 
interview (median = 8.0), and provide medication counselling (median = 8.0) (Table 
17).  
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Table 17. Perceived effectiveness, barriers and confidence to assess adherence in 
patients undergoing dialysis 
Statements Participant’s Response, n (%) Median (IQR) 
Perceived effectiveness Scoring ≤ 5 Scoring ≥ 6  
Interviewing patients to obtain medication history (n = 108) 19 (17.6) 89 (82.4) 8.0 (6.0-9.0) 
Asking patient’s family/carer about medication (n = 108) 14 (13.0) 94 (87.0) 7.0 (6.0-8.0) 
Measuring objective indicators such as SPL/BP (n = 108) 14 (13.0) 94 (87.0) 8.0 (7.0-9.0) 
Asking patients to bring medications and count (n = 107) 45 (42.1) 62 (57.9) 7.0 (4.0-8.0) 
Having a dedicated professional to take medication history (n = 
108) 
12 (11.1) 96 (88.9) 8.0 (7.0-9.0) 
Conducting medication reviews and reconciliation by 
Pharmacist (n = 108) 
14 (13.0) 94 (87.0) 9.0 (8.0-10.0) 
Perceived barriers    
Lack of knowledge and skills to assess nonadherence (n = 108) 96 (88.9) 12 (11.1) 2.0 (2.0-3.0) 
Lack of time (n = 108) 67 (62.0) 41 (38.0) 4.0 (2.0-7.0) 
Not my role (n = 106) 102 (94.4) 6 (5.6) 2.0 (1.0-3.0) 
Patient’s disinterest on discussing medication issues (n = 108) 82 (75.9) 26 (24.1) 3.0 (2.0-5.0) 
No support from hospital administration (n = 106) 66 (62.3) 40 (37.7) 5.0 (2.0-8.0) 
Never thought about adherence before this survey (n = 108) 101 (93.5) 7 (6.5) 1.0 (1.0-2.0) 
Participants’ confidence     
Ability to conduct a medication history interview (n = 108) 16 (14.8) 92 (85.2) 8.0 (7.0-9.0) 
Ability to provide medication counselling (n = 108) 21 (19.4) 87 (80.6) 8.0 (6.0-9.0) 
Ability to clarify patient’s medication queries (n = 108) 17 (15.7) 91 (84.3) 7.0 (6.0-9.0) 
Ability to suggest strategies to improve adherence (n = 108) 8 (7.4) 100 (92.6) 8.0 (7.0-9.0) 
Ability to assess patient’s knowledge and beliefs about 
medications (n = 108) 
14 (13.0) 94 (87.0) 8.0 (7.0-9.0) 
Note: Perception measured on a scale of 1-10, Where 1 = strongly disagree and 10 = strongly agree; 
Abbreviation: IQR, Inter quartile range; SPL, serum phosphate levels; BP, blood pressure. 
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6.5.5. Differences in Perceptions Based on Study Demographics    
Participant age significantly affected their median scores on perceived barriers (χ2 (3, 
N = 108) = 11.52, p < 0.01). Younger nurses, aged 20-30 years perceived more 
barriers than their elder counterparts aged 41-50 years (median: 4.5 vs 2.0, p < 0.05), 
and ≥ 51 years (median: 4.5 vs 2.25, p < 0.05). Similarly, significant differences were 
observed in perceived contributor scores based on professional designation (χ2 (2, N 
= 108) = 6.76, p < 0.05). Registered nurses perceived more contributors to 
nonadherence than the nurse unit managers (median: 7.0 vs 5.0, p < 0.05). 
Participants’ experiences in renal units also influenced their confidence scores (χ2 (2, 
N = 108) = 6.21, p < 0.05). Nurses with 1-10 years of experience were less confident 
in assessing adherence than participants with 11-20 years (median: 7.0 vs 8.0, p < 
0.05), and with ≥ 21 years (median: 7.0 vs 8.0, p < 0.05) of experience (Table 18).  
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Table 18. Differences in perceptions based on study demographics across all scales 
Variables Perceived 
prevalence  
Perceived 
contributors  
Perceived 
effectiveness  
Perceived barriers  Participants’ 
confidence  
 Median Mean 
Rank 
Median Mean 
Rank 
Median Mean 
Rank 
Median Mean 
Rank 
Median Mean 
Rank 
Age, years a           
20-30 6.5 76.3 7.0 55.2 8.5 73.3 4.5 93.1** 7.0 33.9 
31-40 6.25 53.7 7.0 60.7 8.0 56.2 3.0 62.9 8.0 54.2 
41-50 6.0 54.8 6.5 54.3 8.0 58.0 2.0 49.2 8.0 56.2 
≥ 51 6.25 56.8 7.0 53.7 7.75 48.3 2.25 49.8 8.0 55.6 
Gender b           
Male 6.0 52.7 6.5 59.8 8.25 58.6 2.0 48.6 7.5 57.0 
Female 6.0 56.8 7.0 55.2 8.0 54.2 3.0 55.0 8.0 54.3 
Level of education a           
Diploma 5.75 49.7 5.5 42.4 7.0 38.6 3.0 51.8 7.0 38.5 
Bachelors 6.0 51.2 6.75 55.3 8.0 61.3 2.5 54.2 8.0 55.7 
Graduate certificate 6.5 60.0 7.0 57.7 8.0 49.4 3.0 57.0 8.0 55.2 
Masters and doctorate  7.75 78.1 7.0 63.1 8.25 63.1 2.0 46.1 8.0 63.6 
Designation a           
Registered nurse 6.25 56.7 7.0 59.9* 8.0 54.8 2.75 54.1 8.0 51.7 
Nurse practitioner 5.5 44.3 5.5 42.1 7.0 32.3 3.5 69.7 7.0 45.7 
Nurse unit manager 6.5 55.2 5.0 43.5 8.0 55.5 2.0 47.8 8.0 60.3 
Experience in renal 
unit, Years a 
          
1-10 6.0 54.8 7.0 56.8 8.0 55.6 3.0 60.8 7.0 45.2* 
11-20 6.5 60.5 7.0 80.6 8.0 55.4 2.0 48.6 8.0 59.7 
≥ 21 6.0 47.1 6.0 56.0 7.75 48.2 3.0 58.4 8.0 62.3 
 
Note: Perception measured on a scale of 1-10, where 1 = strongly disagree and 10 = strongly agree  
a Kruskal-Wallis Test. b Mann-Whitney Test. 
* P < 0.05; ** P < 0.01 
 
  
140 
 
6.5.6. Current Practices of Assessing Adherence  
Figure 13 depicts the renal nurses’ reports on current adherence assessment 
practices in dialysis centres. Assessing adherence objectively through blood results or 
physical assessment was routinely conducted for every patient (83.2%, n = 89). The 
majority of the participants reported that pharmacists were not available for medication 
reviews and reconciliation activities (65.1%, n = 69), and nearly half of the participants 
mentioned that dedicated professionals were not assigned to conducting medication 
history interviews (46.7%, n = 49). Similarly, only around half of the participants (55.1%, 
n = 59) reported that medication history interviews were conducted for every patient. 
Patients’ families or carers were asked about medications for only some patients with 
a higher risk of adverse effects (45.8%, n = 49). Similarly, asking patients to bring 
medications and counting them was mainly practiced in high-risk patients (33.0%, n = 
35).  
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Figure 13. Nurses’ reports on current practices of assessing medication adherence 
in patients undergoing dialysis in Australia 
 
6.5.7. Qualitative Comments  
The qualitative comments reinforced the survey findings regarding contributors of 
nonadherence, such as lack of knowledge about medicines, comorbid illnesses, tablet 
burden, culture and communication barriers, forgetfulness, lack of support, and 
relative affordability of medicines. Renal nurses also highlighted the need for a 
sustainable strategy to empower self-management in patients taking long-term 
medications. There was a recurring theme in the desire for a designated renal 
pharmacist in dialysis settings to manage medication-related issues. Furthermore, 
participants reported that patients trusted their doctors with medical decisions, and 
preferred communicating with them rather than with nurses. Due to long waiting times 
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for consultations, however, their medication-related queries remain unanswered. This 
subsequently nurtured nonadherence behaviour in patients undergoing dialysis. The 
comments are given in Appendix 16.  
 
6.6. Discussion 
We reported renal nurses’ perceptions on assessing medication adherence in patients 
undergoing dialysis. The internal consistency and reliability of the overall scale was 
good. The findings from this study suggest that current adherence assessment 
practices are suboptimal, and the methods used to screen patients’ medication-taking 
behaviour are used less in dialysis settings. Renal nurses seemed to be confident in 
conducting adherence assessment activities, and their level of confidence increased 
with increased work experience. Lack of time, lack of support from hospitals, and 
patients’ disinterest in discussing medication-related issues with the renal nurses were 
perceived as barriers to assessing adherence. The majority of the nurses 
acknowledged that having a dedicated pharmacist would be effective in promoting 
adherence activities, but these services are rarely available in dialysis centres.   
Health professionals are often overly optimistic about adherence behaviour in 
their patients [250], however, renal nurses in this study acknowledged the high 
prevalence of nonadherence behaviour in patients undergoing dialysis. Nurses’ 
perceptions corroborated with earlier findings that patient-related factors, such as lack 
of knowledge about medicines, lack of family or social support, forgetfulness, comorbid 
conditions, pill burden, relative affordability, and culture and communication barriers 
could influence adherence [141, 226, 228, 252].  
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Renal nurses also emphasised that sustainable strategies for empowering self-
management in patients taking long-term medications, and having trusted 
relationships with healthcare providers, can have a significant influence on patients’ 
medication-taking behaviour. Patients become truthful about taking medication only if 
they feel free to admit their difficulties with no risk of criticism, and when there is a true 
partnership with their healthcare providers [259].  
Patients with CKD who express dissatisfaction due to an absence of guidance 
and a lack of discussion about medication-related issues during consultations are 
found to be less motivated to follow treatment recommendations, to hide their 
concerns, and to acquire nonadherence behaviours [225]. Therefore, it is imperative 
that renal healthcare professionals routinely instigate discussions on medication-
related issues with the patients undergoing dialysis.  
A recent systematic review of trials that assessed the effects of nursing 
interventions on improving medication adherence among discharged, home-dwelling 
and older adults suggested that nurse-led and nurse-collaborative interventions 
moderately improved medication adherence in discharged older adults [270]. Similarly, 
a nurse-delivered, self-care intervention program for chronic heart failure patients has 
been found to be effective in improving patients’ medication adherence [271]. 
Designing nurse-led tailored interventions suitable for use during dialysis sessions that 
educate patients on problem-solving, guide behavioural change, and teach them to 
take action in response to wavering signs and symptoms, can be an effective self-
management strategy for improving medication adherence in patients undergoing 
dialysis [226].   
144 
 
We observed that current adherence assessment practices are limited, and that 
the methods used to monitor nonadherence behaviour, such as medication history 
taking, and medication reviews and reconciliation by pharmacists, were only 
occasionally conducted, whereas objective blood monitoring was a routine practice in 
most settings. A recent survey on renal pharmacists’ perceptions corroborated the 
study’s findings on current adherence assessment practices in dialysis settings [269].  
Objective blood monitoring in patients undergoing dialysis is mainly conducted 
to ensure that the dialysis prescription, i.e. the time and type of the dialysis treatments, 
are optimal. Although we can also draw inferences from blood results to see if patients 
are adherent to their medications, particularly phosphate binders, the reliability of 
these results can be questioned as they can be affected by various dietary and clinical 
factors. A preferable approach would be to combine objective measures with 
subjective ones, such as patient interviews or validated adherence assessment 
questionnaires [252]. This may also help to overcome the subjective bias of patient 
self-reports [208, 272].  
The ability to conduct adherence assessments and promotion activities in 
dialysis settings may largely depend upon overcoming the barriers identified in this 
study, such as time and resource limitations, a lack of hospital support, and most 
importantly unwillingness from both patients and health professionals to actively 
participate in dialogues to resolve medication-related issues. The delivery of 
adherence support activities by renal healthcare professionals will also depend upon 
the knowledge and skills they acquire through tailored education and training, and 
routine practices [260, 261]. Renal nurses in this study largely disagreed that they lack 
the knowledge and skills needed to conduct adherence assessment activities, and 
were instead highly confident about this.  
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The fact that renal nurses are involved in managing and assessing the health 
needs of the dialysis patients on a daily basis, and in educating patients about their 
diseases, prognoses, and treatments may have contributed to higher confidence 
scoring. Not surprisingly, the majority of the renal nurses also endorsed the inclusion 
of dedicated professionals, especially renal pharmacists, in undertaking adherence 
assessment activities in patients undergoing dialysis. Positive perceptions towards 
pharmacists’ roles may be due to past experiences of inter-professional collaborations, 
and awareness of the competency and contribution of pharmacists in delivering 
pharmaceutical care services [263-265]. Pharmacist interventions have contributed to 
reduced hospitalisation, improved patient satisfaction, and decreased overall 
treatment costs in patients undergoing dialysis [245]. 
The availability of renal pharmacy services in Australian outpatient dialysis 
centres is extremely limited [245]. Centres receiving pharmacy services on a 
necessary basis might call upon pharmacists for medication reviews only on occasions 
when the severity of a patient’s condition demands higher scrutiny of their medication 
regimen. Although the presence of a dedicated professional or renal specialised 
pharmacist who can solely focus on medication management and adherence 
promoting activities would be an ideal solution, it is unlikely that this will be 
incorporated into every dialysis centre anytime soon due to time and resource 
availability [111], finances, and organisational factors [245, 266]. 
Alternative measures include empowering the existing renal nursing services 
available in the dialysis centres as they are the professionals who closely interact with 
the patients, and are ideally placed to deliver medicines, monitor patient progress, and 
engage patients in strategies to promote adherence [139, 267]. Unfortunately, the 
existing workload of the renal nurses and the barriers to successful incorporation of 
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auxiliary roles, such as adherence assessment and promotion activities, need to be 
carefully considered in dialysis settings. Moreover, dedicated pharmacists should 
make an effort to educate patients on self-management activities that promote 
adherence and contribute to positive health outcomes in patients undergoing dialysis 
[273]. 
  
6.6.1. Study Limitations 
Participants were not directly recruited, instead email alerts, e-newsletters, and social 
media posts from the professional organisation were relied upon. As such, an absolute 
denominator for the survey response rate could not be ascertained. This may have led 
to the inclusion of self-selected participants who were more interested in sharing their 
perceptions. Nevertheless, an even amount of participation was observed from rural 
and metropolitan areas, as well as from public and private dialysis centres.  
The study findings may not be generalisable to dialysis settings across Australia, 
for example, New South Wales has the highest number of dialysis centres, but there 
was poor representation from the renal nurses. Nevertheless, the scope of this study 
was mainly to generate baseline observations to inform larger nation-wide surveys.   
 
6.7. Conclusion 
Clinicians spend a great deal of time prescribing the best possible medications for their 
patients, yet little attention is paid to measuring adherence and ensuring that patients 
are adhering to their prescribed medications. The current adherence assessment 
practices of renal nurses are limited to selective patients utilising objective laboratory-
based values instead of patient self-reported measures. Lack of time, administrative 
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support, and patient disinterest in communicating medication issues with the renal 
nurses, were commonly perceived as barriers to assessing adherence. Strengthening 
renal nursing services by addressing the existing barriers may be a way to improve 
medication adherence in patients undergoing haemodialysis.   
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Appendix 14. The STROBE checklist 
Appendix 15. Inter-item correlation matrix and Cronbach’s alpha coefficients for each 
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Appendix 16. Comments on perceptions and current practices  
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CHAPTER SEVEN 
 
7. BARRIERS TO ASSESSING ADHERENCE AND CONSIDERATIONS TO 
IMPROVE ADHERENCE ASSESSMENT PRACTICES IN DIALYSIS SETTINGS: A 
QUALITATIVE STUDY 
 
7.1. Abstract 
Background: End-stage kidney disease (ESKD) patients undergoing dialysis are 
typically prescribed multiple complex medication regimens; as such, they are at high 
risk of medication nonadherence. Current clinical practices focuses on prescribing the 
best possible medications for their patients. However, little attention has been given 
towards measuring and ensuring patients’ adherence to the prescribed treatment. The 
aims of this study were to explore barriers to assessing adherence in patients 
undergoing dialysis, and identify strategies to improve adherence assessment 
practices in dialysis settings.   
Study Design: Qualitative study. 
Setting & Participants: 18 health professionals (12 renal nurses and 6 specialist 
renal pharmacists) working in Australian dialysis settings. 
Methodology: Semi-structured individual interviews conducted between November 
and December 2016. 
Analytical Approach: Transcripts were thematically analysed using Braun and 
Clarke’s six-step method of conducting thematic analyses. 
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Results: Participants were 25-60 years old, and had 1-27 years of experience working 
in dialysis settings. Seven themes related to barriers to assessing medication 
adherence were identified: prioritisation of resources, interplay between workload and 
available time, awareness of formalised adherence measures and training deficits, 
concerns around practicality/suitability of adherence measures, communication of 
assessment services, patient participation, and trust. Three themes related to 
strategies to improving adherence assessment practices were identified: formalisation 
of the adherence assessment process, integration of assessment processes/tools into 
routine, and use of multidisciplinary support to assess medication-taking behaviour in 
patients undergoing dialysis.  
Limitations: Individual practices may vary between dialysis settings; as such, the 
views expressed by the participants may not be generalisable to other settings. 
Conclusions: Current adherence assessment practices could be improved through 
formalisation and integration of the assessment process into hospital 
policy/procedures. Additionally, as barriers to assessing adherence were identified at 
organisational, professional and patient levels, there is a need to address barriers from 
each level in order to improve adherence assessment practices in dialysis settings. 
 
INDEX WORDS: Adherence assessment practices; barriers; dialysis; kidney failure, 
chronic; medication adherence; qualitative research; health care professionals.  
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7.2. Introduction 
Medication nonadherence is a well-recognised problem in chronic diseases with the 
global prevalence rate estimated at 50% [16]. Avoidable health care costs attributed 
to medication nonadherence in the US is estimated between $100 and $300 billion 
annually that represents between 3% and 10% of the total US health care costs [274]. 
End-stage kidney disease (ESKD) patients undergoing chronic haemodialysis are at 
high risk of medication nonadherence, due to increased burden of concomitant illness 
and dialysis-associated complications that demands complex treatment regimens [8, 
23]. The prevalence of medication nonadherence in patients undergoing 
haemodialysis range between 12.5% and 98.6% [23]. Poor adherence has led to 
increased morbidity and mortality [8, 142, 143], repeat admissions [142], and 
unwanted treatments [143] in patients undergoing dialysis.  
The primary step towards improving medication adherence involves true assessment 
of whether patients have followed their prescribed regimens [275]. Providing an 
opportunity for patients to express their concerns with their health professionals can 
help elicit information regarding patients' beliefs and attitudes towards medications, 
social and cultural contexts, and emotional health challenges that may impede 
adherence [2, 275, 276]. All of these components are crucial in influencing adherence 
intentions, and thus need to be explored and discussed during therapeutic 
consultations [275]. However, current clinical practices focus more on improving 
treatment outcomes rather than ensuring patient’s adherence to prescribed regimens 
[1], despite the known associations between poor adherence and morbidity and 
mortality rates. As proper assessment of patients' adherence is important to ensure 
the benefits of prescribed therapies, an ongoing assessment of adherence is 
necessary to ensure that patients are taking their medications appropriately [1, 275].  
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Patients with ESKD often undergo haemodialysis three times a week for at least 3-5 
hours per day [277]. This provides a unique opportunity for renal health care 
professionals to interact with their patients. Renal professionals can seize this 
opportunity to assess adherence, educate patient, and promote medication adherence 
in patients undergoing dialysis. However, no prior studies have explored renal 
professionals’ perceptions regarding adherence assessment practices in dialysis 
settings. Understanding renal professionals’ perspectives can help identify underlying 
challenges and potential practical ways by which adherence measurement practices 
could be improved.  
Therefore, the present study aims to explore the perspectives of renal professionals 
in regard to medication adherence assessment practices. Specifically, the present 
study aims to qualitatively: 
1. Explore barriers to assessing adherence, and  
2. Identify strategies to improve adherence measurement practices in 
Australian dialysis settings.  
 
7.3. Methods 
This qualitative study followed the consolidated criteria for reporting qualitative 
research (COREQ) guideline [15] during its conduct and reporting (Appendix 17). The 
Tasmanian Social Sciences Human Research Ethics Committee granted the ethics 
approval (reference no. H0015433).  
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7.3.1. Participants 
Renal professionals including pharmacists and nurses working in Australian dialysis 
centres were eligible to participate. Recruitment was sought from participants who had 
previously participated in a cross-sectional survey of renal professionals that 
measured perceptions and current practices of assessing medication adherence in 
patients undergoing dialysis. Twenty renal professionals from the survey study 
expressed their interest to participate in the present study, however, two participants 
later retracted due to lack of time. 
 
7.3.2. Data Collection and Analysis  
A pharmacist researcher (SG) conducted semi-structured individual phone interviews 
with the participants between November and December 2016 (Interview guide: 
Appendix 18). One-on-one interview was mainly chosen as the research required to 
generate insights based on personal perspectives that are unlikely to be shared in a 
group discussion. Also, due to the busy schedule of the participants it was practically 
not feasible to make focus groups a realistic option. SG has been trained in qualitative 
research, and has conducted individual interviews in the past. Both the participants 
and the interviewer were unknown to each other before the study. At the beginning of 
interview, participants were informed of the professional status of the interviewer and 
the scope of this study. Each participant was provided a AUD $50 gift card as a 
reimbursement for their time. All interview sessions were audio-recorded and 
transcribed verbatim. The median interview duration was 31 minutes (range, 22-50 
minutes). 
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Interview transcripts were thematically analysed, following Braun and Clarke’s six-step 
method of conducting thematic analyses [278]. This method was mainly chosen as it 
provides a clear step-by-step guide to start thematic analysis, and conduct it in a more 
deliberate and rigorous way. Transcripts were repeatedly read for familiarisation and 
data immersion. Following this, initial codes were generated from the data itself without 
using any a priori themes. The long list of initial codes were sorted and aggregated 
into potential themes. This was followed by review and refinement of themes, while 
discarding irrelevant themes and collapsing similar themes into an overarching theme. 
At this point, the themes were defined and further refined to be presentable for analysis. 
These finalised themes were then reported as results. SG independently coded the 
interview transcripts. The other two investigators KL and STRZ reviewed the codes to 
ensure concordance was reached. All the investigators agreed upon the final codes 
and subsequently generated themes. Qualitative data analysis software NVivo (QSR 
International Pty Ltd. Version 11.0) was used to facilitate the generation of preliminary 
codes and themes from the interview transcripts.  
For this study, data saturation was considered as the point where no new codes could 
be generated from the interview transcripts. Data appeared to be saturated after the 
15th interview as no new codes could be generated from the remaining three 
transcripts.  
 
7.4. Results 
Eighteen renal professionals comprising 12 nurses and six pharmacists participated 
in the individual interviews. The median age of participants was 44 years old (range, 
25-60 years), and participants have a median of 11.5 years (range, 1-27 years) of 
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experience working in renal unit(s). Other demographic characteristics are presented 
in Table 19.  
 
Table 19. Demographics of participants (n = 18) 
Characteristics  Category  Value 
Age, Years  44 (25-60) 
 20-30 3 (16.7) 
 31-40 4 (22.2) 
 41-50 8 (44.4) 
 ≥ 51 3 (16.7) 
Gender   
 Male 5 (27.8) 
 Female 13 (72.2) 
Level of education   
 Diploma 2 (11.1) 
 Bachelors 7 (38.9) 
 Graduate certificate 8 (44.4) 
 Masters   1 (5.6) 
Designation   
 Renal Pharmacist 6 (33.3) 
 Registered Nurse 9 (50.0) 
 Nurse Unit Manager 3 (16.7) 
Experience in renal unit, Years  11.5 (1-27) 
  1-10 8 (44.4) 
  11-20 9 (50.0) 
  ≥ 21 1 (5.6) 
Dialysis unit location   
 Metropolitan 12 (66.7) 
 Rural 6 (33.3) 
Note: Values expressed as number (percentage) or median (lower-upper limits of range).  
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The below sections describe the themes identified from the interviews, with a few key 
quotations from participants. A more detailed compilation of exemplar quotations have 
been included as Appendix 20 and 21 to facilitate external confirmability auditing 
[279]. The following abbreviations are used for the section below when quoting 
participants: P = Pharmacist, N = Nurse, and the number indicates interview sequence.  
 
7.4.1. Barriers to Assessing Medication Adherence 
Seven themes were identified: prioritisation of resources, interplay between workload 
and available time, awareness and training deficits, concerns around 
practicality/suitability of adherence measures, communication of assessment services, 
patient participation, and trust. These themes have been categorised into three main 
categories: organisational, professional, and patient-level barriers. A summary of the 
barriers to assessing adherence is depicted in Figure 14, and further details regarding 
each theme is described in the following sections, under the relevant category 
headings.  
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Figure 14. Barriers to assessing medication adherence in patients undergoing 
dialysis 
 
 
7.4.1.1. Organisation-level 
Theme: Prioritisation of resources 
Interviews with participants revealed that a key barrier to assessing medication 
adherence was workplace prioritisation of resources:   
It depends on the organisational priorities. If they are supportive of this 
[assessment process] or have a vested interest in this, or something like this, 
then the organisation is more likely to pursue this, but otherwise if they can’t 
see any value in it, any direct dollar savings then it’s unlikely to be pursued. [P3, 
female, 50 years] 
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Specifically, based on our findings, it appeared that funding was a major factor for 
resource prioritisation. Participants expressed the need for having dedicated 
professionals, improved interpreter services for non-English speaking patients, and 
having a private space/interview room in the dialysis centres for conducting adherence 
assessment and promotion activities. Examples below: 
[A] big limitation for conducting such activity [i.e. assessing adherence] is the 
absence of pharmacist in the unit. We wish to have a dedicated pharmacist to 
carry these activities. [N7, female, 60 years] 
[Interpreters are] not massively accessible. That is a barrier. Availability of an 
interpreter services is a barrier in the case of non-English speaking patients. 
[P4, male, 45 years] 
Privacy can be an issue because most of our patients sit very close to other 
patients and there is no way to go to the staff with anything privately. [N11, 
female, 29 years] 
 
7.4.1.2. Professional-level 
Theme 1: Interplay between workload and available time 
Amidst a variety of tasks performed while caring for patients undergoing dialysis, renal 
professionals may not have sufficient time to spend with their patients, and assessing 
medication adherence may not be a high priority when time is limited. Example:   
If patients have health matters that are urgent, if they have been experiencing 
pain or having a lot of falls, or whatever that sounds like it’s a new problem, the 
focus becomes on that, rather than other aspects like medications. Whereas, if 
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the person is quite stable, probably there is more emphasis towards medicines. 
[P9, female, 34 years] 
Staff compliance towards assessment services would also diminish due to task 
prioritisation and increased workload.  
Staff participation may be poor. Unless it’s really concerned with particular 
patients, or feel we need to monitor, but if we do it for everybody the work load 
is very high and some of the nurses won’t be happy participating. They are 
already pre-occupied and may say oh! it’s not our responsibility. [N15, male, 44 
years] 
 
Theme 2: Awareness and training deficits  
Lack of awareness about formal adherence assessment tool was evident among the 
participants. An example: 
I don’t know any formal [assessment tools].  I’ve never heard about any official 
ones, I think it would be interesting to read about. [P4, male, 45 years] 
However, one suggestion to address this barrier could be to provide training and 
education related to adherence assessments: 
Nursing staff lacks necessary training and skills. I think definitely, there is room 
for improvement in relation to educating the nurses about medication on dialysis 
or all kidney failure patients. [N17, male, 53 years] 
The above example highlights the gaps in training in relation to conducting adherence 
assessments. 
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Theme 3: Concerns around practicality/suitability of adherence tools  
Participants identified several limitations of using formal assessment measures that 
would compromise identification of actual non-adherent behaviour. One perceived 
limitation is that of practicality and reliability of using methods such as validated 
questionnaires or objective pill counting:  
It’s not quite possible, it’s not that easy to measure and absolutely quantify 
[adherence]. The only way you could do is you physically watch the patient for 
a week, you know, taking all their dosage. I don’t think it’s possible. [P1, female, 
32 years] 
Some participants argued that measuring adherence might label a patient as being 
nonadherent. 
I think it’s good to get a general measure of adherence within patients, but I do 
sometimes find questionnaires label patients as being non-adherent and it’s 
sort of taken as quite a nasty term. [P5, female, 31 years] 
 
7.4.1.3. Patient-level  
Theme 1: Communication of assessment services 
Participants reported the need to set expectations to ensure effective assessment of 
medication adherence. A reason for this, given by a participant, is because patients 
may perceive their privacy being invaded and would not participate:   
It would depend on how it is presented, if it wouldn’t be presented in a right way 
there would be patients who would become upset about why we are asking that 
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question, and patients feeling of having their privacy invaded puts a lot of 
significant barriers of trust at the nurses. [N11, female, 29 years] 
However, if the patients knows about the benefits of assessment, and what to expect 
of the assessment process, they would know why they are being asked certain 
questions and respond to assessment services: 
I think most of the patients would be happy to answer the questions definitely, 
if they see the benefit from it that we care about the medicine they are taking. 
[N12, female, 32 years] 
 
Theme 2: Patient participation 
Several factors deterring patient participation in adherence assessment activities, 
based on the perspectives of renal professionals, were identified from our participants. 
These includes treatment fatigue from dialysis, patient activation (i.e. patient’s 
motivation and perceived ability to contribute to their health management) [280], and 
language barriers especially with non-English speakers that would prevent patient 
from conveying their health-related issues to the health care team. Some examples:  
Medical people oversee them and they have so many appointments, and if you 
ask them if they have any worries they will just say no. A lot of them, even if 
you offer review they go, no everything is fine, I actually don’t need to see you. 
[P1, female, 32 years] 
People do have free will. Even though we are trying to do the best to our 
patients, they still can go, ‘I can’t be bothered’. Then you have to go that point, 
well that’s your decision not anybody else’s. [P2, female, 47 years] 
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We had quite a few issues in our unit based on different cultural groups. We do 
have quite a few non-English speaking patients; basically they speak English 
but not enough to understand. [N11, female, 29 years] 
 
Theme 3: Trust 
Participants alluded to the concepts of trust and mistrust, and the impact of these 
concepts on the success of conducting a medication adherence assessment:  
It’s sad, I think some of them have mistrust about what we tell them, they don’t 
trust that we are telling them the right thing or the truth about the medication 
what they require. [N6, male, 44 years] 
They don’t look at the nursing expertise, they also don’t listen to suggestions 
[about taking medications] and, they say the doctors said do this way and they 
won’t take on board with the nursing, also the lack of confidence in the nursing 
that we would know what they are talking about. [N18, female, 50 years] 
Patients feel that they are going to be judged. That, they should by now know 
this information, why they are asking this pointless question, causing time 
wasting. [P3, female, 50 years] 
As implied in the above quotations, it appears participants perceive that patients would 
prefer sharing their concerns with the professionals whom they trust the most, have a 
good rapport, and have no fear of judgement from their professionals regarding their 
adherence issues. 
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7.4.2. Considerations for Improving Adherence Assessment Practices 
When asked to comment on the topic of improving adherence assessment practices, 
participants provided several suggestions. While some of the suggested activities 
coincide with current practice, participants emphasised that these activities should 
continue with routine dialysis care. A summary of considerations to improve adherence 
assessment practices is highlighted in Table 20. 
 
Table 20. Considerations for improving adherence assessment practices 
• Formalisation of the adherence assessment process 
- Formalise the process in hospital policy/procedures 
• Integration of the adherence assessment process and tools into routine  
- Integrate adherence checklist into treatment sheet 
• Multidisciplinary support 
- Partner with doctor and nursing staff 
-  Liaising with interpreters and communication facilitators (e.g. formal/professional 
interpreters, informal/family interpreters, liaison with indigenous/aboriginal co-
operatives)  
• Other specific activities 
- Organise scheduled sessions for medication reviews (e.g. monthly review and 
reconciliation of medicines, patient report card review for blood levels) 
- Verification of objective evidence (e.g. direct observation of medicines, physical 
assessment, calling patient’s local pharmacy, refill history, observing side effects of 
therapy)  
- Assess subjectively through patient communication (e.g. discussing patient 
concerns about medicines, non-judgemental questioning, maintaining good rapport 
and trusting relationships, being a good listener) 
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Underlying the suggested activities, three themes were identified: formalisation of the 
adherence assessment process, integration of the adherence assessment process 
and other adherence tools into routine, and using multidisciplinary support. Further 
details regarding each underlying theme is discussed in the following three sections. 
 
Theme 1: Formalisation of assessment process 
Participants commonly commented on the need to formalise the adherence 
assessment process in the dialysis settings, to prompt other renal professionals to 
perform adherence assessments as part of the care plan: 
I think it might be good [to formalise assessment] because everybody then is 
following the same process. Staff know what to look for and what to ask. If you 
got a tool that it will prompt them to ask questions or prompt them to follow up 
on certain things. [N18, female, 50 years] 
 
Theme 2: Integration of assessment process and tools into routine  
Participants proposed integrating an adherence checklist into their routine medication 
treatment sheets.  
We could possibly have on a care plan a medication check and tick the boxes 
after conversation with the patients. Not so much the questionnaire, but just the 
prompt to have that conversation with the patients. [N14, female, 49 years] 
Well, our daily treatment sheet has, we already have some checklist we go 
through, sort of might be a simplest just adding up [adherence checklist], yeah, 
having any issues with your tablets or um, yeah. [N8, female, 45 years] 
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Theme 3: Multidisciplinary support 
An initiative for multidisciplinary support was advocated for a successful assessment 
of patient’s adherence. An example:  
I think we need to be involved in multidisciplinary approach, so we have support 
from our colleagues, so everybody is on the same page and support its 
initiatives and therefore the patients gets the consistent message that it’s not 
just the pharmacists hounding them, but it’s actually got value and purpose 
behind it. [P3, female, 50 years] 
Participants also expressed a need to liaise with communication facilitators such as 
formal or informal interpreters for non-English speaking patients, or indigenous liaison 
staffs in the case of indigenous or Aboriginal patients, as such patients would require 
support when making medical appointments and when communicating with their 
health professionals:  
We use interpreters where necessary, if they are the patients with different 
languages. [P1, female, 32 years] 
We wait for their carers or family to come in who speak their language and we 
interpret via them. [P3, female, 50 years] 
For the indigenous, we have support from the Aboriginal liaison staffs so they 
can talk to her and help in medication management. [N12, female, 32 years] 
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7.5. Discussion 
We explored specialist renal pharmacists and nurses’ perspectives on their challenges 
of assessing medication adherence in patients undergoing dialysis and ways by which 
adherence assessment practices could be improved in dialysis settings. Our study, for 
the first time, offers a number of insights into the organisational, professional, and 
patient-level factors that may impede adherence assessment activities in dialysis 
settings. In addition, this study also echoes some considerations such as formalisation 
and integration of the adherence assessment process into routine practice, and 
highlights the importance of multidisciplinary support required for a successful 
assessment of patient’s medication-taking behaviour. Organisational and professional 
barriers identified from this study such as resource prioritisation in workplaces, time 
availability, and awareness and training deficits among health professionals 
corroborated with published studies [111, 245, 261, 281, 282]. Similarly, our study 
reiterates concerns surrounding practicality and suitability of adherence measures, 
which has been extensively discussed in studies on medication adherence [2, 10, 23, 
283]. Sections hereafter will mainly discuss the unique findings of this study.  
Our study revealed that, from the perspective of renal professionals, patients would 
prefer sharing their concerns with the professionals whom they trust the most, have 
no fear of judgement or risk of criticism, and have good patient-provider partnerships. 
Having a trustworthy relationship between patient-provider would influence 
assessment activity and can have a significant impact over patient’s medication-taking 
behaviour [225]. While health professionals may have good intentions to assess 
adherence, if they fail to set expectations and identify benefits of assessing adherence, 
patients may turn hostile towards the assessment services and withdraw participation. 
Thus, communication can be a key to bridge the gap between patient-provider 
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relationships. Having good patient-physician communication can improve patient 
adherence, as supported by a meta-analysis study [282]. Communication can also be 
a key to patient activation, which involves providing necessary knowledge, skills and 
motivation to improve patient’s ability to self-care and maintain their health conditions 
[280]. Patients have been found to follow recommended medical advice when they are 
in the higher stages of activation [284]. A recent systematic review has also highlighted 
the fact that increased patient activation scores are associated with decreased 
hospitalisation and emergency room utilisation in chronically ill patients, though the 
relationship with medication adherence were inconclusive [285]. Future research 
should explore the relationship between patient activation and its impact on medication 
adherence in patients with chronic diseases such as in ESKD patients undergoing 
dialysis.  
Renal professionals emphasised on formalising the assessment process. This would 
normalise the activity, and patients would not feel their privacy invaded when inquired 
about their medication-taking behaviour rather would make themselves available for 
assessment. Similarly, participants proposed integrating adherence checklist into their 
routine care plan. Renal professionals can utilise any of the validated questions 
available in literature that non-judgementally asks patients about their medication 
adherence issues for example, “I know it must be difficult to take all your medications 
regularly. How often do you miss taking them?” Alternatively, patients may be asked 
about a particular medication, “How often do you not take medication X?” [1, 286] 
Prompting these questions may open up discussions pertaining to medication-related 
issues in patients undergoing dialysis. Past findings shows that disclosure of 
nonadherence through interviews and questionnaires have accurately represented 
patient’s medication-taking behaviour [286-288]. However, it should be understood 
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that self-reported measures, though inexpensive and easy to use, comes with an 
inherent limitations such as recall bias and social desirability responses [289]. 
Moreover, accompanying challenges from organisation and professional’s level while 
incorporating assessment services needs to be carefully considered. Due to the 
interplay between workload and available time, dialysis staff may seek to prioritize 
their routine task, which would diminish staff compliance towards the assessment 
services. More dedicated professionals may be required to carry out adherence 
assessment and promotion activities. However, organisations may have an altered 
priority for allocation of resources and finances that may discourage implementation 
and/or sustainability of such programs [111, 245, 281]. Further research is warranted 
to assess the feasibility and cost-effectiveness of implementing such programs in 
dialysis settings.    
Our study has several implications for practice and research. As listed in Table 20, 
participants provided some essential and practical considerations to facilitate routine 
assessment process and promote adherence in dialysis settings. One of the key 
considerations was to conduct medication review and reconciliation on a regular basis. 
Medication reconciliation process confirms the accuracy of medication records with 
the patients/caregivers, whereas medication review involves in-depth analysis of 
medication regimen including appropriateness of therapy, dosing requirements, and 
monitoring of side effects and efficacy of the treatment [290]. As patients undergoing 
dialysis sees many prescribers, undergo frequent admissions, and are on multiple 
medications, this increases the risk for medication record discrepancies (MRDs) and 
medication-related problems (MRPs). On an average, 3.1 MRDs and 0.5 MRPs per 
patient has been observed in patients undergoing haemodialysis [290]. Thus, 
conducting a regular medication review and reconciliation by a dedicated professional 
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may facilitate early detection and intervention of medication-related problems in 
patients undergoing dialysis.  
Participants also suggested verifying objective evidence while assessing adherence, 
for example, by calling patient’s local pharmacy, checking refill history, or reviewing 
blood levels for certain drugs like phosphate binders. Pharmacy refill data can be a 
means to identify breaks between medication refills and help initiate patient dialogues 
for exploring medication-related issues. However, this method may only be effective 
within the closed pharmacy system, and does not necessarily provide direct evidence 
of medication administration by the patients [286]. In such cases, triangulation 
approach may be used whereby objective assessment may be carried out in 
conjunction with subjective methods like patient interviews or using self-reported 
questionnaires.   
Participants from the present study also emphasised the role of multidisciplinary 
support for a successful assessment and adherence promotion. Renal professionals 
from disciplines such as medicine, pharmacy and nursing can work together and liaise 
with the interpreters or social workers for assessment services. Creating an 
opportunity for active patient involvement during therapeutic consultations with health 
professionals improves patient adherence to treatment [282]. Practice implications 
also extends to upgrading current renal professionals by providing trainings and skills 
necessary to assess and promote adherence. In addition, dialysis settings may 
upgrade current infrastructure needs by having a private space or interview room that 
may safeguard patients’ privacy and allow exchange of dialogues in confidence. 
Proposed considerations will help inform the design and testing of new model of care 
that incorporates adherence assessment into routine practice for early identification of 
nonadherence issues in patients undergoing chronic dialysis treatment.     
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The present study is not without limitations. Focus group sessions were not attempted 
rather we relied on one-on-one interviews to generate insights based on personal 
perspectives that are unlikely to be shared during group discussions. As individual 
practices may vary between dialysis settings, the views expressed by the participants 
may not be generalisable to other settings; however, it is important to recognise that 
the aim of this study is to identify potential barriers and considerations for improving 
adherence assessment practices, and thus generalisability was not our primary 
purpose. In addition, the specialist renal pharmacists’ viewpoints from Australian 
context may differ from other countries where pharmacists do not have specialised 
clinical roles. Further studies should be conducted to evaluate the applicability of our 
findings to wider populations. Nevertheless, given the diverse sample of renal 
professionals with varied years of experiences and levels of seniority, we believe our 
study captures a breadth of potential barriers and considerations for improving 
adherence assessment practices.  
While the present study does have some limitations, its strength lie in the use of a 
recognised data analysis method proposed by Braun and Clark [278], which adds to 
the rigor of our findings. In addition, the conduct and reporting of this research was in 
accordance with the COREQ guideline [15]; this ensures that the details of the present 
study have been comprehensively reported, thereby facilitating dependability auditing 
[279], if required.  
In conclusion, barriers to assessing adherence were identified at various 
organisational, professional, and patient levels. Current adherence assessment 
practices could be improved through formalisation and integration of the adherence 
assessment process into hospital policy/procedures, and overcoming existing barriers 
by appointing dedicated and trained professionals for conducting adherence 
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assessment and promotion activities in dialysis settings. Most importantly, renal 
professionals should opt for patient engagement where possible, frequently instigate 
dialogues and remain vigilant towards identifying patients’ concerns related to 
medication that may help to resolve this significant issue of medication nonadherence 
in patients undergoing dialysis. Future research should consider designing and testing 
of new programs or model of care that incorporates adherence assessment into 
routine practice for early identification of medication nonadherence issues in patients 
undergoing chronic dialysis treatment.     
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CHAPTER EIGHT 
 
8. CONCLUSION AND FUTURE DIRECTION 
 
Patients often do not take their medications as prescribed, and this has been well 
documented in medical literature [1, 2, 16, 275]. Despite the fact that our 
understanding of the factors responsible for medication nonadherence has advanced 
during recent years, adherence assessment is still not a routine clinical practice. 
Increasing disease and medication regimen complexity can negatively affect patient 
adherence [197], and there is a paucity of data on the prevalence of, and factors 
responsible for, medication nonadherence in patients undergoing haemodialysis. As 
such, this thesis examined the potential predictors of medication adherence, explored 
current practices and barriers to assessing adherence, and identified strategies to 
improve adherence assessment practices in patients undergoing haemodialysis.  
 To adequately comprehend the issues surrounding medication nonadherence 
in the haemodialysis population, a systematic review study was conducted (as 
described in Chapter 2). Our data showed that between 12.5% and 98.6% of patients 
undergoing haemodialysis were nonadherent to their prescribed regimens. This is 
much higher in comparison to other chronic illnesses, such as diabetes (6.9% to 61.5%) 
[47], chronic psychiatric disorders (5.0% to 52.8%) [45], and other dialysis modalities, 
such as peritoneal dialysis (3.9% to 43.0%) [25].  
We observed that a variety of adherence measures are utilised across studies, 
which has resulted in the reporting of this wide-ranging prevalence pattern. Given the 
absence of a unified standardised approach to measuring medication adherence, this 
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systematic review highlights the necessity of a consensus on defining and assessing 
adherence in patients taking long-term medications. An initiative to standardise the 
taxonomy of adherence was attempted by the International Society for 
Pharmacoeconomics and Outcomes Research’s (ISPOR) special interest group [291], 
however, their definitions were impelled by assessment methods related to refill data 
that would only deliver a limited view of adherence. Most recently, the European 
consensus meeting on the taxonomy and terminology of patient compliance has 
proposed a new taxonomy for describing and defining adherence to medications with 
an approach that remains independent of any assessment methods [26].  
The findings of this systematic review further enhanced our understanding of 
the potential risk factors associated with medication nonadherence in patients 
undergoing haemodialysis. A number of patient-, disease-, and medication-related 
factors contributing to nonadherence were identified, which may help healthcare 
professionals to be more strategic in terms of making therapeutic decisions and 
recommendations based on the risk factors and their influence over patients’ 
medication-taking behaviour. Taking account of patients’ concerns and beliefs 
regarding medication can improve the quality of prescribing, help clinicians involve 
patients in therapeutic decisions, and support optimal adherence to prescribed therapy 
[200].  
Although patients undergoing haemodialysis are often prescribed with complex 
medication regimens [203], this systematic review could only identify one article that 
investigated medication regimen complexity as a potential predictor of adherence 
[150]. Furthermore, the study defined regimen complexity based on frequency and 
dosage schedule instead of using a validated measure [201]. Therefore, to address 
the role of medication regimen complexity in determining nonadherence in patients 
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undergoing haemodialysis, we felt there was a need for a more rigorous study design 
that uses a validated tool, such as the medication regimen complexity index (MRCI), 
to determine the association between regimen complexity and adherence in patients 
undergoing haemodialysis.    
  The second study (described in Chapter 3) was instrumental in finding the 
actual association between medication regimen complexity and adherence in patients 
undergoing haemodialysis. An unanticipated association between regimen complexity 
and adherence was observed where older patients undergoing haemodialysis with 
high comorbidity and higher regimen complexity scores were actually more adherent 
to their prescribed regimens compared to their younger counterparts.  
Adherence is a dynamic phenomenon, and it is often the net result of an 
interplay of a number of factors. The negative consequences of poor adherence can 
be more severe in patients undergoing haemodialysis with increasing comorbidities 
and regimen complexity. Importantly, younger patients with less complex regimens 
and fewer comorbidities may not realise the negative consequences of nonadherence, 
and may not realise the importance of adhering to their prescribed medicines.  
Similar to our findings, other studies have also found older patients undergoing 
haemodialysis to be more adherent to medicines than their younger counterparts [11, 
150]. One reason may be that older patients with multiple comorbidities are more 
concerned about mortality and prefer structured lives, and therefore adhere to their 
medication therapy despite increasing polypharmacy and associated regimen 
complexity [11]. Furthermore, older patients may also be more health conscious and 
receive more support and attention from family members and healthcare teams, which 
could potentially help them adhere to their medication [150, 292].  
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This study signifies the need to support younger patients undergoing dialysis 
during their early adjustment to haemodialysis prescriptions [220]. As an exploratory 
single-centric study conducted with a small sample of patients undergoing 
haemodialysis, however, the study findings may not be generalisable, and therefore 
need to be confirmed through larger prospective observational studies. Nonetheless, 
the unanticipated findings of this study necessitate further exploration of patients’ 
perspectives on their medication-taking behaviour, and of why such discrepant 
findings were observed.  
 The third study (described in Chapter 4) was a follow-up qualitative inquiry that 
aimed to explore the differential perspectives on medication-taking behaviour shown 
by adherent and nonadherent patients undergoing haemodialysis. The findings from 
this qualitative exploration identified a number of factors that led to nonadherence 
behaviour in patients undergoing haemodialysis. Some of the unique aspects 
highlighted in this study include patients reporting their poor interaction with healthcare 
professionals, which led to mistrust of the healthcare providers’ recommendations, and 
the making of collateral arrangements by the patients regarding their treatment and 
medications, all of which fosters nonadherence behaviour. This suggests that 
improving patient adherence may require creating an opportunity for active patient 
participation during therapeutic consultations with healthcare providers.  
Developing a trustworthy relationship between patients and providers can have 
a significant impact on patients’ medication-taking behaviour [225]. Furthermore, 
having good patient-physician communication has been found to improve adherence, 
as suggested by a meta-analysis study [282]. Therefore, renal healthcare 
professionals should routinely instigate dialogues and encourage patients to volunteer 
information concerning their current medicines, readiness to start their new therapy, 
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changes in dose or dosage requirements, and concerns related to medication safety 
and side effects from therapy. This would lead to the early identification of any issues 
pertaining to nonadherence behaviour, and preventive measures could be taken pro-
actively.  
Understanding renal healthcare professionals’ perceptions and practices of 
assessing adherence was equally important for having an unbiased insight into the 
problem of nonadherence, and for finding solutions to resolve the significant issue of 
nonadherence in patients undergoing haemodialysis. Hence, the fourth study was 
designed to comprise cross-sectional surveys (described in Chapters 5 and 6), and a 
follow-up qualitative study of renal professionals (described in Chapter 7).  
In the absence of an existing survey tool, a new survey instrument was 
developed and pilot-tested in specialist renal pharmacists (Chapter 5) and renal 
nurses’ cohorts (Chapter 6). As no prior tools were available, we considered 
developing an instrument that would capture various perception domains and which 
consisted of five individual psychometric scales capable of measuring perceived 
prevalence, contributors, effective methods, barriers, and confidence to assess 
adherence, together with a current practices questionnaire.  
These tools can be used in practice settings as part of any quality initiative 
program targeting nonadherence. For instance, the Pharmacy Guild of Australia (PGA) 
has initiated the Medication Adherence Programs (MAP) aimed at improving patients’ 
adherence to medicines [293]. The PGA has recently introduced a new software 
program called ‘Guildcare’ that analyses pharmacies’ dispense database to calculate 
patient’s ‘MedsIndex’ score [293]. Patients with sufficiently low MedsIndex scores are 
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invited to participate in the MAP, where they are provided with a range of services 
focused on improving adherence.  
The MAP align with the Australian government’s National E-Health Strategy 
and the key objectives of Australia’s continuing health reform agenda on Quality Use 
of Medicines (QUM), and is designed to assist pharmacists in assessing patient 
adherence. Whereas the development of a survey instrument such as ours can 
facilitate the understanding of healthcare professionals’ perceptions and actual 
practices of assessing and promoting adherence in routine clinical practices.  
Findings from these surveys and the follow-up qualitative inquiry of renal 
professionals has, for the first time, offered insights into the current adherence 
assessment practices in dialysis settings, and suggest that the practices are 
suboptimal and that the established methods to screen patient adherence are 
underutilised. Furthermore, the majority of the participants acknowledged that having 
a dedicated pharmacist would be effective in promoting adherence activities, but that 
these services were mostly unavailable in dialysis settings.  
Moreover, participants identified several barriers to assessing adherence at 
organisational, professional, and patient levels that need urgent attention in order to 
improve adherence assessment practices in dialysis settings. As more dedicated 
professionals may be required to conduct adherence assessments and promotion 
activities, the feasibility and cost-effectiveness of implementing such programs may 
warrant further research in the future.   
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8.1. Practice Implications 
Patients alone cannot be blamed for not adhering to their prescribed regimens; both 
healthcare providers and the healthcare system should also bear some responsibility 
and play their part in improving adherence. As medication nonadherence is highly 
prevalent among patients undergoing haemodialysis, improving it may require creating 
an opportunity for an open discussion between patients and healthcare professionals. 
There is a need for broader recognition of this often undetected and undertreated 
problem in routine clinical practices. A practical first step to recognise nonadherence 
is to include it in the routine dialysis sessions alongside the measurements of vital 
signs, e.g. pulse monitoring, and temperature or blood pressure measurements.  
Although self-reporting may seem to be an insensitive measure [27], the routine 
instigation of dialogues may encourage patients to volunteer information concerning 
their medicines. Patients may be able to provide useful insights into their readiness to 
start a new therapy, changes in dose or dosage requirements, and any concerns 
regarding medication safety and side effects. As adherence measures differ in their 
definition and assessment methods, the use of multiple measures may be helpful in 
identifying nonadherence and assuring consistent results [33]. As such, self-reporting 
may be supplemented with objective measures, such as the monitoring of blood levels 
[33] and, a history of patient medication purchasing behaviour [294].  
Recognition of medication nonadherence in patients will allow healthcare 
providers and patients to make a collaborative effort in developing patient-specific 
tailored solutions to address the problem. Simple, evidence-based strategies can then 
be offered to patients, such as reducing daily pill burden, organising dosage 
administration aids for forgetful patients, conducting motivational patient-interviews, or 
outlining the rationale and therapeutic need of a prescribed regimen [295].  
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As access to medicines, and issues surrounding continuity of care, can 
contribute to unintentional nonadherence [232], access to dialysis centre-specific 
professional medical and pharmaceutical services may be improved by increasing 
focus on adherence assessment and promotion activities, and on delivering 
educational support to the patients. Practice implications also extend to the 
improvement of current renal professionals by providing the training and skills 
necessary to assess and promote adherence in patients undergoing dialysis. 
 
8.2. Limitations of the research 
The studies reported in this thesis are mainly aimed at understanding the determinants 
of medication adherence in patients undergoing haemodialysis, and how adherence 
is measured within Australian dialysis settings. As such, examining the clinical 
outcomes and consequences of medication nonadherence was beyond the scope of 
this research. The patients undergoing haemodialysis were sourced from a single 
outpatient dialysis centre, which may compromise the generalisability of the findings.  
The use of self-reported questionnaires and data from patient qualitative 
interviews can be susceptible to recall bias and social desirability, resulting in an 
overestimation of actual medication-taking behaviour [32]. Due to the cross-sectional 
nature of this study, the adherence behaviour reported may be influenced by the 
reverse causation bias [206]. Also, during the cross-sectional survey of the renal 
healthcare professionals, various recruitment strategies were used to gather 
responses from the renal physicians. Due to extremely poor representation, however, 
the renal physician survey responses were excluded from the analysis. Poor physician 
responses have been commonly observed in survey research [110, 250].  
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8.3. Future direction 
Several prospects for future research arose from this body of work:  
• The study described in Chapter 3 was exploratory in nature, and was 
conducted in a single centre with a small sample of patients undergoing 
haemodialysis. Future research should aim to recruit a larger sample of 
patients, and should use objective measures of adherence suitable for all 
patients and reflecting all medications (e.g. medication possession ratio), to 
assess the exploratory findings of this study. Furthermore, future studies 
should explore the potential use of the triangulation method, whereby 
subjective and objective adherence assessment measures supplement each 
other in determining actual patient adherence to medication.    
• The qualitative study described in Chapter 4 was limited to English-speaking 
patients only. Future work should aim to include a more diverse cohort of 
patients undergoing haemodialysis, including those from indigenous and 
aboriginal backgrounds, to improve the generalisability of the findings.  
• Due to poor representation from renal doctors during the cross-sectional 
survey study, the understanding of renal professionals’ perception and 
practices of assessing adherence was limited to renal pharmacists (Chapter 5) 
and renal nurses (Chapter 6). Future research should aim to comprehend renal 
doctors’ perspectives on this issue.  
• In the absence of a validated instrument that measures renal professionals’ 
perceptions and practices of assessing adherence, a survey instrument was 
developed and piloted (Chapters 5 and 6). This survey instrument has good 
reliability and future studies can utilise this survey instrument when conducting 
larger nationwide surveys of renal professionals. 
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• The considerations proposed to improve the adherence assessment practices 
of the renal professionals (reported in Chapter 7) can help inform the design 
and testing of new models of care that incorporates adherence assessment 
into routine practice for the early identification of nonadherence issues in 
patients undergoing chronic dialysis treatment. 
 
8.4. Conclusion 
This thesis has addressed important gaps in our understanding of the factors affecting 
medication adherence in patients undergoing haemodialysis, and of the current 
adherence assessment practices in Australian dialysis settings. There is a need for 
broader recognition of this often undetected and undertreated problem in routine 
clinical practices. Improving medication adherence among patients undergoing 
haemodialysis may require creating an opportunity for an open discussion between 
patient and healthcare professionals. This may be the very first step in the right 
direction towards assessment and promotion of medication adherence in patients 
undergoing dialysis.  
In addition, current adherence assessment practices could be improved 
through their formalisation and integration into hospital policies/procedures (e.g. by 
integrating an adherence checklist into the treatment sheet for routine assessment). 
Although it is easier said than done, appointing a dedicated and trained healthcare 
professional to measure adherence is another key initiative that may improve 
medication adherence among patients undergoing dialysis.    
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APPENDICES 
Appendix 1. PRISMA Checklist 
Section/topic  # Checklist item  Reported in section 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Title Page 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic 
review registration number.  
Abstract 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
Introduction 
Objectives  4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
Introduction 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed 
(e.g., Web address), and, if available, provide registration 
information including registration number.  
Study selection 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-up) and 
report characteristics (e.g., years considered, language, publication 
status) used as criteria for eligibility, giving rationale.  
Study selection 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
Data source and 
search strategy 
Search  8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated.  
S2 Appendix 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, 
included in systematic review, and, if applicable, included in the 
meta-analysis).  
Study selection 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.  
Data extraction 
and analysis 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and simplifications 
made.  
Data extraction 
and analysis 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in 
any data synthesis.  
Quality 
assessment 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in 
means).  
Data extraction 
and analysis 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of 
studies, if done, including measures of consistency (e.g., I2) for each 
meta-analysis.  
Data extraction 
and analysis 
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Section/topic  # Checklist item  Reported in section  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective reporting 
within studies).  
Data extraction 
and analysis 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating which 
were pre-specified.  
Data extraction 
and analysis 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
Description of 
included studies 
Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and provide 
the citations.  
Table 1 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any 
outcome level assessment (see item 12).  
Study quality 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each 
study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
Table 1, Figure 2 
Synthesis of 
results  
21 Present results of each meta-analysis done, including confidence 
intervals and measures of consistency.  
NA 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies 
(see Item 15).  
Study quality 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
Perceived 
barriers  
DISCUSSION   
Summary of 
evidence  
24 Summarise the main findings including the strength of evidence for 
each main outcome; consider their relevance to key groups (e.g., 
healthcare providers, users, and policy makers).  
Discussion 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), 
and at review-level (e.g., incomplete retrieval of identified research, 
reporting bias).  
Discussion 
Conclusions  26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research.  
Conclusion 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other 
support (e.g., supply of data); role of funders for the systematic 
review.  
NA 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097. For more information, visit: www.prisma-statement.org.  
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Appendix 2. Electronic search strategy, Systematic Review 
ID Query 
PubMed Search Strategy 
#1 ((((((((hemodialysis[MeSH Terms]) OR hemodialysis, home[MeSH Terms]) OR 
hemodialysis unit, hospital[MeSH Terms]) OR therapy, renal replacement[MeSH 
Terms]) OR disease, end stage kidney[MeSH Terms]) OR chronic renal 
failure[MeSH Terms]) OR chronic renal insufficiency[MeSH Terms]) OR chronic 
kidney failure[MeSH Terms]) OR chronic kidney insufficiency[MeSH Terms] 
 AND 
#2 ((((adherence, medication[MeSH Terms]) OR adherence, patient[MeSH Terms]) 
OR compliance, medication[MeSH Terms]) OR compliance, patient[MeSH 
Terms]) OR concordance 
 AND 
#3 ((((medication*) OR regimen*) OR schedule*)) OR ((session*) OR exchange*) 
 
Embase Search Strategy 
#1 (('hemodialysis'/exp/mj OR 'hemodialysis') OR ('end stage renal disease'/exp/mj 
OR 'end stage renal disease') OR ('chronic kidney failure'/exp/mj OR 'chronic 
kidney failure') OR ('renal replacement therapy-dependent renal 
disease'/exp/mj OR 'renal replacement therapy-dependent renal disease'))  
 AND 
#2 (('drug therapy'/exp OR 'drug therapy') OR ('drug'/exp/mj OR 'drug') OR ('drug 
dose regimen'/exp OR 'drug dose regimen'))  
 AND 
#3 (('medication compliance'/exp OR 'medication compliance') OR 'concordance') 
 
CINAHL Search Strategy 
S1 (MH "Hemodialysis") OR (MM "Renal Replacement Therapy+") OR (MM "Kidney 
Failure, Chronic+") OR (MM "Renal Insufficiency, Chronic+")  
 AND 
S2 (MM "Medication Compliance") OR (MM "Patient Compliance+") OR 
"concordance"  
 AND 
S3 "medication" OR "drug" OR (MH "Medication Regimen (Omaha)") OR "regimen" 
OR (MM "Drug Administration Schedule") 
 
PsycInfo Search Strategy 
S1 hemodialysis OR (hemodialysis unit) OR (renal replacement therapy) OR (end 
stage kidney disease) OR (end stage kidney failure) OR (chronic renal failure) OR 
(chronic kidney failure) OR (chronic kidney insufficiency) OR (chronic renal 
insufficiency) 
 AND 
S2 adherence OR (medication adherence) OR (patient adherence) OR compliance 
OR (medication compliance) OR (patient compliance) OR concordance OR 
(patient concordance) 
 AND 
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S3 medication* OR drug* OR regimen* OR schedule* 
 
Cochrane Search Strategy 
#1 MeSH descriptor: [Renal Dialysis] this term only 
#2 MeSH descriptor: [Hemodialysis Units, Hospital] explode all trees 
#3 MeSH descriptor: [Hemodialysis, Home] 1 tree(s) exploded 
#4 MeSH descriptor: [Renal Replacement Therapy] this term only 
#5 MeSH descriptor: [Kidney Failure, Chronic] this term only 
#6 #1 or #2 or #3 or #4 or #5 
#7 MeSH descriptor: [Medication Adherence] explode all trees 
#8 MeSH descriptor: [Patient Compliance] this term only 
#9 "concordance":ti,ab,kw (Word variations have been searched) 
#10 #7 or #8 or #9 
#11 "medication":ti,ab,kw (Word variations have been searched) 
#12 "drug":ti,ab,kw (Word variations have been searched) 
#13 "regimen":ti,ab,kw (Word variations have been searched) 
#14 "schedule":ti,ab,kw (Word variations have been searched) 
#15 #11 or #12 or #13 or #14 
#16 #6 and #10 and #15 
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Appendix 3. Patient Medication History Interview Questions 
 
A. ALLERGIES 
1. Do you have an allergy to or avoid any medications due to side effects? 
2. What type of reaction do you have? 
 
B. PRESCRIPTION MEDICATIONS 
1. What prescription medications do you take on a regular basis? 
2. When do you take them? 
 
C. NON-PRESCRIPTION MEDICATIONS 
1. What non-prescription over-the-counter (OTC) medications do you take 
on a regular basis? 
2. When do you take them? 
 
D. HERBALS/ COMPLEMENTARY AND ALTERNATIVE/ SUPPLEMENTS/ VITAMINS 
1. What herbal, natural or homeopathic remedies do you take? 
2. What vitamins or minerals do you take? 
3. When do you take them? 
4. How do you take them? 
 
E. ADDITIONAL QUESTIONS 
1. Do you use any: 
• Eye drops 
• Nose sprays 
• Puffer (Inhalers) 
• Medicated lotions or creams 
• Medicated patches 
 
2. Do you receive any: 
• Needles (injections) 
• Samples from the doctor’s office 
 
3. Do you take any medication on a regular basis: 
• For sleep 
• For your stomach 
• For your bowels 
• For pain 
 
4. Do you take any medication on an irregular basis: 
• Weekly/ fortnightly/ monthly 
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Appendix 4. Patient Self-reported Questionnaires 
 
Health outcome measure: 
Patient’s health outcome measure will be assessed using EQ-5D-5L, a standardised 
instrument developed by EuroQol Group. The EQ-5D-5L descriptive system is 
composed of 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, and 
anxiety/ depression. Each of these domains have 5 levels: no problem, slight problems, 
moderate problems, severe problems, and extreme problems. The decision results in 
a 1- digit number expressing the level selected for that dimension. The digits for 5 
dimensions can be combined in a 5- digit number describing the respondent’s health 
state. 
 
Under each heading, please tick the ONE box that best describes your health TODAY. 
 
MOBILITY  
I have no problems with walking around  
I have slight problems with walking around  
I have moderate problems with walking around  
I have severe problems with walking around  
I am unable to walk around  
PERSONAL CARE  
I have no problems with washing or dressing myself  
I have slight problems with washing or dressing myself  
I have moderate problems with washing or dressing myself  
I have severe problems with washing or dressing myself  
I am unable to wash or dress myself  
 
USUAL ACTIVITIES (e.g. work, study, housework, family or 
leisure activities)  
I have no problems doing my usual activities  
I have slight problems doing my usual activities  
I have moderate problems doing my usual activities  
I have severe problems doing my usual activities  
I am unable to do my usual activities  
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PAIN / DISCOMFORT  
I have no pain or discomfort  
I have slight pain or discomfort  
I have moderate pain or discomfort  
I have severe pain or discomfort  
I have extreme pain or discomfort  
 
ANXIETY / DEPRESSION  
I am not anxious or depressed  
I am slightly anxious or depressed  
I am moderately anxious or depressed  
I am severely anxious or depressed  
I am extremely anxious or depressed  
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The worst health 
you can imagine 
 
 
 
 
 
• We would like to know how good or bad your health is TODAY. 
• This scale is numbered from 0 to 100. 
• 100 means the best health you can imagine. 
0 means the worst health you can imagine. 
• Mark an X on the scale to indicate how your health is TODAY. 
• Now, please write the number you marked on the scale in the box 
below. 
 
  
  
The best health 
you can imagine 
YOUR HEALTH TODAY = 
10 
0 
20 
30 
40 
50 
60 
80 
70 
90 
100 
5 
15 
25 
35 
45 
55 
75 
65 
85 
95 
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Self-reported adherence: 
Please answer Yes/ No: 
 
a. Do you ever forget to take your medicine? __________  
b. Are you careless at times about taking your medicine? ________ 
c. When you feel better do you sometimes stop taking your medicine? ________ 
d. Sometimes if you feel worse when you take your medicine, do you stop taking it? 
_______ 
 
 
Perceived burden of medication administration: 
Please score between 1 and 5.  
1 = Not at all bothered 
2 = Slightly bothered 
3 = Moderately bothered 
4 = Severely bothered 
5 = Extremely bothered 
 
How much are you bothered by the:  
a. Number of medication prescribed? ______ 
b. Size of the pills? ______ 
c. Adverse effects of medication? ______ 
d. Number of times medicines should be administered during the day? ______ 
e. Need to take medicines at work or in social contexts? ______ 
f. Need to drink water in order to take medication? ______ 
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Appendix 5. Data collection form 
Patient ID Patient Name 
 
ALLERGIES & ADVERSE DRUG REACTIONS 
(ADR) 
 
  Drug (or Other) Reaction/ Date 
Age Gender   
    
Time of ESKD Education Employment 
   
Marital S Living arrangement Smoking Alcohol 
    
Current medication 
(Generic/ Trade name) 
Dosage form 
(Strength) 
Dosing frequency 
(How often) 
Additional dir 
(With food etc.) 
Current comorbid conditions 
 
     Heart problems (CAD, CHF) 
     Vascular disease (PAD) 
     High blood pressure 
     Diabetes (W/Wo EOD: retino, neuro, nephropathy) 
     Thyroid problems 
     Muscle/ bone disorders 
     Lung problems 
     Liver disease 
     Bleeding problems 
     Stomach problems (Ulcer) 
     Vision problems 
     Infections 
     Arthritis 
     Cancer 
     Neurological problems 
     Mental health issues 
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         Appendix 6. Medication Regimen Complexity Index, MRCI 
  
DPI = dry powder inhaler; MDI = metered- dose inhaler.  
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Medication Regimen Complexity Index (MRCI) (continued) 
 
  
DPI = dry powder inhaler; MDI = metered- dose inhaler.  
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Appendix 7. COREQ Checklist: Patient Interview 
No. Item Guide questions/ description Reported in section/ remarks 
Domain 1: Research team and reflexivity 
Personal Characteristics   
1. Interviewer/ 
facilitator  
Which author/s conducted the 
interview or focus group? 
Research team and reflexivity 
2. Credentials What were the researcher’s 
credentials? E.g. PhD, MD 
PhD 
3. Occupation What was their occupation at the time 
of the study? 
Research team and reflexivity 
4. Gender Was the researcher male or female? Male 
5. Experience and 
training 
What experience or training did the 
researcher have? 
SG was trained for pharmacists 
Home Medicines Review on 
medication history taking and 
collating medication-related 
information and provided one-on-
one coaching to interview complex 
patients by the hospital 
pharmacist.  
Relationship with 
participants 
  
6. Relationship 
established 
Was a relationship established prior to 
study commencement? 
Research team and reflexivity 
7. Participant 
knowledge of the 
interviewer 
What did the participants know about 
the researcher? e.g. personal goals, 
reasons for doing the research 
Research team and reflexivity. 
Data collection.  
8. Interviewer 
characteristics 
What characteristics were reported 
about the interviewer/ facilitator? e.g. 
Bias, assumptions, reasons and interests 
in the research topic 
SG discussed prior literature on 
Medication nonadherence in 
patients undergoing haemodialysis, 
and how little is known about the 
patients’ perspectives in outpatient 
dialysis setting. 
Domain 2: Study design   
Theoretical framework   
9. Methodological 
orientation and Theory 
What methodological orientation was 
stated to underpin the study? e.g. 
grounded theory, discourse analysis, 
ethnography, phenomenology, content 
analysis 
Data collection and analysis 
 
Participant selection   
10. Sampling How were participants selected? e.g. 
purposive, convenience, consecutive, 
snowball 
Participants 
11. Method of approach How were participants approached? 
e.g. face-to-face, telephone, mail, email 
Participants 
12. Sample size How many participants were in the 
study? 
Participants 
13. Non-participation How many people refused to participate 
or dropped out? Reasons? 
Participants 
Setting   
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No. Item Guide questions/ description Reported in section/ remarks 
14. Setting of data 
collection 
Where was the data collected? e.g. 
home, clinic, workplace 
Data collection and analysis 
 
15. Presence of 
nonparticipants 
Was anyone else present besides the 
participants and researchers? 
No 
16. Description of 
sample 
What are the important characteristics 
of the sample? e.g. demographic data, 
date 
Participants 
Data collection   
17. Interview guide Were questions, prompts, guides 
provided by the authors? Was it pilot 
tested? 
Data collection and analysis. 
Appendix 2.  
 
18. Repeat interviews Were repeat interviews carried out? If 
yes, how many? 
Not conducted 
19. Audio/ visual 
recording 
Did the research use audio or visual 
recording to collect the data? 
Data collection and analysis 
20. Field notes Were field notes made during and/or 
after the interview or focus group? 
Data collection and analysis  
21. Duration What was the duration of the 
interviews or focus group? 
Data collection and analysis 
22. Data saturation Was data saturation discussed? Data collection and analysis 
23. Transcripts returned Were transcripts returned to 
participants for comment and/ or 
correction? 
No 
Domain 3: Analysis and findings 
Data analysis   
24. Number of data 
coders 
How many data coders coded the data? Data collection and analysis 
25. Description of the 
coding tree 
Did authors provide a description of the 
coding tree? 
No. Intermediate documentation is 
available upon request. 
26. Derivation of 
themes 
Were themes identified in advance or 
derived from the data? 
Data collection and analysis 
27. Software What software, if applicable, was used 
to manage the data? 
N/A 
28. Participant checking Did participants provide feedback on 
the findings? 
No 
Reporting   
29. Quotations 
presented 
Were participant quotations presented 
to illustrate the themes/ findings? Was 
each quotation identified? e.g. 
participant number 
Results. Table 2.  
Appendix 3.  
30. Data and findings 
consistent 
Was there consistency between the 
data presented and the findings? 
Yes 
31. Clarity of major 
themes 
Were major themes clearly presented in 
the findings? 
Results 
32. Clarity of minor 
themes 
Is there a description of diverse cases or 
discussion of minor themes? 
Results 
 
Developed from: Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research 
(COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in 
Health Care. 2007. Volume 19, Number 6: pp. 349 – 357. 
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Appendix 8. Interview guide: Patient Interview 
 
Opening statement for the participants:  
Thank you for participating in this study. Before we begin, I’d like to summarise the structure 
of this session. At first, I’ll be discussing with you about the medications you are currently 
taking for all your health conditions that may include prescription, non-prescription, and 
complementary or alternative medicines such as herbal medicines. Following that, I’d like to 
hear some of your experiences of taking medicines. I also have some questions discussing 
about your health conditions. These questions will give you an opportunity to talk about your 
medicines, how well you feel they work, side effects, and so on. This interview should take no 
more than 30 minutes. Your participation will be completely voluntary and you may prefer 
not to answer any of the questions if you are not willing to. I’d like to audiotape this 
conversation for future reference however, all your responses will be kept confidential and 
will not affect your medical care in any way. Do you have any questions or concerns you’d like 
to discuss before we begin?  
If yes: (give answer) 
If no: (begin interview) 
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Questions relating to experiences of taking medicines: 
1. How do you feel about your medicines? 
2. How are your medicines helping your illness? 
3. How do your medicines affect your life?  
4. On what way does your medicines affect your family and social life? 
5. What are the things you don’t like about taking your medicines? 
6. What is the most challenging part of taking your medicines? 
7. What situations make it difficult for you to take your medicines? 
8. What are the things that helps you to take your medicines? 
9. In what situations you feel easy taking your medicines? 
10. What are the problems you face while taking your medicines? 
11. What are the ways to fix any of the medication related problems you face? 
12. How do you seek help for the management of specific symptoms? 
13. Where do you go or whom do you seek for help to talk about your medicines? 
14. When you see your doctor, how does the session usually go? 
15. What are the skills that you have adapted for taking your medicines? 
16. How do you manage your expenses for medication? 
References: 
1. Ogedegbe G et al. Barriers and facilitators of medication adherence in hypertensive African 
Americans: a qualitative study. Ethn Dis. 2004;14(1):3-12.  
2. Williams AF et al. Adherence to multiple prescribed medications in diabetic kidney disease: a 
qualitative study of consumers’ and health professionals’ perspectives. Int J Nurs Stud. 
2008;45(12):1742-1756.  
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Appendix 9. Summary of interpretation of themes with exemplar quotes: Patient 
Interview 
Themes based on WHO 
taxonomy 
Exemplar quotes 
Patient-related factorsµ  
Knowledge and beliefs  
- Lack of understanding 
about medicines 
“Well, I just don’t know what some of them are for.” (P1, male, 53 years, 
PSR NAD) 
 “I don’t know what’s really important and… if you missed [medication] once 
or twice it wouldn’t matter, I’ve no idea.” (P5, female, 58 years, PSR NAD) 
 “As far vitamins are no much point for me because it all gets dialysed out 
of here [pointing to the dialysis machine].” (P8, male, 71 years, PSR NAD) 
- Lack of benefit “I don’t know if they doing any good? […] I thought well, you know, I am 
taking all this in the morning, um… are they doing any good? I don’t know.” 
(P5, female, 58 years, PSR NAD) 
- Relative importance “I think blood pressure one is important. Yes, I think that is important to 
keep my blood pressure down…” (P6, female, 74 years, PSR NAD) 
 “Except for the, ah, Atorvastatin, I’m fairly happy with my medicines.” (P6, 
female, 74 years, PSR NAD) 
- Perceived need “I think, you got a put in your head you got a pills because they are trying 
to help you, so you take them.” (P11, male, 84 years, PSR AD) 
 “There’s something to do with my kidney and that. […] it’s not working very 
well. If I started not taking them, I could for been… you know in trouble. 
They all they are for a reason. Yeah.” (P15, male, 78 years, PSR AD) 
 “I always take them. If I stop taking them, I don’t do anything, I can’t move. 
I just stiffen up like this and that’s it.” (P16, male, 65 years, PSR AD) 
- Perceived effectiveness “I put myself on that [medicine] because I didn’t have any arthritis or 
anything before I started [dialysis] and all of a sudden my fingers going, and 
I put it on that now for a month and it stopped the pain…” (P12, female, 80 
years, PSR AD) 
- Safety concerns  “I stopped taking them [phosphate binders]. You know, it got me there 
badly, it got me suffer physically… I mean it must be that one [phosphate 
binders] because all the other one’s are fine. I haven’t vomited for ages, and 
I’m very careful about the diet.” (P5, female, 58 years, PSR NAD) 
 “There’s one medicine that is a statin which I’m very unhappy about. It’s 
Atorvastatin. And, I’m unhappy about that… because they… they, ah, 
studies have shown that there are lots of side effects of that.” (P6, female, 
74 years, PSR NAD) 
Awareness  
- Consequences of 
nonadherence and 
motivation to live 
“I don’t know how much longer I got to live. But I want to get up to 80. If I 
become 80, that will be the longest lived in all our family. And if I make 80…  
I’m the champion.” (P15, male, 78 years, PSR AD) 
 “Oh, it [medicines] doesn’t worry me. Its keeping me alive, this medicines 
keeping me alive so, I do whatever I’ve to. If I don’t take them I’m probably 
dead.” (P12, female, 80 years, PSR AD) 
 “If you don’t [take] you won’t breathe.” (P20, male, 80 years, PSR AD)   
 “doesn’t worry me because they are keeping me alive. Like the treatments 
keep me alive, the medicines are keeping me alive.” (P21, male, 84 years, 
PSR AD) 
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Themes based on WHO 
taxonomy 
Exemplar quotes 
 “If I don’t take them I could possibly die. Without having this [dialysis] plus 
my medication, I wouldn’t last more than two or three weeks.” (P21, male, 
84 years, PSR AD) 
 “Keeps me alive. I want to stay alive. Simple as that.” (P25, male, 72 years, 
PSR AD) 
Attitude  
- Positive attitude “I don’t mind taking them [medicines]. It’s better than being, making them 
worse if you don’t, so.” (P10, female, 53 years, PSR AD) 
 “They [medicines] are here to be taken, so I take them.” (P11, male, 84 
years, PSR AD) 
 “I always take them, all the time. No matter what, I never stop taking 
medication. Only what I’ve been prescribed, I don’t take any other 
medication.” (P15, male, 78 years, PSR AD) 
 “I got to take them as they keep me healthy. And I don’t have a problem 
with it.” (P21, male, 84 years, PSR AD) 
 “[medicines] are to my benefit to take them as prescribed.” (P21, male, 84 
years, PSR AD) 
 “It’s there to take it, you take it. So I don’t have any problem with that.” 
(P24, male, 72 years, PSR AD) 
 “They got to take and you take them. Once you start getting sick, they are 
part of your daily life.” (P24, male, 72 years, PSR AD) 
 “If they are prescribed for me, I take them.” (P28, male, 75 years, PSR AD) 
 “You got to take them so you take them… If I don’t have it, I suffer.”  (P28, 
male, 75 years, PSR AD)  
- General dislike “I don’t like the fact that I need to take them… Not happy about taking 
medications but the alternatives not good.” (P13, female, 63 years, PSR 
NAD) 
Self-efficacy  
- Disruption to daily 
routine  
“Well it’s in the morning and night, I’m just used to doing that. It’s the 
middle one I have to take care of… I take it at night. Take two at night 
instead of three, spreading three during the day, which the doctor asked 
me to try, because it might be more effective. I haven’t yet succeeded.” (P8, 
male, 71 years, PSR NAD) 
 “I had my wife been on the hospital, and I had been doing things for her 
and there’s a lot of running around, and just a midday gets left out, so 
pretty low in the list of priority so, at the moment.” (P18, male, 71 years, 
PSR NAD) 
- Inconvenience during 
travel 
“When I’m camping, you know there’s a lot to do, it’s just this one extra job 
in the morning to, you know, wake up in the little tent in the sleeping bag 
and have to find my pill.” (P3, male, 44 years, PSR NAD) 
 “People don’t make it difficult for me, but it’s the fact that I’ve, I travel, I 
like to travel of course make it difficult, because I’ve got to take all the stuffs 
with me, organise something every day or whatever. Yes, traveling.” (P6, 
female, 74 years, PSR NAD) 
- Accustomed regimen “I got all these medications every day, morning, evening, night. So, I never 
forget it, now.” (P15, male, 78 years, PSR AD) 
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Themes based on WHO 
taxonomy 
Exemplar quotes 
 “Just habit, yeah. In other words, whenever I have my breakfast, my tea, all 
the time they’re there.” (P16, male, 65 years, PSR AD) 
 “I have been taking them for a long time, that’s normal for me. Daily 
routine.” (P20, male, 80 years, PSR AD) 
 “They are just part of my life. For last 9 years now, I’ve been taking them 
and I’ve been accustomed to it.” (P21, male, 84 years, PSR AD) 
 “I’ve been taking it for a long time and it’s just natural.” (P27, male, 79 
years, PSR AD) 
 “I just follow them… [medicines] just normal part of my life.” (P30, male, 87 
years, PSR A) 
- Unaccustomed regimen “I’m supposed to take a medicine for my [restless leg], but I keep 
forgetting… So, um, I’ve only been told this few days ago and I haven’t got 
used to it, to taking it.” (P8, male, 71 years, PSR NAD) 
Action control  
- Forgetfulness “I got some magnesium for cramps, but I forget to take them. I’m also 
supposed to be taking vitamin D but I hardly ever do. That’s one of those I 
forget.” (P8, male, 71 years, PSR NAD) 
 “It’s just that a little forgetful. I’ve put it out at the old age… The only worry 
is to remember to take them.” (P14, male, 83 years, PSR NAD) 
 “Well, I think that I’m much more, I don’t know, forgetful then I used to be, 
I can’t think this clearly, yeah, it’s just a fix with, which seems I pick but I 
don’t. Um. Remembering to take it. I think that’s the biggest thing.” (P6, 
female, 74 years, PSR NAD) 
- Stimuli or cues for 
action 
“I have a little pill boxes, it holds all morning, noon and night… I just take 
whatever is required during dinner, or at meal in the night.” (P15, male, 78 
years, PSR AD) 
 “I have a pill box now. So, I don’t need to worry about remembering. That’s 
the main issue.” (P18, male, 71 Years, PSR NAD) 
 “I’ve got a dosette box. It’s got bed time, lunch, and morning” (P25, male, 
72 years, PSR AD)  
- Visual allocation of pills “I’ve got them [medicines] in the kitchen table, so I can’t forget.” (P10, 
female, 53 years, PSR AD) 
 “Some of the capsules that I’m on, are on my shelves, taking them all in the 
morning. On dialysis days, I make sure I leave them and take them when I 
get home, coz otherwise they just washed forever.” (P12, female, 80 years, 
PSR AD) 
- Association with meals “If I don’t have lunch, I don’t remember my medicines, always. Lunch is sort 
of tied to the medicines. So, if I wouldn’t eat, I wouldn’t take the medicines 
so regularly, I think.” (P6, female, 74 years, PSR NAD) 
Facilitation  
- Role of support “I’m retired. I’ve been looked after. Yes, by my daughter. My daughter does 
all those [medications] for my side and I’ve to put them.” (P12, female, 80 
years, PSR AD) 
 “My wife manages everything. She manages everything. She knows. She’s 
always done it. Ever since I started taking tablets, she looks after it. She 
knows what medications, what I’m supposed to do and not supposed to do. 
You know, she put my tablets at every meal and she’s been doing that for 
last 14 years. Ever since I had my kidney out.” (P15, male, 78 years, PSR AD) 
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Themes based on WHO 
taxonomy 
Exemplar quotes 
 “If I forget to take them, my wife lets me know… She handles all.” (P21, 
male, 84 years, PSR AD) 
 “My wife makes sure I take them... she helps. She gets all medicines ready, 
tablets ready… she does all, mostly.” (P27, male, 79 years, PSR AD) 
 “I all live by myself so, just me, I’ve got to worry about my sickness… It’s just 
me, yeah.” (P2, male, 61 years, PSR NAD) 
 “Some medicines make me dizzy. It is a problem. Especially when I get no 
support at home. Coz my husband, he works at night, and I got to be 
careful. Coz I got no support at home.” (P7, female, 65 years, PSR NAD) 
Health system/ HCT-related 
factors 
 
Quality of interaction with HCT  
- One-way 
communication 
“[Asking Dr about the need of so many medicines…] I saw doctor at the 
clinic last time and he said, “No, they are all good”. He went through one 
by one [medicines] and no, that’s good, you need that, you need that, so…” 
(P7, female, 65 years, PSR NAD) 
- Lack of engagement “[Consultations are] never very long usually, you know. Just checks the 
figures, just look at your blood figures and everything’s ok and you know.” 
(P2, male, 61 years, PSR NAD) 
 “Not usually. Unless I’ve a particular problem like my Gout is worse or I’m 
feeling more depressed. Um, otherwise no. it’s [consultation] all very 
routine.” (P4, male, 56 years, PSR NAD) 
- Lack of time “I really need to speak to the pharmacist. Um, but they’re very busy, but I 
will, I must speak to, I want to know what every medicines, especially 12 
medicines in the morning are for.” (P5, female, 58 years, PSR NAD) 
- Support from HCT “You know, just, give all your tablets to the chemist and he’ll sort them out. 
Makes it so much easier. Coz, he puts them in a pack, a plastic bag 
[Webster-Pak], um, and he get it for two weeks and you got a just twist and 
pop a tablets, all those ones you gonna take, so I don’t need to get worry 
about what one of this, one of this, anymore.” (P16, male, 65 years, PSR 
AD) 
 “It’s always great with my GP. I’ve been going to him for 15 years and we’re 
quite informal and he’s very helpful and if I complained about what these 
things, he investigates them properly.” (P11, male, 84 years, PSR AD) 
Mistrust and collateral 
arrangements 
 
- Pressure to hide “I forgot to say to him [doctor] about it [not taking phosphate binders]. 
Because, I think what they will gonna tell me is, I have to take it. I’m 
frightened obvious the doctor’s gonna say, which they probably will, 
because it’s very important, the phosphate, I know that.” (P5, female, 58 
years, PSR NAD) 
 “I did say the kidney doctor months ago, if they [medicines] were helping 
remove the fluid, um, because I still have a lot of fluid, and he said just keep 
taking them, you know, and don’t worry about that, you need to keep 
taking them so, even if it helps a little bit.” (P5, female, 58 years, PSR NAD) 
- Being a good patient “I just take them because, that I’m following the doctor’s instructions, I 
don’t… Well, he has his own agenda and he usually takes control of the 
situation, all them.” (P6, female, 74 years, PSR NAD) 
 “I don’t. I don’t know I take it because I’ve been told to take it, and I do that. 
But I don’t take it very seriously. And if I miss it, I don’t get panic, so.” (P8, 
male, 71 years, PSR NAD) 
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Themes based on WHO 
taxonomy 
Exemplar quotes 
- Personal control of 
treatment 
“I used to be on Lipitor and stuffs like that, now I don’t use them. I don’t 
think I agree with the doctor… I didn’t like those… had made me problems… 
also doctors don’t put me on Magnesium, I just put myself on it.” (P2, male, 
61 years, PSR NAD) 
 “I discuss it with myself. Or, I go to them [doctor] who gets upset because I 
decide to take more than what I’m prescribed. Yeah, like the Sifrol, it wasn’t 
holding, so I lifted the thing [dose] up to two. And I checked it out [in the 
internet] and it was okay to do that and then she [doctor] got most upset 
because she said it effects the kidney, and I said well they’re pretty shot 
already, and she said they can always get worse.” (P8, male, 71 years, PSR 
NAD) 
 “Because the doses are too, too [high]…, they have got to decrease it. Coz, 
I’m taking one tablet, and then they took me off and put it on the other one, 
and the other one they put me on was too high. Makes me dizzy. So I didn’t 
take anymore.”  (P7, female, 65 years, PSR NAD)  
 “I’m supposed to take it [blood pressure medicine] every day but, I’ve been 
taking it every second or third day because of the, coz my blood pressure 
really low. So, so far I’ve been able to control at that way. So I decided to 
stop, if I can do without it, I will… I don’t take it terribly seriously.” (P8, male, 
71 years, PSR NAD) 
- Trust in HCT “I take my medicines. They give me the right thing, so I just take them. 
Except when I’m allergic to.”  (P10, female, 53 years, PSR AD) 
 “I’m consistent about it. Because I’ve got to take them daily or as 
prescribed, so I always do as I’m told.” (P11, male, 84 years, PSR AD) 
 “My doctor is a gentleman and the scholar. He is in charge of it, and he put 
me in these medication, I take.” (P15, male, 78 years, PSR AD) 
 “That’s what doctor prescribes and I take them.” (P20, male, 80 years, PSR 
AD) 
 “I keep taking them until my doctor takes me out of it. I just take the dose 
that’s on the charts I got.” (P25, male, 72 years, PSR AD) 
Therapy-related factors  
Physical characteristics of 
medicines 
 
- Pill size “I’ve got the one [medicine], got to cut it half, I’ve got a cut five or six in half 
so I’ve got half for in the morning and half at night.” (P9, female, 63 years, 
PSR NAD) 
 “I can’t take the big ones. The size of the [phosphate binders], sometimes I 
vomit in backyard. I can’t handle big tablets. Large tablet size, too hard, 
yes, to swallow. Yeah.” (P10, female, 53 years, PSR AD) 
- Palatability “Some of them, as soon as you get them on the tongue, I think that, why 
not take… I swear it, dissolves straight away and it tastes disgusting! First 
thing in the morning they, oh! You know, then try to get the water, buff! 
Just bitter, you know, one of them.” (P5, female, 58 years, PSR NAD) 
 “Apart from anything else, some of them taste absolutely disgusting… 
especially, when the ones like the Allopurinol where you’ve got them to cut 
in half, they taste pretty disgusting.” (P13, female, 63 years, PSR NAD) 
 “There was one tablet that taste like a lolly, and now they don’t. They have 
changed the medicine.” (P22, male, 65 years, PSR NAD) 
Medicine packaging “One I have very hard to get it out. A little capsule, that for pain. Yeah. Very 
hard to put out. The capsules are completely crushed by the time it gets out 
of its thing! That’s the only problem.” (P11, male, 84 years, PSR AD) 
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Themes based on WHO 
taxonomy 
Exemplar quotes 
Side effects of medicines “Sometimes they work, sometimes they really make me sick.  Makes me 
dizzy. Coz it’s a bit stronger. I don’t take them. Well, if they are not too 
strong, I’ll take them. I always take my medicines, but if they will make me 
dizzy, I don’t.” (P7, female, 65 years, PSR NAD) 
 “I know, when I don’t take them, I feel better. That feel so severe, vomiting 
and nausea… so, when I was taking [phosphate binders] it was quite 
severe… so, I thought no to horrible thing!” (P5, female, 58 years, PSR NAD) 
 “I don’t like taking them, the [antibiotics], they give me toilet all the time.” 
(P29, male, 65 years, PSR NAD) 
Social/ economic factors  
Access to medicines  
- Acquiring script “I was hoping if someone can bring those [scripts] here at dialysis unit, so I 
can just pick them up, when I’m on dialysis. It would be lot easier.” (P2, 
male, 61 years, PSR NAD) 
 “The only hassle is, as far as [blood pressure medicine] is concerned, its 
supply is only 25 days, so I have to keep asking for repeat.” (P23, male, 86 
years, PSR NAD) 
 “I’m taking a lot of pain tablets at the moment. Finger’s pain at all time. I 
was taking patches, but you can’t get it more than a month’s supply. So, 
that means going back on doctors, and when I get out of here [dialysis], I 
don’t want have to go waiting, in a waiting room to get to the doctors on 
my days off [from dialysis], so I’m just taking Panadol and Panadol with 
Codeine. But, is not really enough, to be honest.” (P2, male, 61 years, PSR 
NAD) 
- Clinic and pharmacy 
location 
“Because I live out of town, I live an hour out of Hobart, and about 40 
minutes from the chemist, just kind of be aware how many more medicines 
I’ve got, it’s nothing worse than running out and having to drive especially 
for that, yeah.” (P3, male, 44 years, PSR NAD) 
 “Some of the scripts you can’t get from pharmacy [local pharmacy]. So, I’ve 
had issues actually getting them in the past… When my doctor goes on 
holidays, I can’t acquire a script without doing it a 100 km drive. They 
[dialysis staffs] refused to help me, and the public doctors refused to give 
me scripts over the phone. I can’t acquire a script over the phone. So I got 
a drive, do a 100 km drive just to get a script from the public doctors.” (P1, 
male, 53 years, PSR NAD) 
Relative affordability “Well, they’re quite expensive! So they do affect me, the cost. I don’t have 
a health care card. I’ve to pay the full subsidised price… I’ve retired and so 
I’m living of an allocated pension from my superannuation.” (P4, male, 56 
years, PSR NAD) 
 “The only thing that worries me is, coz I’m in a wheel chair and I need to 
get to the hospital to get the scripts, it means for $ 30 to get in the taxi to 
go in there and pick up the script or I drive my mobility scooter all the way 
in there, which means two hours and an hour of each waiting to pick them 
up.” (P2, male, 61 years, PSR NAD) 
 “It’s mainly because it costs me a lot of money every month… it is very 
expensive… I think I take 12 [medications]. It’s mainly the expense of the 
medications. I added it up the other day, for one month... Sixty-a-dollars, 
sometimes it varies.” (P5, female, 58 years, PSR NAD) 
Condition-related factors  
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Themes based on WHO 
taxonomy 
Exemplar quotes 
Symptom severity “Have you seen me 12 months ago, I am on a 100 % better [condition] after 
this year but last year and a year before, no, I didn’t really think I’m gonna 
make it. Not even everybody else also gonna make it either.” (P12, female, 
80 years, PSR AD) 
 “I don’t notice any [improvement] from my medications, whatsoever.” (P1, 
male, 53 years, PSR NAD) 
Abbreviations: AD, Adherent; NAD, nonadherent; HCT, healthcare team; PSR, patient self-reports 
µ Patient-related factors further classified based on adherence support taxonomy by de Bruin et al., 
2010.  
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Appendix 10. STROBE Checklist: Pharmacist Survey 
 
 Item 
No 
Recommendation Reported in section 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in 
the title or the abstract 
Title, Abstract and 
Methods 
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found 
Abstract 
Introduction  
Background/ 
rationale 
2 Explain the scientific background and rationale for the 
investigation being reported 
Introduction 
Objectives 3 State specific objectives, including any pre-specified 
hypotheses 
Introduction 
Methods  
Study design 4 Present key elements of study design early in the paper Methods, Study 
design 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data 
collection 
Setting and 
recruitment of 
participants 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources 
and methods of selection of participants. Describe methods of 
follow-up 
Case-control study—Give the eligibility criteria, and the sources 
and methods of case ascertainment and control selection. Give 
the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the 
sources and methods of selection of participants 
Setting and 
recruitment of 
participants 
(b) Cohort study—For matched studies, give matching criteria 
and number of exposed and unexposed 
Case-control study—For matched studies, give matching 
criteria and the number of controls per case 
 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
Methods, Data 
collection 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details 
of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one 
group 
Data collection 
Bias 9 Describe any efforts to address potential sources of bias  
Study size 10 Explain how the study size was arrived at Setting and 
recruitment of 
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 Item 
No 
Recommendation Reported in section 
participants; Data 
collection 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were chosen 
and why 
Statistical analysis 
Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
Statistical analysis 
(b) Describe any methods used to examine subgroups and 
interactions 
 
(c) Explain how missing data were addressed  
(d) Cohort study—If applicable, explain how loss to follow-up 
was addressed 
Case-control study—If applicable, explain how matching of 
cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical 
methods taking account of sampling strategy 
 
(e) Describe any sensitivity analyses  
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and 
analysed 
Results 
(b) Give reasons for non-participation at each stage  
(c) Consider use of a flow diagram  
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders 
Results; Table 1 
(b) Indicate number of participants with missing data for each 
variable of interest 
Table 2; Fig 1; Fig 2 
(c) Cohort study—Summarise follow-up time (eg, average and 
total amount) 
 
Outcome data 15* Cohort study—Report numbers of outcome events or summary 
measures over time 
 
Case-control study—Report numbers in each exposure 
category, or summary measures of exposure 
 
Cross-sectional study—Report numbers of outcome events or 
summary measures 
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 Item 
No 
Recommendation Reported in section 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and 
why they were included 
 
(b) Report category boundaries when continuous variables 
were categorised 
 
(c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period 
 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
 
Discussion  
Key results 18 Summarise key results with reference to study objectives Discussion 
Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias 
Study limitations 
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study 
results 
Discussion 
Other information  
Funding 22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on which 
the present article is based 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and 
unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in conjunction 
with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of 
Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the 
STROBE Initiative is available at www.strobe-statement.org. 
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Appendix 11. Survey Questionnaire: Renal Professionals 
 
Instructions 
1. This survey contains seven sections and will take about 10-15 minutes to complete. If 
you do not wish to answer a question or if it does not apply to you, please leave your 
answer blank.  
2. “Adherence” in this survey is defined as the extent to which patients take medications 
as prescribed by their healthcare providers. Similarly, “nonadherence” refers to number 
of doses not taken or taken incorrectly that can adversely affect the patient’s therapeutic 
outcomes.  
3. Please complete this paper-based survey and return it in the reply-paid envelope 
provided. 
 
Section 1. Demographic information 
 
1. Profession: [   ] Doctor [   ] Nurse [   ] Pharmacist 
[   ] Other (please specify): _____________ 
 
2. Designation:  [   ] Nurse Unit Manager  [   ] Registered Nurse   
[   ] Enrolled Nurse  [   ] Pharmacist (not specific) 
[   ] Renal Pharmacist  [   ] Intern  
[   ] Registrar   [   ] Consultant 
[   ] Resident    [   ] Other (please specify): ___________ 
 
3. Age: ______     4. Gender: _______  5. Highest degree achieved: __________ 
 
6. Years of post-registration: ________  7. Years of experience (renal unit): ____ 
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8. State:  [   ] TAS  [   ] NSW   [   ] VIC  [   ] NT  [   ] ACT 
  [   ] WA  [   ] QLD  [   ] SA 
 
 
9. Dialysis unit location:  [   ] Metropolitan 
[   ] Rural 
 
10. Organisation type:  [   ] Public   [   ] Private 
 
 
11. Size of dialysis unit: 
Number of dialysis chairs/ beds/ stations: ________ 
Number of Full time equivalent (FTE) of Dialysis Nurse: ________  
 
 
12. Presence of Nursing educator:  [   ] Yes   
[   ] No 
If yes,  
% of FTE of service (0.1 – 1.0 FTE): ______ 
 
 
13. Presence of pharmacist in renal unit:  [   ] Yes   
[   ] No 
If yes,  
% of FTE of service (0.1 – 1.0 FTE): ______ 
 
 
14. Types of modalities delivered (select all that apply): 
[   ] In-centre daytime haemodialysis  [   ] In-centre nocturnal haemodialysis 
[   ] Home haemodialysis   [   ] Peritoneal dialysis  
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Section 2. Perceived prevalence of medication nonadherence 
 
Please circle the number that best represents your perception about prevalence of medication 
nonadherence, where 1 means you strongly disagree, and 10 means you strongly agree with 
the following statements: 
 
Based on my observations in practice, I 
believe that patients in my unit:                                                                     
Strongly                                           Strongly  
Disagree              Agree 
1. Have limited understanding of their 
medications. 
1----2----3----4----5----6----7----8----9----10 
2. Rarely ask questions about their 
medications. 
1----2----3----4----5----6----7----8----9----10 
3. Do not take their medications as 
prescribed. 
1----2----3----4----5----6----7----8----9----10 
4. Stop taking some medications when 
they feel better (for e.g. blood 
pressure, phosphate binders). 
1----2----3----4----5----6----7----8----9----10 
5. Are often confused about their 
medicines. 
1----2----3----4----5----6----7----8----9----10 
6. Change their dose/dosing interval 
that suits their lifestyles. 
1----2----3----4----5----6----7----8----9----10 
7. Express difficulty in swallowing 
larger pills. 
1----2----3----4----5----6----7----8----9----10 
8. Do not believe their current 
medicines are helping them. 
1----2----3----4----5----6----7----8----9----10 
9. Can’t answer questions about their 
current medications. 
1----2----3----4----5----6----7----8----9----10 
10. Forget to take their medications 
sometimes.  
1----2----3----4----5----6----7----8----9----10 
 
Please use the following space to provide any other comments, suggestions or opinions about 
the prevalence of medication nonadherence in your centre: 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
………………………………………………………………………………………………….. 
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Section 3. Perceived contributors of medication nonadherence 
 
Please circle the number that best represents your perception about contributors of medication 
nonadherence, where 1 means you strongly disagree, and 10 means you strongly agree with 
the following statements: 
Based on my understanding in practice, I 
believe the following contribute to 
nonadherence: 
Strongly                                           Strongly  
Disagree                                           Agree 
1. Older patients are more nonadherent 
than younger patients. 
1----2----3----4----5----6----7----8----9----10 
2. Male patients are more nonadherent 
than female. 
1----2----3----4----5----6----7----8----9----10 
3. Patients with multiple co-morbidities 
(blood pressure, heart disease, 
diabetes etc.). 
1----2----3----4----5----6----7----8----9----10 
4. Patients lacking family/ social 
support. 
1----2----3----4----5----6----7----8----9----10 
5. Patients having low income. 
 
1----2----3----4----5----6----7----8----9----10 
6. Patients having low level education 
background (≤ high school). 
1----2----3----4----5----6----7----8----9----10 
7. Patients having different 
language/cultural background (non-
English speakers or migrants). 
1----2----3----4----5----6----7----8----9----10 
8. Patient who have limited 
understanding of their disease state. 
1----2----3----4----5----6----7----8----9----10 
9. Patients who are not satisfied with 
their treatment or care they are 
receiving. 
1----2----3----4----5----6----7----8----9----10 
10. Patients with complex medication 
regimens (injections, too many pills 
etc.). 
1----2----3----4----5----6----7----8----9----10 
 
Please use the following space to provide any other comments, suggestions or opinions about 
the factors contributing medication nonadherence: 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
………………………………………………………………………………………………….. 
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Section 4. Perceived effectiveness of methods that identify medication nonadherence 
 
Please circle the number that best represents your perception about effective methods of 
identifying nonadherence, where 1 means least effective, and 10 means most effective method 
of identifying nonadherence: 
 
Based on my understanding in practice, I 
believe the following are effective in 
identifying nonadherence: 
Least                                                Most 
Effective                                          Effective 
1. Interviewing patients to obtain 
medication history. 
1----2----3----4----5----6----7----8----9----10 
2. Asking a patient’s family/ carer/ 
spouse about their medication. 
1----2----3----4----5----6----7----8----9----10 
3. Objective measures such as serum 
phosphate levels or blood pressure to 
see if they are taking medicines.  
1----2----3----4----5----6----7----8----9----10 
4. Asking patients to bring their 
medications and count them. 
1----2----3----4----5----6----7----8----9----10 
5. Having a dedicated healthcare 
professional (Nurse/ Doctor/ 
Pharmacist) to take medication 
history. 
1----2----3----4----5----6----7----8----9----10 
6. Including a pharmacist in 
medication reviews and 
reconciliation. 
1----2----3----4----5----6----7----8----9----10 
 
Please use the following space to provide any other comments, suggestions or opinions about 
the effective methods to identify medication nonadherence: 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
………………………………………………………………………………………………….. 
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Section 5. Barriers to assessing medication nonadherence 
 
Please circle the number that best represents your opinion about barriers to assessing 
nonadherence, where 1 means you strongly disagree, and 10 means you strongly agree with 
the following statements: 
 
Barriers Strongly                                           Strongly  
Disagree                                           Agree 
1. I don’t have knowledge and skills to 
assess nonadherence in my patients. 
 
1----2----3----4----5----6----7----8----9----10 
2. I don’t have time to undertake 
activities that improves adherence.  
 
1----2----3----4----5----6----7----8----9----10 
3. I don’t think it is my role.  
 
1----2----3----4----5----6----7----8----9----10 
4. I think patients are not interested in 
discussing medication related issues 
with me.   
1----2----3----4----5----6----7----8----9----10 
5. There is no support from hospital 
administration on conducting such 
activity.  
1----2----3----4----5----6----7----8----9----10 
6. I have never given a thought about 
adherence before this survey.  
1----2----3----4----5----6----7----8----9----10 
 
Please use the following space to provide any other comments, suggestions or opinions about 
the barriers to counselling on medication adherence: 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
………………………………………………………………………………………………….. 
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Section 6. Participants’ confidence in identifying medication nonadherence 
 
Please circle the number that best reflect your confidence in identifying medication 
nonadherence, where 1 means you are not at all confident, and 10 means you are highly 
confident in identifying nonadherence: 
 
How confident do you feel in the following 
situations? 
Not at all                                             Highly 
Confident                                       Confident 
1. Ability to conduct a medication 
history interview. 
1----2----3----4----5----6----7----8----9----10 
2. Ability to provide medication 
counselling. 
1----2----3----4----5----6----7----8----9----10 
3. Ability to clarify any questions 
about medications that patients have. 
1----2----3----4----5----6----7----8----9----10 
4. Ability to suggest strategies to 
improve adherence.  
1----2----3----4----5----6----7----8----9----10 
5. Ability to assess patient’s 
knowledge and beliefs about their 
medications.  
1----2----3----4----5----6----7----8----9----10 
 
 
 
Section 7. Current practices of assessing medication nonadherence 
 
In the following page, we would like to know the current practices of assessing medication 
nonadherence in your dialysis unit.  
Please note the scale has been changed and we want a graded response that range from not 
applicable (do not practice at all) to practice for every patient.  
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Please tick the box (√) that best represent the current practices in your dialysis unit.  
Current practices Not 
applicable 
(Do not 
practice 
at all) 
For some 
patients 
(With higher 
risk of 
adverse 
effects) 
For most 
patients 
(Routine 
practice except 
for lower risk 
patients) 
Practice 
for 
every 
patients 
1. Interviewing patients to 
obtain medication history. 
    
2. Asking a patient’s family/ 
carer/ spouse about their 
medication. 
    
3. Objective measures such 
as serum phosphate levels 
or blood pressure to see if 
they are taking medicines. 
    
4. Asking patients to bring 
their medications and 
count them. 
    
5. Having a dedicated 
healthcare professional 
(Nurse/ Doctor/ 
Pharmacist) to take 
medication history. 
    
6. Including a pharmacist in 
medication reviews and 
reconciliation. 
    
 
Thank you for your participation, the survey is now complete. Please use the following space 
to provide any other comments, suggestions or opinions about the current practices in your 
centre: 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
………………………………………………………………………………………………….. 
 
---Thank you for taking the time to complete this survey---
233 
 
Appendix 12. Inter-item correlation matrix and Cronbach’s alpha coefficients for 
psychometric scales: Pharmacist Survey 
 
Prevalence scale 1 2 3 4 5 6 7 8 9 10 
1. Have limited understanding 
of medications  
0.90          
2. Rarely ask questions about 
medications  
0.77** 0.91         
3. Do not take their 
medications as prescribed  
0.54** 0.57** 0.89        
4. Stop taking some 
medications when feel better  
0.25 0.29 0.79** 0.90       
5. Are often confused about 
medicines  
0.57** 0.49** 0.64** 0.58** 0.90      
6. Change dose/dosing 
interval that suits lifestyles  
0.47** 0.38** 0.57** 0.41** 0.65** 0.90     
7. Express difficulty in 
swallowing larger pills  
0.46** 0.29 0.53** 0.54** 0.64** 0.55** 0.91    
8. Do not believe current 
medicines are helping them  
0.51** 0.52** 0.69** 0.60** 0.53** 0.47** 0.56** 0.90   
9. Can’t answer questions 
about current medications  
0.65** 0.51** 0.68** 0.53** 0.54** 0.49** 0.35* 0.66** 0.90  
10. Forget to take 
medications sometimes  
0.20 0.03 0.55** 0.55** 0.60** 0.53** 0.38* 0.43** 0.46** 0.91 
Note: Bold values indicates Cronbach’s alpha coefficients if item deleted. 
**. Correlation is significant at p < 0.01 level (2-tailed). 
*. Correlation is significant at p < 0.05 level (2-tailed). 
 
 
Contributors scale 1 2 3 4 5 6 7 8 9 10 
1. Older patients are more 
nonadherent  
0.77          
2. Male patients are more 
nonadherent  
0.54** 0.75         
3. Patients with multiple co-
morbidities  
0.23 0.31 0.71        
4. Patients lacking 
family/social support  
-0.02 -0.03 0.48** 0.68       
5. Patients having low income 
 
0.23 0.21 0.37* 0.53** 0.71      
6. Patients having low level 
education background  
-0.01 0.16 0.34 0.42* 0.40* 0.68     
7. Having different 
language/cultural background  
-0.19 0.02 -0.07 0.18 -0.19 0.39* 0.74    
8. Having limited 
understanding of disease 
state  
-0.16 -0.13 0.23 0.64** 0.22 0.43* 0.45** 0.70   
9. Patients not satisfied with 
their treatment/care  
-0.28 -0.10 0.13 0.42* 0.03 0.34 0.32 0.57** 0.72  
10. Patients with complex 
medication regimens  
-0.27 -0.11 0.22 0.75** 0.43* 0.47** 0.31 0.65** 0.67** 0.68 
Note: Bold values indicates Cronbach’s alpha coefficients if item deleted. 
**. Correlation is significant at p < 0.01 level (2-tailed). 
*. Correlation is significant at p < 0.05 level (2-tailed). 
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Effectiveness scale 1 2 3 4 5 6     
1. Interviewing patients to obtain 
medication history  
0.48          
2. Asking patient’s family/carer about 
medication  
0.49** 0.39         
3. Measuring objective indicators such as 
SPL/BP  
-0.13 0.16 0.64        
4. Asking patients to bring medications 
and count  
-0.07 0.22 -0.03 0.67       
5. Having a dedicated healthcare 
professional (Nurse/ Doctor/Pharmacist) 
to take medication history  
0.57** 0.42* -0.12 0.30 0.41      
6. Medication reviews and reconciliation 
by pharmacist  
0.60** 0.41* 0.06 -0.16 0.48** 0.50     
Note: Bold values indicates Cronbach’s alpha coefficients if item deleted. 
**. Correlation is significant at p < 0.01 level (2-tailed). 
*. Correlation is significant at p < 0.05 level (2-tailed). 
 
 
Barriers scale 1 2 3 4 5 6     
1. Lack of knowledge and 
skills to assess nonadherence  
0.41          
2. Lack of time  -0.04 0.60         
3. Not my role  0.50** -0.06 0.45        
4. Patient not interested in 
discussing medication issues  
0.46** 0.24 0.54** 0.35       
5. No support from hospital 
administration  
0.28 0.02 0.21 0.07 0.53      
6. Never thought about 
adherence before this survey  
0.58** 0.13 0.50** 0.51** 0.31 0.41     
Note: Bold values indicates Cronbach’s alpha coefficients if item deleted. 
**. Correlation is significant at p < 0.01 level (2-tailed). 
*. Correlation is significant at p < 0.05 level (2-tailed). 
 
 
Confidence scale 1 2 3 4 5      
1. Ability to conduct a 
medication history interview  
0.91          
2 .Ability to provide 
medication counselling  
0.96** 0.91         
3. Ability to clarify patient’s 
medication queries 
0.90** 0.93** 0.90        
4. Ability to suggest strategies 
to improve adherence 
0.64** 0.67** 0.75** 0.91       
5. Ability to assess patient’s 
knowledge and beliefs about 
medications  
0.58** 0.56** 0.65** 0.88** 0.92      
Note: Bold values indicates Cronbach’s alpha coefficients if item deleted. 
**. Correlation is significant at p < 0.01 level (2-tailed). 
*. Correlation is significant at p < 0.05 level (2-tailed). 
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Appendix 13. Comments on perceptions and current practices: Pharmacist Survey 
Themes Exemplar quotes 
Adjusting to lifestyles 
- Adjusting to 
lifestyles 
Pts are generally good at taking their medications, however will adjust to their 
lifestyle.  For example, phosphate binders 3 times daily with meals.  Some 
patients eat one meal a day so won’t take tablets if not eating. P3 
- Priority of life 
events 
Is very individual. Even within the same patient, sometimes if things in their life 
are generally going well then they will cope better with a complex meds regime 
then if things are not going so well their motivation and therefore adherence 
drops off. P40 
Knowledge and understanding about medicines 
- Limited 
understanding 
of medicines 
Working with a large population of indigenous patients in remote areas.  Most 
have limited understanding of their medications to limit to "helping kidneys" for 
their heart or blood sugars. P3 
 It's hard to give a definite figure here. Some patients are fantastic with their 
medications, but there are plenty who have very little understanding of what the 
agents are for. P8 
 Many patients do not understand what the phosphate binders are for. Education 
is a big focus in our unit. P14 
- Lack of 
tolerability or 
perceived 
benefit 
Phosphate binders are probably the most prevalent medicines to be not taken 
correctly - due to lack of tolerability/perceived benefit and understanding. More 
education time with patients may be a beneficial means to improved compliance 
and address problems. P4 
 Not a strong prevalence but more on ignorance and selective non-compliance, 
i.e. certain medications are purposely missed if they are perceived as not 
affecting final outcome. Often they have some understanding then choose what 
they like. P19 
Relative affordability 
 In a low socio-economic town, pts on 20+ dose a day can find difficult affording 
their medications in the first 5-7 months in the year. P34 
Culture and communication barriers 
 Very high level of noncompliance in the Northern Territory. Our patients are 
largely Indigenous. Language and Cultural barriers in addition to other factors. 
P11 
 Pts rarely ask questions about their tablets due to language barriers or not 
knowing staff. P3 
 I probably find in our centre that it is more prevalent in the aboriginal 
population, including those who have had to move from remote areas to the city 
for haemodialysis and have to wait years for a dialysis bed near their regional 
areas. P39 
 NESB and migrants may have poorer comprehension, but are not necessarily 
more non-compliant by intention. P4 
Forgetfulness, role of dose administration aid and support 
- Decreased 
cognitive 
function 
I think that dialysis affects cognitive function and the patients really can't think 
properly whilst having treatment. P16 
- Role of 
reminders 
All renal patients in the top end receive medications packed into Webster packs 
so confusion around what to take and when not such a big issue. P3 
- Role of 
support 
Family/social support big part of engaging patients in treatment up here.  Most 
dialysis patients separated from their communities forced to live in a strange 
environment.  Often don't cope and don't engage in treatment as a 
consequence. P3 
Role of comorbid illness 
- Tablet burden Pts have a huge tablet burden which is one of the main reasons for confusion, 
non-compliance.  I have found that by reducing the number of tablets 
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particularly phosphate binders when pts have been prescribed >1 has make a 
huge difference in their compliance. P17 
Need for designated renal pharmacists 
- Lack of 
designated 
renal 
pharmacists 
I think our lack of a designated renal pharmacist heavily contributes to the 
problem. Lack of medication review and thorough medication counselling. P9 
 We do not have a pharmacist in the dialysis unit but we have a pharmacist in 
outpatients that does some of these things for patients including home dialysis 
pts. P41 
 The renal pharmacist at our hospital (1 FTE) looks after the renal ward and 
inpatient and outpatient dialysis units. Medication review is not performed on all 
dialysis patients. Only when asked to review them or when we notice there is 
something that needs following up. This is based in an outpatient unit. As an 
inpatient, all responses are for every patient. P39 
 As mentioned previously I only see hospital inpatients. Cannot comment on 
practice in the actual dialysis unit which is community run. They have no 
pharmacy service on site. P33 
 The pharmacy has insufficient clinical staff. P24 
 No formal pharmacy service funded to our dialysis unit. P20 
 There is no funding for a designated renal pharmacist. P8 
 Currently we only have a pharmacist who sees patients when they get admitted 
to the acute hospital setting so all the patients outside of this do not get seen - 
plans are afoot to remedy this situation. P40 
 These factors could be addressed in dedicated medication management reviews. 
P9 
Perceived barriers 
- Lack of time Time and access (multi-site, patients change dialysis times and 'forgetting' to 
bring medicines to appointments) are the major barriers. P4 
- Staff shortage I do see that there is generally decent transfer of information, and when patients 
are admitted directly from dialysis to the hospital their medications are usually 
reasonably accurate. We have just started an initiative where upon discharge the 
ward pharmacist will send an updated medication list to the dialysis unit, but 
sadly this is only one way with present staffing levels. P8 
Multidisciplinary role 
 Adherence issues should be everyone's role; pts, carer, doctor, nurse and 
pharmacist. Very hard if message just from one person. P11 
Ongoing education 
 Looking at strategies to improve adherence and nursing students conducting 
PHD on phosphate binder adherence. P10 
Current practices 
 When performing a medication history, I always get the pts to bring in their 
medicines to ensure we have the correct information. I don't however count 
them. P17 
Note: P = Pharmacist participant (with a number to indicate the participant ID for example, P5 is the fifth 
respondent). 
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Appendix 14. STROBE Checklist: Nurses Survey 
 
 Item 
No 
Recommendation Reported in section 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in 
the title or the abstract 
Title, Abstract and 
Methods 
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found 
Abstract 
Introduction  
Background/ 
rationale 
2 Explain the scientific background and rationale for the 
investigation being reported 
Introduction 
Objectives 3 State specific objectives, including any pre-specified 
hypotheses 
Introduction 
Methods  
Study design 4 Present key elements of study design early in the paper Methods, Study 
design 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data 
collection 
Setting and 
recruitment of 
participants 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources 
and methods of selection of participants. Describe methods of 
follow-up 
Case-control study—Give the eligibility criteria, and the sources 
and methods of case ascertainment and control selection. Give 
the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the 
sources and methods of selection of participants 
Setting and 
recruitment of 
participants 
(b) Cohort study—For matched studies, give matching criteria 
and number of exposed and unexposed 
Case-control study—For matched studies, give matching 
criteria and the number of controls per case 
 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
Methods, Data 
collection 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details 
of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one 
group 
Data collection 
Bias 9 Describe any efforts to address potential sources of bias  
Study size 10 Explain how the study size was arrived at Setting and 
recruitment of 
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 Item 
No 
Recommendation Reported in section 
participants; Data 
collection 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were chosen 
and why 
Statistical analysis 
Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
Statistical analysis 
(b) Describe any methods used to examine subgroups and 
interactions 
 
(c) Explain how missing data were addressed  
(d) Cohort study—If applicable, explain how loss to follow-up 
was addressed 
Case-control study—If applicable, explain how matching of 
cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical 
methods taking account of sampling strategy 
 
(e) Describe any sensitivity analyses  
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and 
analysed 
Results 
(b) Give reasons for non-participation at each stage  
(c) Consider use of a flow diagram  
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders 
Results; Table 1 
(b) Indicate number of participants with missing data for each 
variable of interest 
Table 2; Fig 1; Fig 2 
(c) Cohort study—Summarise follow-up time (eg, average and 
total amount) 
 
Outcome data 15* Cohort study—Report numbers of outcome events or summary 
measures over time 
 
Case-control study—Report numbers in each exposure 
category, or summary measures of exposure 
 
Cross-sectional study—Report numbers of outcome events or 
summary measures 
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 Item 
No 
Recommendation Reported in section 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and 
why they were included 
 
(b) Report category boundaries when continuous variables 
were categorised 
 
(c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period 
 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
 
Discussion  
Key results 18 Summarise key results with reference to study objectives Discussion 
Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias 
Study limitations 
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study 
results 
Discussion 
Other information  
Funding 22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on which 
the present article is based 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and 
unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in conjunction 
with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of 
Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the 
STROBE Initiative is available at www.strobe-statement.org. 
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Appendix 15. Inter-item correlation matrix and Cronbach’s alpha coefficients for 
psychometric scales: Nurses Survey 
 
Prevalence scale 1 2 3 4 5 6 7 8 9 10 
1. Have limited understanding 
of medications  
0.85          
2. Rarely ask questions about 
medications  
0.59** 0.85         
3. Do not take their 
medications as prescribed  
0.46** 0.32** 0.83        
4. Stop taking some 
medications when feel better  
0.24* 0.17 0.52** 0.83       
5. Are often confused about 
medicines  
0.49** 0.50** 0.60** 0.53** 0.82      
6. Change dose/dosing 
interval that suits lifestyles  
0.12 0.22* 0.48** 0.37** 0.32** 0.85     
7. Express difficulty in 
swallowing larger pills  
-0.06 -0.01 0.35** 0.43** 0.35** 0.29** 0.86    
8. Do not believe current 
medicines are helping them  
0.16 0.16 0.30** 0.53** 0.40** 0.28** 0.51** 0.84   
9. Can’t answer questions 
about current medications  
0.57** 0.46** 0.36** 0.43** 0.71** 0.10 0.21** 0.38** 0.83  
10. Forget to take 
medications sometimes  
0.34** 0.26** 0.56** 0.59** 0.58** 0.45** 0.35** 0.43** 0.52** 0.83 
Note: Bold values indicates Cronbach’s alpha coefficients if item deleted. 
**. Correlation is significant at p < 0.01 level (2-tailed). 
*. Correlation is significant at p < 0.05 level (2-tailed). 
 
 
Contributors scale 1 2 3 4 5 6 7 8 9 10 
1. Older patients are more 
nonadherent  
0.84          
2. Male patients are more 
nonadherent  
0.45** 0.83         
3. Patients with multiple co-
morbidities  
0.23* 0.19** 0.83        
4. Patients lacking 
family/social support  
0.19* 0.30** 0.30** 0.80       
5. Patients having low income 
 
0.21* 0.23* 0.33** 0.67** 0.81      
6. Patients having low level 
education background  
0.18 0.33** 0.29** 0.66** 0.67** 0.80     
7. Having different 
language/cultural background  
0.06 0.05 0.36** 0.44** 0.38** 0.47** 0.83    
8. Having limited 
understanding of disease 
state  
0.08 0.25** 0.21* 0.64** 0.47** 0.63** 0.38** 0.81   
9. Patients not satisfied with 
their treatment/care  
0.09 0.22* 0.04 0.29** 0.15 0.22* 0.16 0.39** 0.84  
10. Patients with complex 
medication regimens  
0.13 0.28** 0.39** 0.55** 0.50** 0.49** 0.32** 0.69** 0.45** 0.80 
Note: Bold values indicates Cronbach’s alpha coefficients if item deleted. 
**. Correlation is significant at p < 0.01 level (2-tailed). 
*. Correlation is significant at p < 0.05 level (2-tailed). 
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Effectiveness scale 1 2 3 4 5 6     
1. Interviewing patients to obtain 
medication history  
0.66          
2. Asking patient’s family/carer about 
medication  
0.41** 0.58         
3. Measuring objective indicators such as 
SPL/BP  
0.17 0.31** 0.65        
4. Asking patients to bring medications 
and count  
0.07 0.40** 0.29** 0.65       
5. Having a dedicated healthcare 
professional (Nurse/ Doctor/Pharmacist) 
to take medication history  
0.23* 0.39** 0.18 0.29** 0.58      
6. Medication reviews and reconciliation 
by pharmacist  
0.16 0.17 0.09 0.16 0.59** 0.64     
Note: Bold values indicates Cronbach’s alpha coefficients if item deleted. 
**. Correlation is significant at p < 0.01 level (2-tailed). 
*. Correlation is significant at p < 0.05 level (2-tailed). 
 
 
Barriers scale 1 2 3 4 5 6     
1. Lack of knowledge and 
skills to assess nonadherence  
0.64          
2. Lack of time  0.47** 0.61         
3. Not my role  0.37** 0.27** 0.69        
4. Patient not interested in 
discussing medication issues  
0.22* 0.29** 0.26** 0.67       
5. No support from hospital 
administration  
0.43** 0.49** 0.19 0.35** 0.65      
6. Never thought about 
adherence before this survey  
0.25** 0.29** 0.19 0.22* 0.05 0.71     
Note: Bold values indicates Cronbach’s alpha coefficients if item deleted. 
**. Correlation is significant at p < 0.01 level (2-tailed). 
*. Correlation is significant at p < 0.05 level (2-tailed). 
 
 
Confidence scale 1 2 3 4 5      
1. Ability to conduct a 
medication history interview  
0.88          
2 .Ability to provide 
medication counselling  
0.74** 0.87         
3. Ability to clarify patient’s 
medication queries 
0.62** 0.77** 0.88        
4. Ability to suggest strategies 
to improve adherence 
0.63** 0.61** 0.60** 0.89       
5. Ability to assess patient’s 
knowledge and beliefs about 
medications  
0.63** 0.57** 0.62** 0.72** 0.89      
Note: Bold values indicates Cronbach’s alpha coefficients if item deleted. 
**. Correlation is significant at p < 0.01 level (2-tailed). 
*. Correlation is significant at p < 0.05 level (2-tailed). 
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Appendix 16. Comments on perceptions and current practices: Nurses Survey 
Themes Exemplar quotes 
Lack of sustainable strategy for empowering self-management 
- Medication 
self-
management 
Nonadherence also includes poor management of having their medications 
available to them at all times, places etc. It is not the patients' intention to be 
nonadherent. Sometimes it's just difficult to take all medications at all times. In 
fewer cases, patients intentionally do not take their medication for reasons such 
as; they think they do not need it, it's not doing anything, they don't know what 
it's for, or due to the side effects. It's the nurses who may be able to change 
these latter habits. N104 
 Lack of acknowledgment of pts need to have individual self-management 
strategies and various different approaches to empowering self-management. 
N94 
 Lack of chronic conditions self-management strategies and lack of ability to 
empower self-management that is truly patient centred (staff). N94 
- Adjusting to 
lifestyles 
Mostly younger pts adjust their medications to what suits them or how they feel. 
N55 
 Not taking meds as prescribed is limited i.e. long term younger patients are more 
likely to adjust tablets i.e.  Antihypertensive. N29 
- Priority of life 
events 
Stressful home situations mean that their own life is put on hold as they are 
more worried about others and medications isn't a priority. N14 
- Disinterest  Have found that the patients who are most non-adherent, are the ones not 
interested in learning about them. N93 
 They do receive enough education and support from our health system. 
However, they do not follow instructions or/and are compliable with 
medications and haemodialysis. N108 
- Respect to 
choice 
Some of our home patients make well informed decisions about their 
medications that we don't necessarily agree with! Sometimes we have to agree 
amongst ourselves with the medical staff as well, to respect their choices. N18 
Knowledge and understanding about medicines 
- Limited 
understanding 
of medicines 
Some patients do not take phosphate binders correctly - e.g. they don't take 
with food. The way these are prescribed sometimes says TDS rather than take 
with food. N19 
 Some patient even don't know what medication they are supposed to take. N27 
 Often patients need to know that binders need some flexibility according to 
when they eat. N36 
 Our 2 older patients have very little understanding/ interest/ control in their 
medications. They leave it all to their wives. N41 
- Good 
understanding 
of medicines 
If patients have a good understanding about why they need to take their 
prescribed medications and the consequences of not doing so, adherence 
probably increases. Blood results help as then they can see what happens if they 
don't take their medications and it reinforces the reasons for taking them. N45 
 This clinic has all Patients who are interested in their health and well-being. Their 
understanding to their medication is good. N6 
 Pts in our dialysis unit are very informed regarding their medications…. Potential 
for future transplant used as a motivator. N114 
- Lack of 
tolerability or 
perceived 
benefit 
Difficult for patients to comprehend well enough that the long term outcomes 
are worse than taking a large tablet load now i.e. PO4 binders. N68 
 Phosphate binders to be had with meals is often omitted by the patients. N60 
 My patients are very empowered about their meds especially binders. N56 
 Phosphate binders have the poorest compliance. 
 Main problems are with Phosphate binders: Forget, avoid and wrong timing is 
frequent despite continuing education by dialysis nurses. N37 
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 A lot of patients find it difficult to adhere to their phosphate binder regimens. 
Those with Webster packs are generally compliant, but definitely less 
knowledgeable about their meds. Non-adherence tends to be higher with 
phosphate binders. N92 
 Generally medications taken as prescribed agent for e.g. phosphate binders and 
other meds due at 'odd' times during the day. N106 
Clinic locations 
- Long waiting 
times for 
consultation 
As we are a satellite dialysis unit, we do not have a renal doctor on site to 
answer pts medication questions as they arise. they wait a long time between 
renal clinic appointments and often forget their questions about medications 
before they attend. N64 
Lack of discharge counselling 
 When patient discharge no clearly explain or remind them any change or what 
medication they should continuous. 
 Lack of health literacy (patients). N94 
Professional competence and trust 
- Perceived 
competence 
Many patients will only listen to information about medication compliance from 
their renal doctor or GP. They do not accept the information from a nurse with 
the same degree of weight or respect. N64 
- Professional 
trust 
Staff attitude is very dictatorial and non-adherence is viewed as 'deviant" thus 
pts often provide the answers they think the staff wants to hear and the true 
discussion of why non-adherence occurs hardly ever occurs as pts fear being 
labelled as 'deviant'. N94 
 Pts will frequently tell you they are taking their medicines when in fact they are 
not. N63 
 At times feel the patients just say they forgot or yes I’m taking them, only to see 
their blood results tells us they are not. N71 
Relative affordability 
 The cost of medications is an issue for some, their medicines run out and they 
don't have any money to buy them. N65 
 Pts with low income tend to use old medications before swapping to new 
prescription due to cost. N103 
 People let their scripts run out, don't see a GP to renew them and often tell the 
dialysis nurse when they have already run out. This is often the case for 
indigenous patients. N57 
 Blister packs are helpful, but many can't/won't pay the extra needed to have 
them provided.  On the other hand, having blister packs often do not help with 
phosphate binders. Difficult even with a pharmacist input. N8 
Prescription refill Failure to fill script at pharmacy resulting in no medication to be taken. N14 
Culture and communication barriers 
 Indigenous status is a good indicator of overall health status. N21 
 Increased number of patients live in aged care facility, they receive good care 
but can cause confusion with duplication and communication regarding 
medication. N95 
Forgetfulness, role of dose administration aid and support 
- Forgetfulness There is a high number of elderly patients in our unit, a lot of them don’t seem 
to retain much information or forget quite easily what was told to them. N44 
 Forgetfulness is a factor. N68 
 Patients not always good with memory but if they have meds with them, this 
might be better. Probably would forget, counting doesn't reveal when or how 
they took them. N12 
- Decreased 
cognitive 
function 
Regarding limited understanding, it has more to do with their cognitive state, not 
their knowledge of the disease. N8 
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- Role of 
reminders 
Tablet load is a factor. Difficult to generalise here, but people with low 
education, difficult culture, language etc. are assisted by using dosettes etc. N68 
 Patients bringing in medications (Webster packs) do present usually reflect good 
adherence. 
 Webster packs assist. N112 
 Getting a copy of Webster pack medication list for people on multiple 
meds/elderly/memory issues. N93 
Role of comorbid illness 
- Comorbid 
illness 
Diabetics seem to be the most affected by non-adherence. N31 
 Diabetics the most non-compliant with medications. N31 
 Often with so many co morbidities medications themselves are making the 
patients feel unwell. N36 
- Tablet burden Some patient's express frustration at having to take so many tablets, especially 
phosphate binders. N45 
 Large pill load doesn't help. N65 
 Many have polypharmacy and this can add to their confusion over medication 
but also the taking of them, they just would like to sit and eat a meal without 
having to take a cupful of medicines. N8 
 Patients have so many tablets to take. They require large amounts of water to 
take them (eats into their fluid restriction) Some meds need to be chewed (not 
palatable). Often meds in blister packs and don't correspond with times meds 
need to be taken (binders). N79 
- Recent 
changes with 
medicines 
Patients often get confused, particularly when there are dosage changes.  Asking 
them to bring in their medications and to show you what they are taking can 
highlight variances between what they have been prescribed. N8 
Need for designated renal pharmacists 
Lack of designated 
renal pharmacists 
Have been requesting a renal pharmacist for years! N20 
 All other department in this hospital have a dedicated pharmacist but not the 
dialysis unit. N89 
 I'm the pharmacist. Much as we would like to have a dedicated healthcare 
professional to deal with these issues we don't have one. N86 
 Rarely see the pharmacist and do not see her giving pts education. N57 
 There is no staff development nose attached to my hospital as it was thought we 
did not need one specific to the dialysis unit. We share the SND from the next 
ward but they are flat out, stressed and one has just resigned. For a major 
teaching hospital it is shocking. N57 
 Attempting to get a pharmacist for Dialysis... Currently available for inpatients .... 
Able to contact them, however very limited service... N29 
 I often ring pharmacy to check when last obtained. N71 
 Don't have a pharmacist connected to unit. N58 
 We have an excellent relationship with community pharmacist which potent a 
use as a resource tool. N56 
 Our patients use different pharmacies and our hospital pharmacists does not see 
our pts. N65 
 We don't have a pharmacist on site here, but in other areas where I worked this 
was very helpful & reassuring to patients. N18 
 Ideally dedicated healthcare professionals should be engaged in medication 
history taking and reviews but doesn't happen in the dialysis unit. Most patients 
are assessed at clinic or nephrologists' appointments only. N11 
 A pharmacist goes through medications if patient has been in hospital. Prior to 
discharge. Not done routinely with O.P. N79 
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 We used to spend a lot of time doing up med profiles and getting patients to 
bring in their medications and liaising with local pharmacies. This was very time 
consuming and patients wouldn't bother to tell you when a medication was 
changed. We now rely on local pharmacies to send a copy of medication profile 
to us. N16 
 Including pharmacist in medication reviews only in inpatients. N13 
Perceived barriers 
- Lack of time Time is poor on a typical nursing shift, particularly as nurses seem to take on 
every increasing roles and responsibilities. Medication is, however, as essential 
component of thorough and holistic nursing care. I find that some patients find it 
boring or repetitive to discuss medications, so perhaps it should not be done too 
often. N104 
- Lack of 
training 
Lack of training for renal nurses in this area. N94 
 I have been working in renal system for few years. I have a lot of knowledge of 
renal medicines. However, I still feel myself need more comprehensive study and 
in services. There will be helpful to have self-learning package. N108 
- Staff shortage When the above actions are combined, it may make a difference, but difficult to 
achieve with patient/professional ratios. N104 
Multidisciplinary role 
 How to build up the beliefs of medication and is more important haemodialysis 
will give them better health outcomes. Of course the better health outcome 
could bring them normal life and enjoy life. I think the social worker should be 
involved more. N107 
 More social worker input and regularly interview and blood tests for patients. N108 
- Role of nurse It is part of the dialysis nurse role to help pts with education and understanding 
of adherence to medication regimen. N68 
 Discussing/liaising/monitoring pts meds/pathology and reporting to RMO as 
integral part of a renal nurse role. N106 
 Need to initiation for nursing staff on coordination whenever 
medication/dosage/pathology-this info needs to be consistently fed back to the 
patients. N106 
Ongoing education 
 I always talk to my patients regarding their medications and if they take them or 
not. If I am not sure about any of their medication, I'll search to found out. N15   
 We utilise a monthly 'report card' to discuss pathology results and potential to 
improve outcomes i.e. taking meds at appropriate times... N29 
 We take routine blood pre- and post- dialysis every month and then the nurse 
unit manager, nurse practitioner, pharmacist, and renal nephrologist meet to 
discuss the results and make any relevant changes to the patient's medications 
based on these results. The clinical nurse or nurse unit manager then goes to 
each patient to discuss the blood results and talk about their medications plus 
adherence to these. N45 
Current practices 
 Serum PO4 and BP are not solely done to check med compliance, but are 
routinely done on all patients. Poor results act as a flag for checking medications. 
Interviewing for med history is meant to be done for all patients - not always 
attended. N93 
 Unless symptomatic, medication history not reviewed. Education more likely to 
change behaviours but not identifying issues unless problem arise. N12 
 We ask patients to bring in their meds, but we don't count them to see how 
many they have taken.  We treat them as adults and therefore educate them 
regarding how and when to take.  They have to take some responsibility unless 
they have other medical/psycho social issues that impact on this. N8 
Note: N = Nurse participant (with a number to indicate the participant ID for example, N5 is the fifth respondent).  
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Appendix 17. COREQ Checklist: Renal Professionals Interview 
No. Item Guide questions/ description Reported in section/ remarks 
Domain 1: Research team and reflexivity 
Personal Characteristics   
1. Interviewer/ 
facilitator  
Which author/s conducted the 
interview or focus group? 
Section: Data collection and 
analysis 
 
2. Credentials What were the researcher’s 
credentials? E.g. PhD, MD 
Remark: SG (Masters); KL, MJ, RLC 
and STRZ (PhD) 
3. Occupation What was their occupation at the time 
of the study? 
Section: Data collection and 
analysis 
 
4. Gender Was the researcher male or female? Remark: All male 
5. Experience and 
training 
What experience or training did the 
researcher have? 
Remark: Researcher were trained 
in the design and conduct of 
qualitative research, and have 
authored qualitative research 
article in the past.  
Relationship with 
participants 
  
6. Relationship 
established 
Was a relationship established prior to 
study commencement? 
Section: Data collection and 
analysis. 
Remark: The interviewer was 
unknown to the participants prior 
to study commencement. 
7. Participant 
knowledge of the 
interviewer 
What did the participants know about 
the researcher? e.g. personal goals, 
reasons for doing the research 
Section: Data collection and 
analysis.  
Remark: Participants were 
informed of the interviewer’s 
background and expertise, at the 
beginning of interview.  
8. Interviewer 
characteristics 
What characteristics were reported 
about the interviewer/ facilitator? e.g. 
Bias, assumptions, reasons and interests 
in the research topic 
Section: SG introduced himself as a 
researcher and explained the 
purpose of interview i.e. to explore 
barriers to assessing adherence, 
and identify strategies to improve 
adherence assessment practices in 
dialysis settings.   
Domain 2: Study design   
Theoretical framework   
9. Methodological 
orientation and Theory 
What methodological orientation was 
stated to underpin the study? e.g. 
grounded theory, discourse analysis, 
ethnography, phenomenology, content 
analysis 
Section: Data collection and 
analysis 
 
Participant selection   
10. Sampling How were participants selected? e.g. 
purposive, convenience, consecutive, 
snowball 
Section: Participants 
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No. Item Guide questions/ description Reported in section/ remarks 
11. Method of approach How were participants approached? 
e.g. face-to-face, telephone, mail, email 
Section: Participants 
12. Sample size How many participants were in the 
study? 
Section: Participants 
13. Non-participation How many people refused to participate 
or dropped out? Reasons? 
Section: Participants 
Setting   
14. Setting of data 
collection 
Where was the data collected? e.g. 
home, clinic, workplace 
Section: Data collection and 
analysis 
 
15. Presence of 
nonparticipants 
Was anyone else present besides the 
participants and researchers? 
Remark: No 
16. Description of 
sample 
What are the important characteristics 
of the sample? e.g. demographic data, 
date 
Section: Participants 
Data collection   
17. Interview guide Were questions, prompts, guides 
provided by the authors? Was it pilot 
tested? 
Section: Data collection and 
analysis. Appendix 2.  
 
18. Repeat interviews Were repeat interviews carried out? If 
yes, how many? 
Remark: Not conducted 
19. Audio/ visual 
recording 
Did the research use audio or visual 
recording to collect the data? 
Section: Data collection and 
analysis 
20. Field notes Were field notes made during and/or 
after the interview or focus group? 
Section: Data collection and 
analysis  
21. Duration What was the duration of the 
interviews or focus group? 
Section: Data collection and 
analysis 
22. Data saturation Was data saturation discussed? Section: Data collection and 
analysis 
23. Transcripts returned Were transcripts returned to 
participants for comment and/ or 
correction? 
Remark: No 
Domain 3: Analysis and findings 
Data analysis   
24. Number of data 
coders 
How many data coders coded the data? Section: Data collection and 
analysis 
25. Description of the 
coding tree 
Did authors provide a description of the 
coding tree? 
Remark: No. Intermediate 
documentation is available upon 
request. 
26. Derivation of 
themes 
Were themes identified in advance or 
derived from the data? 
Section: Data collection and 
analysis 
27. Software What software, if applicable, was used 
to manage the data? 
Section: Data collection and 
analysis 
28. Participant checking Did participants provide feedback on 
the findings? 
Remark: No 
Reporting   
29. Quotations 
presented 
Were participant quotations presented 
to illustrate the themes/ findings? Was 
each quotation identified? e.g. 
participant number 
Section: Results.  
Appendix 3 & 4.  
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No. Item Guide questions/ description Reported in section/ remarks 
30. Data and findings 
consistent 
Was there consistency between the 
data presented and the findings? 
Remark: Yes 
31. Clarity of major 
themes 
Were major themes clearly presented in 
the findings? 
Section: Results 
32. Clarity of minor 
themes 
Is there a description of diverse cases or 
discussion of minor themes? 
Section: Results 
 
Developed from: Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research 
(COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in 
Health Care. 2007. Volume 19, Number 6: pp. 349 – 357. 
 
 
Appendix 18. Interview Guide: Renal Professionals 
 
Interview guide 
Hi [name of participant],  
Thank you for participating in this study. Our aim is to understand how you assess medication-related 
issues in dialysis patients and any problems you experience in your practice. Please feel free to add any 
comments during the discussion to clarify things. As stated on the information and consent form, this 
session will be recorded, but confidentiality will be maintained at all times. Do you have any questions 
before we begin?  
 
Before we start, may I ask some of the demographic details from you?  
- Age, Gender, Profession/ designation, Year of experience in renal unit, State, Unit location 
(metro/ rural), Type (public/ private), Number of dialysis chairs, Number of FTE 
nurse/pharmacist, Modalities delivered 
 
Section 1: Opinion on patients’ concerns about medicines 
From interviews I conducted with some patients, it seems that some patients don’t feel comfortable 
openly asking questions of their health professionals. 
 
Q. In your experience, is this something you’ve noticed in your practice? If so, what do you think 
could be the reasons? Why? 
Q. Do you think there is enough time for you to sit with them and answer some of their 
questions?  
Q. What do you think about the trust that patient have in their health care professionals in 
today’s work place environment?  
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Q. In your experience working with dialysis patients, how well do you think they know about their 
disease/medications? Could you elaborate. 
PROMPT: Do you think they know why they are taking all these pills or do you think they know 
how to manage their disease well?  
 
Q. In your opinion, how do patients’ perceptions about their medicines influence their medication-
taking behaviour? 
 
We all know about clinical effectiveness of medicines, but there is something like perceived 
effectiveness that patients might have regarding their medicines.  
 
Section 2: Current Practices of assessing adherence 
Now let’s talk about your daily routine at work and occasions how you identify medication-related issues 
in patients.   
 
Q. Thinking about your typical daily routine at work, 
Could you walk me through how you check the progress of your patients? Or, how you monitor their 
disease progression, and self-management? 
 
Q. How do you identify medication-related issues? I mean how do you figure out if someone is not 
taking their medicines as prescribed? 
For e.g. through formal interview or other informal discussion, observing their charts, lab 
reports, physical assessments etc.  
 
Q. Do patients actually admit not taking their medicines or it is something implied through 
observations? 
Q. Have patients ever told you about any difficulty they face about taking their medicines or 
following their treatment? 
Q. What is you take on the likely barriers to taking medicines by the patients? 
 
Q. Are you aware of any formal adherence assessment methods that can identify medication-
related issues in patients?  
 
Broadly speaking, these issues can be assessed objectively by looking at pill count, pharmacy 
refill, checking lab indices etc. or subjectively through patient interviews or using validated 
questionnaires.     
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Q. In your view, how practical do you think these methods are, and what do you believe to 
be the more practical methods that could be used in your practice? 
 
 Q. How effective would you say they are in the short and the long run? 
If No,  Q. Why do you think [certain methods] are not practical in your setting? 
  Q. What are the potential ways to address barriers to implement these methods? 
 
Section 3: Practice models 
Now I’d like to know your views on some of the practice models that can be used to assess 
medication-related issues in dialysis patients.  
 
Q. What is your opinion on introducing medication adherence assessment into practice the way we 
measure vital signs such as blood pressure, pulse, temperature etc.?  
 
If NO, Why? 
If YES, how could this be implemented/incorporated in your setting?  
Let me give you some scenarios,  
Q. How appropriate do you think about, 
- Asking patients to write down their concerns related to medications and discuss in a 
regular basis while they wait to finish their dialysis procedure? Or, 
 
- Asking patients to fill up a validated questionnaire to assess medication adherence in a 
regular basis? 
 
- Conduct on a regular basis, a 24-hour recall history by looking into patient’s personal 
medication list to check if they are taking their medicines properly? 
 
FOLLOW-UP: Who should take this role [dialysis nurses/ renal pharmacists/ renal physicians]?  
FOLLOW-UP:  What more could be done to ensure that dialysis patients continue to use their 
medications as prescribed over the long term? 
 
With this we come to an end of this interview. Do you like to add anything? Or anything that is 
important that we have left out?  
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Appendix 19. Barriers to assessing medication adherence: Exemplar quotes Renal 
Professionals 
Themes Exemplar quotes 
A. Organisational barriers  
Theme: Prioritisation of 
resources 
It depends on the organisational priorities. If they are supportive of this or have a 
vested interest in this… or something like this, then the organisation is more likely to 
pursue this, but otherwise if they can’t see any value in it, any direct dollar savings 
then it’s unlikely to be pursued. P3 
 Well, it’s really funny when [hospital administration] change the standards, a lot of the 
areas they fund them, I see there is a lot in their hospital, who have one [pharmacist], 
they all got one… how come everybody else got one we still don’t, it was insane… N10 
 Getting funding for a full-time pharmacist... Here we have two sites, so we need to 
have some kind of [funding] you know, so both sites [have pharmacists] in them. P2 
 The barrier is funding, it’s all that money to hire dedicated staffs. N10 
 I don’t think there will be enough funding to add another staff in the unit. N14 
Sub-theme 1: Human 
resources 
 
- Shortage of 
dedicated 
professionals 
Oh, human resources… I am a senior pharmacist, but I don’t have any juniors on my 
ward that could do that for me at certain time… one solution would be to have 
technicians trained in nephrology and then know the things to ask patients about, to 
get good histories. P4 
 Big limitation for conducting such activity is the absence of pharmacist in the unit. We 
wish to have a dedicated pharmacist in our unit to carry these activities. N7 
- Availability of 
interpreter 
services 
Not massively accessible, no… we would wait until they are coming to the ward for 
another reason for that patients and then we will tackle on. So it is not accessible but 
you can sort of call on them may be five minutes for different things, you really have to 
plan it. That is a barrier. Availability of an interpreter services is a barrier in the case of 
non-English speaking patients. P4 
 We do try to use the interpreter services but it’s not easily available and it’s not always 
possible. N11 
 Getting an interpreter would be useful in some situation, but I have never seen anyone 
sent to the unit. N13 
Sub-theme 2: Infrastructure  
- Availability of 
private space 
or interview 
room 
Privacy can be an issue because most of our patients sit very close to three other 
patients and there is no way to go to the staff with anything privately with them and 
it’s um, some people are not very interested in talking about their health issues when 
other people are listening to them. N11 
 In our setting here, we don’t have single rooms mostly they are open based, people 
they can see each other, if I am doing care for other patient they can see that. So 
probably, that may be one of the reason. N17 
 We have got an isolation chair, a room on its own. So if we plan ahead, like we did in 
advanced care plan and things like that… and put the person in the quite room so they 
are in private… then they would probably open up more and be more truthful, instead 
when they are in the main unit where they have been observed by everybody. N18 
B. Professionals-related 
barriers 
 
Theme 1: Interplay between 
workload and available time 
 
Professionals' role, 
responsibility, and scope of 
practice 
I guess the nurses has a lot of other tasks, jobs and things that they should be doing as 
well. Sometimes it isn’t in her priority… maybe there are other needs that need to get 
completed on the day, which isn’t a good thing to say but that could be the reason... I 
guess that’s the complication… it’s not necessarily dedicated part of their role. N12 
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Themes Exemplar quotes 
 I’m not discerning nursing role, but I am just saying that it’s not ideal to have nurses 
taking histories over above pharmacists, because we know more about the drugs and 
about the kind of, um, range of drugs. P4 
 In our setting where we are, I’d say it has to be a nursing role because there’s one 
pharmacist on site for the whole hospital, and they are not specialist in renal, so I’d say 
it has to be nurse. We have no doctor on site so it has to be nursing, with an escalation 
plan if we got issues, which we always do anyway. N18 
 we are renal nurses so we are confident with the renal medications, but these guys 
have got numerous other diseases, in which our knowledge is negligible about them so, 
so really should be somebody who has a broader range of medication knowledge that 
can take that on board. N10 
 [Patients] have demanded pharmacists and sometimes, I mean pharmacists are 
knowledgeable but sometimes they are not as knowledgeable, they didn’t know renal-
related medication which we will be educated in, they have to go and look, you know, 
follow up…N18 
Time constraints  We are lot busier now. I think the morbidity of the patients is getting worse they are 
more acute. So we do have less time but we make time… to sit with our patients and 
talk to them. N6 
 To be honest, here we don’t have much time to talk to or go into deep conversation. 
We are only four staffs and we have 22 patients in a shift, so we really don’t have time 
to go into very deep conversation with them. N16 
 When we put the patients on, that’s not only our duty of care, we have other duties to 
be attended as well while they are under dialysis machines and the time we are 
finished with other duty this patient is about to come out from the machine, so we 
don’t really have much time to talk to them. N15 
 [Time] is something we wish we had. But, we try to make it our priority when patients 
come with some issue to discuss. N7 
 There would be. If I know they have questions, then there is time. You know, we make 
that our priority. So yeah, there is time. P4 
Workload No, because the staff would go insane. I think it’s, if we are looking for someone to stay 
full-time, it probable need to swap around about every 8 weeks, because it would have 
a significant toll in the staff member involved. P2 
 It’s just more job for us, increases work load. We already have workload and we have 
our primary patients to take care. Some day when we are on leave the other nurse may 
have to take charge over our primary patients and that can increase the workload for 
the day. N15 
Access to patients Unless they come in during the day for a review, if they come in for a special 
appointment then there might be an opportunity to capture them, but this could be 
sometimes missed or just the timing doesn’t allow for pharmacists to see them on that 
particular day because of work load issues, so that would be a hidden miss. P3 
 Quite often, our patients will also travel back home, coz many of our patients are force 
to come in to Darwin and stay in a metro area when they are quite far away, so they 
will frequently return home and will go without their medications, so lot of lifestyle 
issues as well would lead them not taking their tablets. P5 
Sub-theme 1: Task 
prioritisation 
If patients have a lot of health matters that are more urgent… if they been 
experiencing pain or having a lot of fall… or whatever that sounds like it’s a new 
problem that hasn’t been looked into then the focus becomes on that, rather than the 
other aspects, like the medications. Whereas if the person is quite stable than… 
probably there is more emphasis towards…their medicines. P9 
 We do have registrars that come and visit the patients but they don’t have a lot of time 
to spend with, they more deal with issues rather than spending time actually seeing 
how everyone’s going, they will just come and see the problems that they are already 
facing. N11 
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Sub-theme 2: Staff 
compliance towards 
assessment service 
Staff participation may be poor. Unless it’s really concerned with particular patients, or 
feel we need to monitor, but if we gonna do it for everybody the work load is very high 
and some of the nurses won’t be happy participating with this. They are already pre-
occupied with many things to do and may say oh it’s not our responsibility. N15 
 The nursing staff don’t realise how important these kind of things are. We administer 
medication, our duty is to care patients but it’s not compulsory for us to assess 
adherence, it’s more of a pharmacists kind of job. N16 
 I think knowing the nurses that I work with there will be some challenges in additional 
form to be filled out, but if they saw the benefits of doing so then even if it’s on a 
weekly basis would be good. N12 
Theme 2: Awareness and 
training deficits  
Lack of knowledge about 
formal assessment tools 
No, not really. I don’t know any formal ones… If I wish to teach, I’ve got my one to be a 
formal one coz I think it works throughout well, but it does depend on the patients 
going to the same pharmacy… I’ve never heard about any official ones, I think it would 
be interesting to read about. P4 
 I know there are some of [formal tools] around, but to name them I wouldn’t be able 
to… P5 
 I’m not aware of any [formal assessment tools], no. Not that I use personally. N6 
 No, we didn’t really have one previously, no I’m not aware of any [formal tools]. N12 
 No, I’m not aware of any formal tool, no… if the patient is confused about what 
medications they are taking, we ask them to bring their medication from home and we 
go through them. N14 
Lack of training and skills Nursing staff lacks necessary training and skills. I think definitely, there is room for 
improvement here in relation to educating the nurses about medication on dialysis or 
all kidney failure patients. N17 
 Nurses given the right education would be able to do it. They are seeing these patients 
every dialysis day, so they will have more opportunities to assess it, but I think they 
would need a lot of training and sort of intervention in some ways in order to help 
them identify what sort of things to look for. P5 
 We have a nurse educator… who tries to support us in getting education opportunities. 
I would say that does not support enough by any means because it’s very hard to get 
time to study while you are at work. And in order to do any study days you need to get 
private study leave and in our particular unit, over the last eighteen months, we have 
had a shortage of casual nurses in particular, so it’s been impossible to have study days 
or study leave to really do any sort of renal conference or any other educational things. 
N11 
Theme 3: Concerns around 
practicality/suitability of 
adherence tools 
 
Limitation of assessment tool  
- Labels a patient I think it’s good to get a general measure of adherence within patients, but I do find 
this scaling and labelling of patients to be not adhering to be quite harsh. Um, if you 
remember some of the ones they use in transplant would definitely look at, you know, 
if they delayed their dosage greater than 2 hours then that would label the patient to 
be nonadherent, so I do sometimes find questionnaires do label patients as being 
nonadherent and its sort of taken as quite a nasty term. P5 
- Not quantifiable It’s not quite possible in that sense, because it’s not that easy to measure and 
absolutely quantify, the only way you could do that is you physically watch the patient 
for a week, you know, taking all their dosage… I don’t think it’s possible. P1 
- Practicality of tools I think the practicality is not there to do this. Unless we specifically said to the patients 
can you please bring in your tablets with you each time, but then we have to dedicate 
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time to making assessment each time to show the patients that we are truly interested 
in this. P3 
 To use a validated questionnaire to our client would be actually quite difficult, coz, I 
mean you have to use interpreters quite frequently for a lot of our patients and the 
questions would have to be tailored for our clients. P5 
- Suitability in clinical 
settings 
I’m doing a research study and part of it requires them to take medications, I check 
compliance by counting how many tablets are left in their box, but clinically I don’t. P9 
- Reliability of tools Pill counting, I think is always a disaster. Patients will give it to their dog before they 
actually come in, and it’s also prescriptive, isn’t that? P2 
 I think the validated questionnaire could be useful but it would really depend… on 
literacy as well of the patients, depends on who is asking how is asking… because 
otherwise they will tick the box as what you want to hear. P1 
Proper timing for assessment In a real world [during dialysis] is not the ideal time but that’s all we have got because 
like as I said they won’t come in early to talk to you, they won’t stay beyond, they just 
want to go, so they only want to be here minimal. N18 
 I think… often they are in dialysis and they don’t feel well, so it’s not an ideal place to 
go and do any kind of interview. So at times normally understanding they are trapped 
there for hours and hours, but often they just don’t feel well. So you’re not going to 
taking anything at that point. However, it’s better than not doing it at all. P2 
 When they coming for dialysis, they come at their appointment time and then we have 
half an hour to assess the patients, have a chat about how they are going in general, so 
this is when we can talk about their medication, about general health. N11 
 I think, during dialysis is very good time to do at because they are stuck there, they 
can’t be off working or here and there so, its practical to do that but, you’ll have to 
make sure that patients have their medications with them or the list with them. P4 
Frequency of assessment I think something is necessary. I think it’s not probably be going to necessary in our 
field on a daily basis. I think the patients would probably find that too much, but 
certainly on a monthly basis at least, I think that’s a really good idea. N11 
 I think formally assessing adherence is a good idea, but how often is it you want to do 
it? Look, at the satellite unit I work, we do it once a month… it works well. N13 
 Yeah, that would benefit, but that would be really very time consuming to ask patients 
every couple of days, but I think that would be a good way to have a look or assess, but 
yeah would be quite difficult. P5 
C. Patient-related barriers  
Theme 1: Communication of 
assessment services 
 
Benefit of assessment I think most of the patients would be happy to answer the questions definitely, if they 
see the benefit from it that we care about the medicine they are taking. N12 
 There needs to be a business case per together to show the benefits of doing this. And 
I know anecdotally that patients who I interact with, definitely the next time they come 
in, they definitely more, um, on the board with their medications and may know what 
they are taking and what they are not taking, and they have the confidence to say to 
me look I don’t take that one because of this problem. P4 
Setting expectations of the 
assessment 
I think that a lot of our patients would feel like they are being treated like children, 
they would probably feel like their privacy is being invaded if we would start doing 
that. N11 
 It would depend on how it is presented, if it wouldn’t be presented in a right way there 
would be patients who would become upset about why we are asking that question all 
the time and things like that, and patients feeling of having their privacy invaded puts a 
lot of significant barriers of trust at the nurses. N11 
 No, they like to keep their health to themselves. Some of them they don’t like to kind 
of share may be their past history so much unless they are prompted. Actually more 
than that they don’t relate past history or medical issues to their current life. N14 
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Theme 2: Patient 
participation  
Treatment fatigue They are so much overseen by medical people and they have so many 
appointments, and if you ask them if they have any worries they will just say 
no. I’m not sure that one will work. A lot of them, even if you offer review 
they go, no everything is fine, I actually don’t need to see you. P1 
 I think, again, often they are in dialysis and they don’t feel well, so it’s not an 
ideal place to go and do any kind of interview. So at times normally 
understanding they are trapped there for hours and hours, but often they just 
don’t feel well. So you’re not gonna taking anything at that point. P2 
Patient willingness to 
participate 
People do have free will… even though we are trying to do the best to our patients, 
they still can go, did I can’t be bothered? Then you have to go that point, well that’s 
your decision not anybody else’s. P2 
 If the patient is truly noncompliant and they don’t want to know this information, they 
might make excuses why they don’t bring in their medicines, that they forgot or they 
were running low, nobody was there to get it dispensed from the pharmacy … so again 
there is this barrier there. P3 
 We can do that but again depends on the patients. Some of the patients are not keen 
for all these type of questionnaires. They are only concerned about visible gains from 
their treatment. But some of the patients will be willing to participate. N15 
Language barriers We had quite a few issues in our unit based on different cultural groups, um 
we do have quite a few non-English speaking patients, basically they speak 
English but not enough to understand, so that can be a challenge as well. N11 
 Language barrier is a huge issue in our unit. We have many non-English 
speaking patients. N13 
Theme 3: Trust  
 It’s sad, I think some of them have mistrust about what we tell them, they don’t trust 
that we are telling them the right thing or the truth about the medication what they 
require. N6 
 There are always some patients, who for whatever reason, they are not interested in 
having a trusting good relationship. They are very private. N11 
Patient preference of 
professionals for consultation 
We definitely get requests by the patients who wants to speak with the doctors. Often, 
patients come to the nurse to ask us to talk to the doctors. We are kind of like the 
middle person. N13 
 I think they sometimes think our lack of knowledge, we are not doctors, also the 
doctors put them in the medications that we won’t know what it does and things like 
that. They don’t look at the nursing expertise in our area… they also don’t listen to 
suggestions. You know, how they take their medications, like with the Caltrate, we 
suggest how they should take it and, you know, they say the doctors said do this way 
and they won’t take on board with the nursing, also the lack of confidence in the 
nursing that we would know what they are talking about. N18 
 Their GPs knows them the best they always think, so the GPs although he is not 
specialist in any field in particular, but that’s the one they usually go in to rather than 
the renal physician. And most of our patients are elderly, our average age here is like 
75 years so, and they have been in the system for a long time and they know their GPs 
for long time, so I think because of that they trust them. N18 
Fear of judgement Patients feel that they are going to be judged. That, they should by now know this 
information, why they are asking now this pointless question, causing time wasting. P3 
 I think there is a few reasons why they don’t ask and one of them is getting an answer 
they don’t like… they probably don’t feel there is a problem… N6 
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Themes Exemplar quotes 
 I guess, may be fear of getting in trouble, they might feel that we might trouble them 
for not taking their medicines or not following what doctors has said or they are just 
worried what doctors or nurses would say, or they might have fear if they could ask 
any questions to us , I suppose… N12 
P = Pharmacist, N = Nurse 
 
Appendix 20. Considerations to improve adherence assessment practices: Exemplar 
quotes Renal Professionals 
Themes Exemplar quotes 
Theme 1: Formalisation of the 
adherence assessment process 
 
 It’s a great idea! To trigger it, so it becomes normal, it’s really normal, this is normal. 
P2 
 That could surely be a good way at least to show the patient that we are formalising 
the process… and could be a better way to encourage them to take their tablets. 
More likely, because they think all they ask me interests about me, so questionnaire 
might be a good way as long as we might be able to really use it. N12 
 I think it might be good because everybody then is following the same process. The 
most senior staff knows what to look for and what to ask and more junior staff might 
miss something or might not be prompted by something, whereas if you got a tool 
that it will prompt them to ask like questions or prompt them to follow up on certain 
things. N18 
Theme 2: Integration of 
process and tools into routine  
Incorporating adherence 
checklist in routine 
documentation 
Well, our daily treatment sheet has, we already have some checklist we go through, 
sort of might be a simplest just adding up that one, yeah, having any issues with your 
tablets or um, yeah. N8 
 I think it can be like a tick box. We have a care plan for each patients. So, for e.g. 
once every six months we check the decline or positive response to treatment so 
may be with medication formally checking we could have kind of a tick box in the 
care plan once a month or something. We could possibly have on a care plan a 
medication check and tick the boxes after conversation with the patients. Not so 
much the questionnaire but just the prompt to have that conversation with the 
patients. N14 
Organizing scheduled sessions 
for medication reviews 
 
- Monthly medication 
review and 
reconciliation 
I guess, we can go through like the monthly assessment of the patients, it includes 
medications, and we just ask their general medications questions, you know, what 
medications you are taking and do you understand what they are for, and if you have 
any problems, that’s pretty much all we ask. N6 
 Having a monthly meeting to discuss the patients’ blood results and we can then 
highlight the need for an increase or decrease in medication or start something else. 
N8 
- Monthly report card 
review 
We started doing a report card for our patients with their blood results and there are 
some prompts in there like, you know, if your phosphate is too high, and are you 
taking your binders correctly, you need to take them with your first meal for food. 
Um, when sevelamer was on the PBS there was a lot of education around that, and 
yeah with the same sort of thing. Just simple prompts on that report card, we found 
that that’s been quite good and it just gives them a clear, yeah, just makes them very 
clear to them what effect its gonna have them on their body. N8 
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Themes Exemplar quotes 
 One of the thing that our staff has created was a patient diary. So in that it went all 
their blood results and our role is to sit down with them once a month and go 
through their blood results, and explain what was good and what was bad and ask 
them how they going. That’s being quite a good thing for our unit, it’s a way of them 
being I guess invested in their own health, but also gives us an opportunity to sit 
down and discuss what’s happening with their dialysis treatment as well. A report 
card that was what it’s called the patient report card. N10 
Verification of objective 
evidence 
 
- Direct observation of 
medicines, physical 
assessment, and 
questioning 
If the blood pressure is not adjusting the way it should be or if it’s too low or too high 
for some reason then we are always asking first about medications whether they 
have taken them, how they taking them. N11 
 By doing the physical observations, blood pressure, weights, and also they have their 
monthly blood, so their blood shows lot of things, how they are progressing, how 
well they are. We also ask our patients their general feeling, how they are feeling, 
everyday… N12 
 Webster pack that got hardly anything taken out of it or completely unopened one 
makes you wonder, other than that, the boxes dispensed in July should have run out 
in July and now its November that sort of things tells you, I’m a 100% certain this 
person does or does not take their medicines. P1 
- Asking patient's local 
pharmacy 
I’m a great believer of just getting a fax from their community pharmacy and that 
could be done as an outpatient as well. If we have the resources, we would do that, 
get a fax from their pharmacy and compare with what they say they are taking, 
assuming they always go to the same pharmacy. You can say, okay we’ll see if it does 
match, look at the histories from the pharmacy, and get an idea of their adherence. 
P4 
 Lot of scripts are filled at an outside chemist, so we can liaise with chemist and say 
look what tablets they are taking or get them to bring in there, their packet of 
medications and see what they are actually taking… N8 
- Refill history And I’ll see if any of the latest dispensing are more than a month ago, then I’ll know 
well hang on, may be they are not compliant with that medicine, they are not 
adherent with that medicines because it’s been a more than a month ago they have 
lost, had it dispensed, how can they still be on it. Now it might be a drug with a big 
pack size like the allopurinol, and I’ll allow for that so okay, but hang on that was 
more than a month ago but that was 100 in a box, so that they probably are still on 
that, and then I’ll go back and back, and this is before I even speak to the patients. P4 
 So most patients we keep their prescription in the hospital so we can see when they 
are running out, and we can put it on another script for them but it doesn’t always 
work, and some people keep their own scripts. So, yeah, some people say oh yeah 
I’m taking that, another people will say oh haven’t, or forgot or run out or yeah. N6 
- Monitoring of blood 
levels 
Yeah, they don’t really discuss their medication with us unless we find something 
with their blood, you know a lot of them calcium is too high or too low, phosphate 
too high and then we try and discuss compliance with them then. N8 
 I certainly think it’s a very accurate way of figuring out whether or not, with the 
whole clinical picture obviously, you don’t want to rely on just one thing but if one 
does not know about issues going on, then definitely blood results can definitely 
reflect what’s been going on with medications at home. N11 
- Observing side-effects 
of therapy 
When they have symptoms of the problems, let’s say for phosphate, if they become 
itchy all of a sudden, and we can look at their phosphates increasing than that makes 
it easier. N6 
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Themes Exemplar quotes 
 I guess symptoms, if the patients report any symptoms like tiredness or itchiness or 
things like that we would assess but we don’t regularly ask the patients if they taking 
their medications. N12 
 If someone is taking iron tablets, I know the iron tablets makes their poo black or 
rifampicin or something that makes the urine orange, then I ask them about the side 
effects and if they are not reporting that side effects than that makes me think also 
are they taking the medicines. P9 
Subjective assessment through 
patient-centric communication 
 
- General discussion on 
medication issues 
I think that is definitely a good approach to start with, because from this you can say 
at what level the patient is at, and what their baseline understanding is and this way 
you know how to target your initiatives, whether you bypass the simple things and 
go to the more complex things. P3 
 We also check how they are feeling generally. We have a sort of a holistic 
conversation with them in terms of how they are coping in life, because if they are 
having trouble with other things then they are probably going to be having troubles 
adhering to medications and keeping themselves healthy, we are keen if they are 
hemodynamically stable and so forth. N6 
- Asking non-
judgemental 
questions   
You have to be diplomatic of course, you can’t accuse them but you can say did you 
may be stop it for a while, did you doctor stopped it… you have to give the patient a 
way of admitting low adherence without being shamed, because if you scare patients 
they will, make up lies. So you have to let them know, it’s okay for you to tell me that 
you don’t take these tablets, you can give them excuses to not take it. P4 
 One of those things where we can be too abrupt I guess with medication adherence, 
because mainly adherence or compliance can be construed as being rude or whether 
we are questioning the patients, so I think we have to treat lightly when we ask such 
sort of questions, you probably come up with the same problems. N6 
- Building good rapport 
with patients 
I think the issue particularly as pharmacists, is that they don’t understand why we are 
asking what we are asking. Therefore, the good thing about renal patients is that 
because they’ve got a chronic condition they will come back in again and again and 
so when you see them for the third or fourth time, the trust close because they’ve 
met you before, they understand what you are at for, and they understand how 
useful you can be. P4 
 When they are comfortable, they tend to open up a little bit more and talk about 
what issues they have. Generally they like to share stories amongst each other, so 
that tends to help sort of identify any issues and then obviously building that rapport 
takes a while, so that needs to get to know you until comfortable saying their 
concerns about medications. P5 
- Being a good listener I think all aspects of professional health could be slightly more empathic about what 
they do. Coz, sometimes there is a lack of empathy with somebody who has been 
coming every day for four years, or three times a day for four years. The empathy 
drops off. P2 
 We have to be more empathetic with our patients, they have a chronic condition and 
have been taking medicines for a long time, so we should be empathetic towards 
them and try to understand their concerns. N7 
Theme 3: Multidisciplinary 
support 
 
Partnering with doctor and 
nursing staff 
I think we need to be involved in multi-disciplinary approach, so we have support 
from our colleagues, so everybody is on the same page and support its initiatives and 
therefore the patients gets the consistent message that it’s not just the pharmacists 
hounding them, but it’s actually got value and purpose behind it. P3 
 We can talk to the dialysis nurses and they can give us a bit of a briefing about the 
patients whether or not they do take their medications… P5 
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Themes Exemplar quotes 
 You need pharmacy input and you need medical staff input, and you need to have a 
clinician champion who is at the absolute top of the chain. You can’t do this from a 
nursing perspectives, we can’t do it as pharmacists, it has to be clinician led and it’s 
got a come from the top, or there is no funding, there is no support and nothing to 
care those guys in the bad times. P2 
 Encouraging doctors to discuss patient’s medications with them on a regular basis, 
not just to assume that they understand. N11 
 I think if we are having any issues with someone who is just, you know continuing not 
taking their tablets then we get the renal physicians to have a word to them and he 
basically just go through the reasons why and what will happen if you don’t take 
them so, yeah…  N8 
 Their GPs knows them the best they always think, so the GPs although he is not 
specialist in any field in particular, but that’s the one they usually go in to rather than 
the renal physician. And most of our patients are elderly, our average age here is like 
75 years so, and they have been in the system for a long time and they know their 
GPs for long time, so I think because of that they trust them. N18 
Liaising with Interpreters and 
communication facilitators   
 
- Formal or 
professional 
interpreters 
Sometimes we get interpreters in, the Chinese and Greek patients although they 
don’t speak English very well, they do understand and have a basic English level, but 
we do use assistance from interpreters when it requires. P5 
 We use interpreters where necessary, if they are the patients with different 
languages… P1 
- Informal or family 
interpreters 
We wait for their carers or family to come in who speak their language and we 
interpret via them. P3 
 We try our best. Sometimes who have their family members there who can translate 
and help with that. N11 
- Liaison staffs for 
indigenous or non-
English speaking 
patients 
For the indigenous, we have support from the aboriginal liaison staffs so they can 
talk to her and help in medication management. N12 
 [Indigenous patients] rely heavily on the aboriginal co-op so, if they don’t know 
anything they go there and the aboriginal nurse come up to help them, so we liaise 
with her quite a bit too, in regard to any issues that comes up with those patients. N8 
P = Pharmacist, N = Nurse 
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Appendix 21. Tasmanian Health and Medical HREC Approval 
 
 
  
261 
 
 
 
 
 
262 
 
Appendix 22. Tasmanian Social Sciences HREC Approval 
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Appendix 23. Invitation Letter for Nurses Survey 
 
Date: 16/02/2016 
 
Dear Nurse Unit Manager, 
Medication nonadherence may lead to poor patient outcomes and costs millions of dollars to the 
healthcare system. As such, I am studying medication adherence in dialysis patients across Australia 
for my PhD. Dialysis nurses may play a pivotal role in managing dialysis treatment prescriptions and 
improving dialysis attendance and adherence among patients and their opinions may guide 
interventions to improve medication adherence.  
I would like to invite you to complete an online survey that seek dialysis nurse practitioners’ 
opinions on medication nonadherence, its causes & how it may be improved in patients undergoing 
dialysis. The survey should take approximately 10-15 minutes to complete, and is available through 
the link: https://www.pharm.utas.edu.au/surveys/index.php/423245?lang=en   
I also need your assistance in forwarding the study invitations to the doctors, nurses and 
pharmacists involved in patient care at your dialysis unit. Alternatively, we have also send few paper-
based copies of survey packs to complete. If you have any general queries regarding this survey, please 
do not hesitate to contact me at saurav.ghimire@utas.edu.au  or Dr Syed Tabish R Zaidi through 
tabish.razizaidi@utas.edu.au.  
I appreciate your time and assistance in promoting our study at your dialysis centre. I will be more 
than happy to answer any questions that you may have in this regards.  
 
Yours Sincerely, 
 
Saurav Ghimire 
PhD Candidate 
 
Dr Syed Tabish R Zaidi 
Lecturer in Pharmacy 
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Appendix 24. Participant Information Sheet for Survey Participants 
 
Participant information sheet [Ver 1.0][20/11/2015] 
 
Project title   
Cross-sectional survey of current practices in measuring medication adherence at Australian dialysis 
centres- a pilot study 
 
Invitation 
You have been invited to participate in this survey as you are the healthcare professionals (clinicians, 
nursing and pharmacy staffs) providing care to the end-stage kidney disease (ESKD) patients undergoing 
maintenance dialysis treatment at the dialysis centres in Australia.  
My name is Saurav Ghimire, and this research has been conducted as part of my PhD research project in 
Clinical Pharmacy, and in conjunction with my supervisors Dr Tabish Razi Zaidi, Lecturer in Pharmacy, 
School of Medicine, UTAS and Dr Ronald L Castelino, Lecturer in Therapeutics, Pharmacy, School of 
Medicine, UTAS and our research collaborators Dr Matthew D Jose, Professor of Medicine, School of 
Medicine, UTAS and Mr Colin Banks, Nursing Unit Manager, Nephrology South, Royal Hobart Hospital, 
Hobart, Australia.  
What is the purpose of this research? 
The aim of this survey and research is to measure healthcare professionals’ perception of prevalence and 
contributors of medication nonadherence among ESKD patients attending dialysis centres, as well as to 
identify areas of current practices and the barriers to assessing and improving adherence among ESKD 
patients in dialysis centres in Australia. This research will in turn assist with identifying ways in which 
medication adherence can be improved among ESKD patients undergoing chronic dialysis treatment. 
What will I be asked to do?  
You will be asked to complete an online or a paper-based survey (whichever appropriate) which will take 
approximately 10-15 minutes to complete. The survey will involve questions asking about your perceived 
knowledge on medication adherence and its consequences on patient’s clinical outcomes, what you see 
as the most important contributors of nonadherence, barriers to assessing and improving medication 
adherence, areas of current practices in effective medication management, and confidence in accurately 
assessing and resolving issues related to adherence in your dialysis centres. There will also be a section 
where you can include other relevant comments. The responses will be completely anonymous, and only 
the research team members will have access to your answers and results.  
Do I have to take part in this research project? 
Your involvement in this study is entirely voluntary, and as the results will be de-identified, it will not be 
possible for either anyone involved in this study or others in the workplace to know your individual 
responses. 
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Are they any benefits associated with being in this study? 
There is an opportunity to win a prepaid gift voucher worth $100 by eight participants that will be drawn 
at the conclusion of the survey availability, should you wish to include your contact details in order to be 
considered for this prize draw. In addition to this, you will be contributing valuable information on critical 
issues related with medication nonadherence by the dialysis patients, as often adherence research 
involving patients is not being translated into practice. Hence, the knowledge gained from this study will 
be used in the future to best tailor medication management practices in dialysis centres to improve 
medication adherence outcomes. 
Are they any risks or cost associated with being in this study? 
There are no risks associated with being involved in this study, as the results will be de-identified, and 
neither those directly involved in the study nor others in either the workplace will be able to link results 
to individual participants. 
What will happen to the information collected when the study is over? 
Once the survey is completed from all participants, data gathered from this study will be collated and 
analysed to determine the overall trends and answers to the study objectives. The results of the study 
will be de-identified and stored within the university database according to protocols outlined by the 
university and ethics committee. 
How will the results of the study be published? 
The results of this study will be published in peer-reviewed journals, however the study results will be de-
identified when presenting the findings. 
What if I have a complaint or any concerns about the study? 
If you have any questions or concerns about any aspect of this study please do not hesitate to contact 
either myself through email (saurav.ghimire@utas.edu.au) or Dr Tabish Razi Zaidi through email 
(Tabish.RaziZaidi@utas.edu.au). This study has been approved by the Tasmanian Social Sciences Human 
Research Ethics Committee. If you have concerns or complaints about the conduct of this study, please 
contact the Executive Officer of the HREC (Tasmania) Network on +61 3 6226 6254 or 
email human.ethics@utas.edu.au. The Executive Officer is the person nominated to 
receive complaints from research participants. Please quote ethics reference number 
H0015433. Thank you for taking time to consider this study. This information sheet is 
for you to keep for your record. If you wish to participate in this study, you may either:  
1. Complete a paper-based survey and return it in the reply-paid envelope. Or, 
2. Complete an online version of the survey, by entering the URL 
https://www.pharm.utas.edu.au/surveys/index.php/423245?lang=en into your browser or 
alternately simply scan the QR code opposite with your smart phone or other QR enabled device 
to gain access. In both the cases, completion and return of the survey implies consent to 
participate in the research.  
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Appendix 25. Participant Information Sheet: Renal Dialysis Patients 
 
PARTICIPANT INFORMATION SHEET 
Medication regimen complexity, concordance to prescribed medications and a survey of 
complementary and alternative medications in haemodialysis patients 
 
Invitation 
You are invited to participate in a research study that evaluates the impact of medication complexity 
on medication taking behaviour and to survey the use of natural medicines by chronic kidney disease 
patients.  
 
The study is being conducted by Dr Tabish Razi Zaidi, Lecturer in Pharmacy, School of Pharmacy at 
the University of Tasmania. The other researchers are: 
 
• Professor Matthew Jose, Professor of Medicine, School of Medicine UTAS 
• Dr Ronald Castelino, Lecturer in Therapeutics, School of Pharmacy UTAS 
• Mr Saurav Ghimire, PhD Candidate, School of Pharmacy UTAS 
 
Before you decide whether or not you wish to participate in this study, it is important for you to 
understand why the research is being done and what it will involve. Please take the time to read the 
following information carefully and discuss it with others if you wish. 
 
1. ‘What is the purpose of this study?’ 
The purpose is to investigate the impact of medication complexity on medication taking behaviour 
and to survey the use of natural medicines by chronic kidney disease patients.  
 
2. ‘Why have I been invited to participate in this study?’  
You are eligible to participate in this study because you have been identified as fitting the specific 
criteria of the study, which is; 
  
Adult patient (18 years or over) and currently receiving maintenance dialysis treatment in the 
outpatient dialysis facility of Royal Hobart Hospital (RHH)/ Nephrology South, New Town, Tasmania. 
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3. ‘What if I don’t want to take part in this study, or if I want to withdraw later?’ 
Participation in this study is voluntary. It is completely up to you whether or not you participate. You 
will be kept informed of any significant new findings that may affect your willingness to continue in 
the study.  If you wish to withdraw from the study once it has started, you can do so at any time 
without having to give a reason.  However, it may not be possible to return or withdraw your data 
from the study results if these have already had your identifying details removed. 
 
4. ‘What does this study involve?’ 
If you agree to participate in this study, you will be asked to sign the Participant 
Consent Form.  You will then be interviewed for your medication history that involves your current 
prescription medicines, non-prescription and herbal medicines. At the end of the interview you will 
be requested to answer a self-administered questionnaire to obtain information on your health 
outcomes and perceived burden of medication administration. This will take approximately 30 
minutes and can be done at an agreed time between you and the researchers. The accuracy of the 
medication history provided by you will be verified by reviewing your medication records, inspecting 
medicines containers (including blister packs) and contacting other prescribers and pharmacist 
involved in care. 
 
5. ‘How is this study being paid for?’ 
The study is a part of a PhD project and all the cost incurred during the study will be managed by 
School of Pharmacy, UTAS. No money is paid directly to individual researchers. 
 
6. ‘Are there risks to me in taking part in this study?’ 
All we need is your convenient time to talk with us about your medication history. The study does 
not involve any foreseeable risk to your health and well-being.    
 
7. ‘Will I benefit from the study?’ 
This study will identify unique challenges faced by chronic kidney disease patients in adhering to 
their complex medication therapy. Therefore, as knowledge is gained after analysis, future 
interventions aimed at improving the quality use of medicines and drug therapy outcomes can be 
implemented. However, no immediate benefit from the study can be assured for you.  
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8. ‘Will taking part in this study cost me anything, and will I be paid? 
Participation in this study will not cost you anything. Interview sessions will be arranged during your 
regular visit to dialysis unit. 
 
9. ‘How will my confidentiality be protected?’ 
Only the researchers named above will know whether or not you are participating in this study. Any 
identifiable information that is collected about you in connection with this study will remain 
confidential and will be disclosed only with your permission, or except as required by law. Only the 
researchers named above will have access to your details and results that will be held securely at 
School of Pharmacy UTAS. 
 
10. ‘What happens with the results?’ 
If you give us your permission by signing the consent document, we plan to present the results at 
conferences or other professional forums, publish the results in peer-reviewed journals and disclose 
the results to the sponsor for monitoring purposes and the HREC for monitoring purposes. 
In any publication, information will be provided in such a way that you cannot be identified. Results 
of the study will be provided to you, if you wish. 
 
11. ‘What should I do if I want to discuss this study further before I decide?’ 
When you have read this information, the researcher Saurav Ghimire, will discuss it with you and 
any queries you may have. If you would like to know more at any stage, please do not hesitate to 
contact him on 03 6226 1069. 
 
12. ‘Who should I contact if I have concerns about the conduct of this study?’ 
This study has been approved by the Tasmanian Health and Medical Human Research Ethics 
Committee.  If you have concerns or complaints about the conduct of this study should contact the 
Executive Officer of the HREC (Tasmania) Network on (03) 6226 6254 or email 
human.ethics@utas.edu.au.  The Executive Officer is the person nominated to receive complaints 
from research participants. You will need to quote [HREC number: H0014506]. 
Thank you for taking the time to consider this study. 
If you wish to take part in it, please sign the attached consent form. This information sheet is for 
you to keep. 
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Appendix 26. Consent Form: Renal dialysis Patients 
 
CONSENT FORM 
Medication regimen complexity, concordance to prescribed medications and a survey of 
complementary and alternative medications in haemodialysis patients  
1. I acknowledge that the nature, purpose and anticipated effects of the project so far as it affects 
me, have been fully explained to my satisfaction by the research worker and my consent is 
given voluntarily. 
 
2. I understand that in order to be eligible for the study, I must be 18 years or above and currently 
receiving maintenance dialysis treatment in the outpatient dialysis facility of Royal Hobart 
Hospital (RHH)/ Nephrology South, New Town, Tasmania. 
   
3. The details of the procedure proposed have also been explained to me, including the 
anticipated length of time it will take, the frequency with which the procedure will be 
performed, and an indication of any discomfort, which may be expected.   
 
4. I understand that there are the following risks or possible discomfort: No any foreseeable risk to 
my health and well-being 
 
5. Although I understand that the purpose of this research project is to improve the quality of 
medical care, it has also been explained that my involvement may not be of any benefit to me. 
 
6. I have been given the opportunity to have a member of my family or friend present while the 
project was explained to me. 
 
7. I am informed that no information regarding any medical history will be divulged and the results 
of any tests involving me will not be published so as to reveal my identity.  
 
8. I understand that I will be given a signed copy of this patient information sheet and consent 
form.  I am not giving up my legal rights by signing this consent form. 
 
9. I understand that the study will be conducted in accordance with the latest versions of the 
National Statement on Ethical Conduct in Human Research 2007 and applicable privacy laws. 
 
10. Name of participant  
 
 Signature of participant     Date  
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The following section regarding the witness is not essential but may be appropriate for patients where 
the research teams feel that the participant should have a witness to the consent procedure or 
where the protocol insists upon witnesses. 
 
 Name of witness (if appropriate) 
 
 Signature of witness              Date 
 
11. I have explained this project and the implications of participation in it to this volunteer and I 
believe that the consent is informed and that he/she understands the implications of 
participation. 
 
 Name of investigator   
   
 Signature of investigator   Date 
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Appendix 27. Participant Information Sheet: Renal Professionals Interview 
 
 
Participant information sheet [Ver 2.0][10/08/2016] 
This information sheet is for participants who have completed the survey.  
 
Project title   
Cross-sectional survey of current practices in measuring medication adherence at Australian dialysis 
centres- a pilot study 
 
Invitation 
You have been invited to participate in this follow-up interview study as you are the healthcare 
professionals (clinicians, nursing and pharmacy staffs) providing care to the end-stage kidney disease 
(ESKD) patients undergoing maintenance dialysis treatment at the dialysis centres in Australia.  
My name is Saurav Ghimire, and this research has been conducted as part of my PhD research project in 
Clinical Pharmacy, and in conjunction with my supervisors Dr Syed Tabish Razi Zaidi, Lecturer in 
Pharmacy, School of Medicine, UTAS and Dr Ronald L Castelino, Lecturer in Therapeutics, Pharmacy, 
School of Medicine, UTAS and our research collaborators Dr Matthew D Jose, Professor of Medicine, 
School of Medicine, UTAS and Mr Colin Banks, Nursing Unit Manager, Nephrology South, Royal Hobart 
Hospital, Hobart, Australia.  
What is the purpose of this research? 
The aim of this research is to measure healthcare professionals’ perception of prevalence and 
contributors of medication nonadherence among ESKD patients attending dialysis centres, as well as to 
identify areas of current practices and the barriers to assessing and improving adherence among ESKD 
patients in dialysis centres in Australia. This research will in turn assist with identifying ways in which 
medication adherence can be improved among ESKD patients undergoing chronic dialysis treatment. 
What will I be asked to do?  
You will be asked to participate in a semi-structured one-on-one phone interview that seeks information 
on current practices and barriers faced by the healthcare professionals while assessing and addressing 
medication adherence in dialysis patients. This will take between 15-20 minutes and can be done at an 
agreed time between you and the research team.   
Do I have to take part in this research project? 
Your involvement in this study is entirely voluntary, and as the results will be de-identified, it will not be 
possible for either anyone involved in this study or others in the workplace to know your individual 
response.  
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Are they any benefits associated with being in this study? 
A gratitude prepaid gift voucher worth $50 will be provided for each participants in the follow-up 
interview study. In addition to this, you will be contributing valuable information on critical issues related 
with medication nonadherence in the dialysis patients, as often adherence research involving patients is 
not being translated into practice. Hence, the knowledge gained from this study will be used in the future  
 
to best tailor medication management practices in dialysis centres to improve medication adherence 
outcomes. 
Are they any risks or cost associated with being in this study? 
There are no risks associated with being involved in this study, as the results will be de-identified, and 
neither those directly involved in the study nor others in either the workplace will be able to link results 
to individual participants. 
What will happen to the information collected when the study is over? 
Once the study is completed from all participants, data gathered from this study will be collated and 
analysed to determine the overall trends and answers to the study objectives. The results of the study 
will be de-identified and stored within the university database according to protocols outlined by the 
university and ethics committee. 
How will the results of the study be published? 
The results of this study will be published in peer-reviewed journals, however the study results will be de-
identified when presenting the findings. 
What if I have a complaint or any concerns about the study? 
If you have any questions or concerns about any aspect of this study please do not hesitate to contact 
either myself through email (saurav.ghimire@utas.edu.au) or Dr Syed Tabish Razi Zaidi through email 
(Tabish.RaziZaidi@utas.edu.au). This study has been approved by the Tasmanian Social Sciences Human 
Research Ethics Committee. If you have concerns or complaints about the conduct of this study, please 
contact the Executive Officer of the HREC (Tasmania) Network on +61 3 6226 6254 or email 
human.ethics@utas.edu.au. The Executive Officer is the person nominated to receive complaints from 
research participants. Please quote ethics reference number H0015433. 
 
Thank you for taking time to consider this study.  
This information sheet is for you to keep for your record.  
If you wish to participate in this study, please sign the attached consent form.  
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Appendix 28. Consent Form: Renal Professionals 
 
 
Participant Consent Form [Ver 2.0] [10/08/2016] 
 
Project title   
Cross-sectional survey of current practices in measuring medication adherence at Australian dialysis 
centres- a pilot study 
CONSENT FORM FOR INTERVIEW PARTICIPANTS 
1. I agree to take part in the research study named above. 
2. I have read and understood the Information Sheet for this study. 
3. The nature and possible effects of the study have been explained to me. 
4. I understand this study involves participating in an interview that seeks my opinion on 
medication adherence issues in dialysis patients and will take approximately 15-20 minutes 
to complete. 
5. I understand that participation in this study involves no foreseeable risks.  
6. I understand that all research data will be securely stored on the premises of the University 
of Tasmania for five years from the publication of the study results, and will then be 
destroyed.  
7. Any questions that I have asked have been answered to my satisfaction. 
8. I understand that the researcher(s) will maintain confidentiality and that any information I 
supply to the researcher(s) will be used only for the research.  
9. I understand that the study results will be published such that I cannot be identified as a 
participant.  
10. I understand that my participation is voluntary and that I may withdraw at any time without 
any effect.  
 
Participant’s name: _____ Date: _____ 
Participant’s signature: _____   
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Statement by the Investigator  
 I have explained the project and the implications of participation in it to this volunteer, 
and I believe that the consent is informed and that he/she understands the implications 
of participation. 
If the Investigator has not had an opportunity to talk to participants prior to them participating, the 
following must be ticked. 
 The participant has received the Information Sheet where my details have been provided 
so participants have had the opportunity to contact me prior to consenting to participate 
in this project. 
 
Investigator’s name:   Saurav Ghimire  
 
Date:   17/10/2016 
 
Investigator’s signature:   
 
 
  
 
 
  
X 
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Appendix 29. Recruitment advertisement: Renal dialysis patients 
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Appendix 30. Recruitment advertisement: Renal Professionals 
 
 
